

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12392771
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Song; Hye-Won et al.

Single cell secretome analysis

Abstract

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and/or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

Inventors:	Song; Hye-Won (San Jose, CA), Martin; Jody (San Jose, CA)
Applicant:	Becton, Dickinson and Company (Franklin Lakes, NJ)
Family ID:	1000008766666
Assignee:	BECTON, DICKINSON AND COMPANY (Franklin Lakes, NJ)
Appl. No.:	17/151050
Filed:	January 15, 2021

Prior Publication Data

Document Identifier	Publication Date
US 20220187286 A1	Jun. 16, 2022

Related U.S. Application Data

us-provisional-application US 63125629 20201215

Publication Classification

Int. Cl.: G01N33/543 (20060101); **G01N33/563** (20060101); **G01N33/68** (20060101);
G01N33/74 (20060101)

U.S. Cl.:

CPC G01N33/54306 (20130101); **G01N33/563** (20130101); **G01N33/6866** (20130101);
G01N33/6869 (20130101); **G01N33/74** (20130101); **G01N2458/10** (20130101)

Field of Classification Search

USPC: None

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
4510244	12/1984	Parks et al.	N/A	N/A
4725536	12/1987	Fritsch et al.	N/A	N/A
5124246	12/1991	Urdea et al.	N/A	N/A
5137809	12/1991	Loken et al.	N/A	N/A
5149625	12/1991	Church et al.	N/A	N/A
5200314	12/1992	Urdea	N/A	N/A
5308990	12/1993	Takahashi et al.	N/A	N/A
5424186	12/1994	Fodor et al.	N/A	N/A
5424413	12/1994	Hogan et al.	N/A	N/A
5445934	12/1994	Fodor et al.	N/A	N/A
5470570	12/1994	Taylor et al.	N/A	N/A
5604097	12/1996	Brenner	N/A	N/A
5635352	12/1996	Urdea et al.	N/A	N/A
5635400	12/1996	Brenner	N/A	N/A
5648245	12/1996	Fire et al.	N/A	N/A
5654413	12/1996	Brenner	N/A	N/A
5656731	12/1996	Urdea	N/A	N/A
5658737	12/1996	Nelson et al.	N/A	N/A
5714330	12/1997	Brenner et al.	N/A	N/A
5744305	12/1997	Fodor et al.	N/A	N/A
5759778	12/1997	Li et al.	N/A	N/A
5763175	12/1997	Brenner	N/A	N/A
5800992	12/1997	Fodor et al.	N/A	N/A
5830712	12/1997	Rampersad et al.	N/A	N/A
5846719	12/1997	Brenner et al.	N/A	N/A
5854033	12/1997	Lizardi	N/A	N/A
5871928	12/1998	Fodor et al.	N/A	N/A
5925525	12/1998	Fodor et al.	N/A	N/A
5935793	12/1998	Wong	N/A	N/A
5962271	12/1998	Chenchik et al.	N/A	N/A
5962272	12/1998	Chenchik et al.	N/A	N/A
5968740	12/1998	Fodor et al.	N/A	N/A
5981176	12/1998	Wallace	N/A	N/A

5981179	12/1998	Lorinez et al.	N/A	N/A
6013445	12/1999	Albrecht et al.	N/A	N/A
6040138	12/1999	Lockhart et al.	N/A	N/A
6046005	12/1999	Ju et al.	N/A	N/A
6060596	12/1999	Lerner et al.	N/A	N/A
6064755	12/1999	Some	N/A	N/A
6114149	12/1999	Fry et al.	N/A	N/A
6117631	12/1999	Nilsen	N/A	N/A
6124092	12/1999	O'Neill et al.	N/A	N/A
6138077	12/1999	Brenner	N/A	N/A
6140489	12/1999	Brenner	N/A	N/A
6172214	12/2000	Brenner	N/A	N/A
6197506	12/2000	Fodor et al.	N/A	N/A
6197554	12/2000	Lin et al.	N/A	N/A
6214558	12/2000	Shuber et al.	N/A	N/A
6235475	12/2000	Brenner et al.	N/A	N/A
6235483	12/2000	Wolber et al.	N/A	N/A
6265163	12/2000	Albrecht et al.	N/A	N/A
6268152	12/2000	Fodor et al.	N/A	N/A
6284460	12/2000	Fodor et al.	N/A	N/A
6284485	12/2000	Boyle et al.	N/A	N/A
6309822	12/2000	Fodor et al.	N/A	N/A
6309823	12/2000	Cronin et al.	N/A	N/A
6326148	12/2000	Pauletti et al.	N/A	N/A
6355431	12/2001	Chee et al.	N/A	N/A
6355432	12/2001	Fodor et al.	N/A	N/A
6372813	12/2001	Johnson et al.	N/A	N/A
6395491	12/2001	Fodor et al.	N/A	N/A
6406848	12/2001	Bridgham et al.	N/A	N/A
6436675	12/2001	Welch et al.	N/A	N/A
6440667	12/2001	Fodor et al.	N/A	N/A
6440706	12/2001	Vogelstein et al.	N/A	N/A
6451536	12/2001	Fodor et al.	N/A	N/A
6458530	12/2001	Morris et al.	N/A	N/A
6468744	12/2001	Cronin et al.	N/A	N/A
6480791	12/2001	Strathmann	N/A	N/A
6489114	12/2001	Laayoun et al.	N/A	N/A
6489116	12/2001	Wagner	N/A	N/A
6492121	12/2001	Kurane et al.	N/A	N/A
6500620	12/2001	Yu et al.	N/A	N/A
6512105	12/2002	Hogan et al.	N/A	N/A
6514699	12/2002	O'Neill et al.	N/A	N/A
6544739	12/2002	Fodor et al.	N/A	N/A
6551784	12/2002	Fodor et al.	N/A	N/A
6576424	12/2002	Fodor et al.	N/A	N/A
6600996	12/2002	Webster et al.	N/A	N/A
6629040	12/2002	Goodlett et al.	N/A	N/A
6653077	12/2002	Brenner	N/A	N/A
6753147	12/2003	Vogelstein et al.	N/A	N/A

6787308	12/2003	Balasubramanian et al.	N/A	N/A
6808906	12/2003	Shen et al.	N/A	N/A
6849404	12/2004	Park et al.	N/A	N/A
6852488	12/2004	Fodor et al.	N/A	N/A
6858412	12/2004	Willis et al.	N/A	N/A
6890741	12/2004	Fan et al.	N/A	N/A
6946251	12/2004	Kurn	N/A	N/A
6974669	12/2004	Mirkin et al.	N/A	N/A
7022479	12/2005	Wagner	N/A	N/A
7034145	12/2005	Shen et al.	N/A	N/A
7155050	12/2005	Sloge	N/A	N/A
7294466	12/2006	McMillan	N/A	N/A
7323309	12/2007	Mirkin et al.	N/A	N/A
7393665	12/2007	Brenner	N/A	N/A
7407757	12/2007	Brenner	N/A	N/A
7424368	12/2007	Huang et al.	N/A	N/A
7432055	12/2007	Pemov et al.	N/A	N/A
7470515	12/2007	Rashtchian et al.	N/A	N/A
7473767	12/2008	Dimitrov	N/A	N/A
7476786	12/2008	Chan et al.	N/A	N/A
7537897	12/2008	Brenner et al.	N/A	N/A
7544473	12/2008	Brenner	N/A	N/A
7635566	12/2008	Brenner	N/A	N/A
7638612	12/2008	Rashtchian et al.	N/A	N/A
7718403	12/2009	Kamberov et al.	N/A	N/A
7771946	12/2009	Kurn	N/A	N/A
7822555	12/2009	Huang et al.	N/A	N/A
7824856	12/2009	Monforte	N/A	N/A
7824889	12/2009	Vogelstein et al.	N/A	N/A
7915015	12/2010	Vogelstein et al.	N/A	N/A
7985546	12/2010	Church et al.	N/A	N/A
8071311	12/2010	Kurn	N/A	N/A
8110351	12/2011	Bosnes	N/A	N/A
8114681	12/2011	Martin et al.	N/A	N/A
8148068	12/2011	Brenner	N/A	N/A
8168385	12/2011	Brenner	N/A	N/A
8206913	12/2011	Kamberov et al.	N/A	N/A
8241850	12/2011	Brenner	N/A	N/A
8298767	12/2011	Brenner et al.	N/A	N/A
8318433	12/2011	Brenner	N/A	N/A
8367051	12/2012	Matyjaszewski et al.	N/A	N/A
8420324	12/2012	Rashtchian et al.	N/A	N/A
8445205	12/2012	Brenner	N/A	N/A
8470996	12/2012	Brenner	N/A	N/A
8476018	12/2012	Brenner	N/A	N/A
8481292	12/2012	Casbon et al.	N/A	N/A
8535889	12/2012	Larson et al.	N/A	N/A
8563274	12/2012	Brenner et al.	N/A	N/A
8603749	12/2012	Gillevet et al.	N/A	N/A

8679756	12/2013	Brenner et al.	N/A	N/A
8685678	12/2013	Casbon et al.	N/A	N/A
8685753	12/2013	Martin et al.	N/A	N/A
8715967	12/2013	Casbon et al.	N/A	N/A
8722368	12/2013	Casbon et al.	N/A	N/A
8728766	12/2013	Casbon et al.	N/A	N/A
8741606	12/2013	Casbon et al.	N/A	N/A
8835110	12/2013	Wang et al.	N/A	N/A
8841071	12/2013	Link	N/A	N/A
8856410	12/2013	Park	N/A	N/A
8865470	12/2013	Yan et al.	N/A	N/A
9150852	12/2014	Samuels et al.	N/A	N/A
9181582	12/2014	Kurn	N/A	N/A
9188586	12/2014	Fan et al.	N/A	N/A
9228229	12/2015	Olson et al.	N/A	N/A
9262376	12/2015	Tsuto	N/A	N/A
9297047	12/2015	Furchak et al.	N/A	N/A
9371598	12/2015	Chee	N/A	N/A
9582877	12/2016	Fu et al.	N/A	N/A
9593365	12/2016	Frisen et al.	N/A	N/A
9644204	12/2016	Hindson et al.	N/A	N/A
9677131	12/2016	Fredriksson et al.	N/A	N/A
9689024	12/2016	Hindson et al.	N/A	N/A
9695468	12/2016	Hindson et al.	N/A	N/A
9787810	12/2016	Chiang	N/A	N/A
9850515	12/2016	McCoy et al.	N/A	N/A
9856530	12/2017	Hindson et al.	N/A	N/A
9868979	12/2017	Chee et al.	N/A	N/A
9879313	12/2017	Chee et al.	N/A	N/A
9905005	12/2017	Fu et al.	N/A	N/A
9938523	12/2017	LaBaer	N/A	N/A
9951386	12/2017	Hindson et al.	N/A	N/A
9988660	12/2017	Rashtchian et al.	N/A	N/A
10002316	12/2017	Fodor et al.	N/A	N/A
10011872	12/2017	Belgrader et al.	N/A	N/A
10017761	12/2017	Weissman et al.	N/A	N/A
10023910	12/2017	Drmanac et al.	N/A	N/A
10030267	12/2017	Hindson et al.	N/A	N/A
10041116	12/2017	Hindson et al.	N/A	N/A
10131958	12/2017	Fan et al.	N/A	N/A
10138518	12/2017	Chun	N/A	N/A
10151003	12/2017	Fan et al.	N/A	N/A
10208343	12/2018	Hindson et al.	N/A	N/A
10227648	12/2018	Hindson et al.	N/A	N/A
10246703	12/2018	Church et al.	N/A	N/A
10253364	12/2018	Hindson et al.	N/A	N/A
10266874	12/2018	Weissleder et al.	N/A	N/A
10273541	12/2018	Hindson et al.	N/A	N/A
10288608	12/2018	Kozlov et al.	N/A	N/A

10294511	12/2018	Sanches-Kuiper et al.	N/A	N/A
10308982	12/2018	Chee	N/A	N/A
10323278	12/2018	Belgrader et al.	N/A	N/A
10337061	12/2018	Hindson et al.	N/A	N/A
10344329	12/2018	Hindson et al.	N/A	N/A
10450607	12/2018	Hindson et al.	N/A	N/A
10550429	12/2019	Harada et al.	N/A	N/A
RE47983	12/2019	Gao et al.	N/A	N/A
11092607	12/2020	Gaublomme et al.	N/A	N/A
11460468	12/2021	Fan	N/A	C12Q 1/6806
11467157	12/2021	Fan	N/A	C12Q 1/6806
11535882	12/2021	Fu et al.	N/A	N/A
2001/0024784	12/2000	Wagner	N/A	N/A
2001/0036632	12/2000	Yu et al.	N/A	N/A
2002/0019005	12/2001	Kamb	N/A	N/A
2002/0051986	12/2001	Baez et al.	N/A	N/A
2002/0065609	12/2001	Ashby	N/A	N/A
2002/0072058	12/2001	Voelker et al.	N/A	N/A
2002/0094116	12/2001	Forst et al.	N/A	N/A
2002/0106666	12/2001	Hayashizaki	N/A	N/A
2002/0132241	12/2001	Fan et al.	N/A	N/A
2002/0168665	12/2001	Okawa	N/A	N/A
2002/0172953	12/2001	Mirkin et al.	N/A	N/A
2002/0187480	12/2001	Brandon	N/A	N/A
2002/0192687	12/2001	Mirkin et al.	N/A	N/A
2003/0003490	12/2002	Fan et al.	N/A	N/A
2003/0013091	12/2002	Dimitrov	N/A	N/A
2003/0032049	12/2002	Wagner	N/A	N/A
2003/0049616	12/2002	Brenner et al.	N/A	N/A
2003/0077611	12/2002	Slepnev	N/A	N/A
2003/0082818	12/2002	Bahnson et al.	N/A	N/A
2003/0087242	12/2002	Mirkin et al.	N/A	N/A
2003/0104436	12/2002	Morris et al.	N/A	N/A
2003/0165935	12/2002	Vann et al.	N/A	N/A
2003/0175908	12/2002	Linnarsson	N/A	N/A
2003/0186251	12/2002	Dunn et al.	N/A	N/A
2003/0207296	12/2002	Park et al.	N/A	N/A
2003/0207300	12/2002	Matray et al.	N/A	N/A
2004/0047769	12/2003	Tanaami	N/A	N/A
2004/0091864	12/2003	French et al.	N/A	N/A
2004/0096368	12/2003	Davis et al.	N/A	N/A
2004/0096892	12/2003	Wang et al.	N/A	N/A
2004/0121342	12/2003	McKeown	N/A	N/A
2004/0146901	12/2003	Morris et al.	N/A	N/A
2004/0147435	12/2003	Hawiger et al.	N/A	N/A
2004/0157243	12/2003	Huang et al.	N/A	N/A
2004/0209298	12/2003	Kamberov et al.	N/A	N/A

2004/0224325	12/2003	Knapp et al.	N/A	N/A
2004/0259118	12/2003	Macevicz	N/A	N/A
2005/0019776	12/2004	Callow et al.	N/A	N/A
2005/0032110	12/2004	Shen et al.	N/A	N/A
2005/0048500	12/2004	Lawton	N/A	N/A
2005/0053952	12/2004	Hong et al.	N/A	N/A
2005/0105077	12/2004	Padmanabhan et al.	N/A	N/A
2005/0170373	12/2004	Monforte	N/A	N/A
2005/0175993	12/2004	Wei	N/A	N/A
2005/0196760	12/2004	Pemov et al.	N/A	N/A
2005/0214825	12/2004	Stuelpnagel	N/A	N/A
2005/0250146	12/2004	McMillan	N/A	N/A
2005/0250147	12/2004	Macevicz	N/A	N/A
2006/0002824	12/2005	Chang et al.	N/A	N/A
2006/0035258	12/2005	Tadakamalla et al.	N/A	N/A
2006/0040297	12/2005	Leamon et al.	N/A	N/A
2006/0041385	12/2005	Bauer	N/A	N/A
2006/0057634	12/2005	Rye	N/A	N/A
2006/0073506	12/2005	Christians et al.	N/A	N/A
2006/0211030	12/2005	Brenner	N/A	N/A
2006/0257902	12/2005	Mendoza et al.	N/A	N/A
2006/0263709	12/2005	Matsumura et al.	N/A	N/A
2006/0263789	12/2005	Kincaid	N/A	N/A
2006/0280352	12/2005	Muschler et al.	N/A	N/A
2006/0281092	12/2005	Wille et al.	N/A	N/A
2006/0286570	12/2005	Rowlen et al.	N/A	N/A
2007/0020640	12/2006	Mccloskey et al.	N/A	N/A
2007/0031829	12/2006	Yasuno et al.	N/A	N/A
2007/0042400	12/2006	Choi et al.	N/A	N/A
2007/0042419	12/2006	Barany et al.	N/A	N/A
2007/0065823	12/2006	Dressman et al.	N/A	N/A
2007/0065844	12/2006	Golub et al.	N/A	N/A
2007/0105090	12/2006	Cassidy et al.	N/A	N/A
2007/0117121	12/2006	Hutchison et al.	N/A	N/A
2007/0117134	12/2006	Kou	N/A	N/A
2007/0117177	12/2006	Luo et al.	N/A	N/A
2007/0133856	12/2006	Dutta-Choudhury	N/A	N/A
2007/0172873	12/2006	Brenner et al.	N/A	N/A
2007/0178478	12/2006	Dhallan et al.	N/A	N/A
2007/0202523	12/2006	Becker et al.	N/A	N/A
2007/0281317	12/2006	Becker et al.	N/A	N/A
2008/0038727	12/2007	Spier	N/A	N/A
2008/0070303	12/2007	West et al.	N/A	N/A
2008/0119736	12/2007	Dentinger	N/A	N/A
2008/0194414	12/2007	Albert et al.	N/A	N/A
2008/0261204	12/2007	Lexow	N/A	N/A
2008/0268508	12/2007	Sowlay	N/A	N/A
2008/0269068	12/2007	Church et al.	N/A	N/A
2008/0274458	12/2007	Latham et al.	N/A	N/A
2008/0299609	12/2007	Kwon et al.	N/A	N/A

2008/0318802	12/2007	Brenner	N/A	N/A
2009/0053669	12/2008	Liu et al.	N/A	N/A
2009/0061513	12/2008	Andersson Svahn et al.	N/A	N/A
2009/0105959	12/2008	Braverman et al.	N/A	N/A
2009/0131269	12/2008	Martin et al.	N/A	N/A
2009/0137407	12/2008	Church et al.	N/A	N/A
2009/0208936	12/2008	Tan et al.	N/A	N/A
2009/0220385	12/2008	Brown et al.	N/A	N/A
2009/0226891	12/2008	Nova et al.	N/A	N/A
2009/0252414	12/2008	Suzuki	N/A	N/A
2009/0253586	12/2008	Nelson et al.	N/A	N/A
2009/0283676	12/2008	Skoglund	N/A	N/A
2009/0290151	12/2008	Agrawal et al.	N/A	N/A
2009/0298709	12/2008	Ma	N/A	N/A
2009/0311694	12/2008	Gallagher et al.	N/A	N/A
2010/0069250	12/2009	White, III	N/A	N/A
2010/0105049	12/2009	Ehrich et al.	N/A	N/A
2010/0105112	12/2009	Holtze et al.	N/A	N/A
2010/0105886	12/2009	Woudenberg et al.	N/A	N/A
2010/0120098	12/2009	Grunenwald et al.	N/A	N/A
2010/0120630	12/2009	Huang et al.	N/A	N/A
2010/0136544	12/2009	Agresti et al.	N/A	N/A
2010/0159533	12/2009	Lipson et al.	N/A	N/A
2010/0167354	12/2009	Kurn	N/A	N/A
2010/0184076	12/2009	Lawton	N/A	N/A
2010/0255471	12/2009	Clarke	N/A	N/A
2010/0267028	12/2009	Pasche	N/A	N/A
2010/0291666	12/2009	Collier et al.	N/A	N/A
2010/0300895	12/2009	Nobile et al.	N/A	N/A
2010/0323348	12/2009	Hamady et al.	N/A	N/A
2010/0330574	12/2009	Whitman	N/A	N/A
2011/0038507	12/2010	Hager	N/A	N/A
2011/0059436	12/2010	Hardin et al.	N/A	N/A
2011/0059556	12/2010	Strey et al.	N/A	N/A
2011/0070584	12/2010	Wohlgemuth et al.	N/A	N/A
2011/0072889	12/2010	Albitar et al.	N/A	N/A
2011/0160078	12/2010	Fodor et al.	N/A	N/A
2011/0201507	12/2010	Rava et al.	N/A	N/A
2011/0230358	12/2010	Rava	N/A	N/A
2011/0244455	12/2010	Larson et al.	N/A	N/A
2011/0245111	12/2010	Chee	N/A	N/A
2011/0263457	12/2010	Krutzik et al.	N/A	N/A
2011/0294689	12/2010	Namsaraev	N/A	N/A
2011/0312511	12/2010	Winqvist et al.	N/A	N/A
2012/0004132	12/2011	Zhang et al.	N/A	N/A
2012/0010091	12/2011	Linnarson	N/A	N/A
2012/0014977	12/2011	Furihata et al.	N/A	N/A
2012/0034607	12/2011	Rothberg et al.	N/A	N/A
2012/0040843	12/2011	Ducree et al.	N/A	N/A

2012/0045844	12/2011	Rothberg et al.	N/A	N/A
2012/0058520	12/2011	Hayashida	N/A	N/A
2012/0058902	12/2011	Livingston et al.	N/A	N/A
2012/0065081	12/2011	Chee	N/A	N/A
2012/0071331	12/2011	Casbon	N/A	N/A
2012/0087862	12/2011	Hood et al.	N/A	N/A
2012/0142018	12/2011	Jiang	N/A	N/A
2012/0149603	12/2011	Cooney et al.	N/A	N/A
2012/0156675	12/2011	Lueerssen et al.	N/A	N/A
2012/0163681	12/2011	Lohse	N/A	N/A
2012/0165219	12/2011	Van Der Zaag et al.	N/A	N/A
2012/0173159	12/2011	Davey et al.	N/A	N/A
2012/0190020	12/2011	Oliphant et al.	N/A	N/A
2012/0202293	12/2011	Martin et al.	N/A	N/A
2012/0220022	12/2011	Ehrlich et al.	N/A	N/A
2012/0220494	12/2011	Samuels et al.	N/A	N/A
2012/0231972	12/2011	Golyshin et al.	N/A	N/A
2012/0252012	12/2011	Armougom et al.	N/A	N/A
2012/0253689	12/2011	Rogan	N/A	N/A
2012/0316074	12/2011	Saxonov	N/A	N/A
2012/0322681	12/2011	Kung et al.	N/A	N/A
2013/0005585	12/2012	Anderson et al.	N/A	N/A
2013/0022977	12/2012	Lapidus et al.	N/A	N/A
2013/0045994	12/2012	Shinozuka et al.	N/A	N/A
2013/0116130	12/2012	Fu et al.	N/A	N/A
2013/0190206	12/2012	Leonard	N/A	N/A
2013/0203047	12/2012	Casbon et al.	N/A	N/A
2013/0210643	12/2012	Casbon et al.	N/A	N/A
2013/0210659	12/2012	Watson et al.	N/A	N/A
2013/0224743	12/2012	Casbon et al.	N/A	N/A
2013/0225418	12/2012	Watson	N/A	N/A
2013/0225623	12/2012	Buxbaum et al.	N/A	N/A
2013/0237458	12/2012	Casbon et al.	N/A	N/A
2013/0267424	12/2012	Casbon et al.	N/A	N/A
2013/0274117	12/2012	Church	N/A	N/A
2013/0323732	12/2012	Anderson et al.	N/A	N/A
2014/0004569	12/2013	Lambowitz et al.	N/A	N/A
2014/0057799	12/2013	Johnson et al.	N/A	N/A
2014/0066318	12/2013	Frisen et al.	N/A	N/A
2014/0147860	12/2013	Kaduchak et al.	N/A	N/A
2014/0155274	12/2013	Xie et al.	N/A	N/A
2014/0155295	12/2013	Hindson et al.	N/A	N/A
2014/0178438	12/2013	Sahin et al.	N/A	N/A
2014/0194324	12/2013	Gormley et al.	N/A	N/A
2014/0206079	12/2013	Malinoski et al.	N/A	N/A
2014/0206547	12/2013	Wang	N/A	N/A
2014/0216128	12/2013	Trotter et al.	N/A	N/A
2014/0227684	12/2013	Hindson et al.	N/A	N/A
2014/0227705	12/2013	Vogelstein et al.	N/A	N/A
2014/0228239	12/2013	McCoy et al.	N/A	N/A

2014/0228255	12/2013	Hindson et al.	N/A	N/A
2014/0235506	12/2013	Hindson et al.	N/A	N/A
2014/0243242	12/2013	Nicol et al.	N/A	N/A
2014/0244742	12/2013	Yu et al.	N/A	N/A
2014/0272952	12/2013	May et al.	N/A	N/A
2014/0274811	12/2013	Arnold	N/A	N/A
2014/0287963	12/2013	Hindson et al.	N/A	N/A
2014/0303005	12/2013	Samuels et al.	N/A	N/A
2014/0309945	12/2013	Park et al.	N/A	N/A
2014/0315211	12/2013	Sugino et al.	N/A	N/A
2014/0322716	12/2013	Robins	N/A	N/A
2014/0357500	12/2013	Vigneault et al.	N/A	N/A
2014/0378322	12/2013	Hindson et al.	N/A	N/A
2014/0378345	12/2013	Hindson et al.	N/A	N/A
2014/0378349	12/2013	Hindson et al.	N/A	N/A
2014/0378350	12/2013	Hindson et al.	N/A	N/A
2015/0005199	12/2014	Hindson et al.	N/A	N/A
2015/0005200	12/2014	Hindson et al.	N/A	N/A
2015/0011396	12/2014	Schroeder et al.	N/A	N/A
2015/0017654	12/2014	Gorfinkel et al.	N/A	N/A
2015/0066385	12/2014	Schnall-levin et al.	N/A	N/A
2015/0072867	12/2014	Soldatov et al.	N/A	N/A
2015/0072873	12/2014	Heinz et al.	N/A	N/A
2015/0080266	12/2014	Volkmuth et al.	N/A	N/A
2015/0099661	12/2014	Fodor et al.	N/A	N/A
2015/0099673	12/2014	Fodor et al.	N/A	N/A
2015/0111256	12/2014	Church et al.	N/A	N/A
2015/0118680	12/2014	Fodor et al.	N/A	N/A
2015/0119255	12/2014	Fodor et al.	N/A	N/A
2015/0119256	12/2014	Fodor et al.	N/A	N/A
2015/0119257	12/2014	Fodor et al.	N/A	N/A
2015/0119258	12/2014	Fodor et al.	N/A	N/A
2015/0119290	12/2014	Fodor et al.	N/A	N/A
2015/0133319	12/2014	Fu et al.	N/A	N/A
2015/0141292	12/2014	Fodor et al.	N/A	N/A
2015/0152409	12/2014	Seitz et al.	N/A	N/A
2015/0203897	12/2014	Robons et al.	N/A	N/A
2015/0211050	12/2014	Iafrate et al.	N/A	N/A
2015/0218620	12/2014	Behlke et al.	N/A	N/A
2015/0225777	12/2014	Hindson et al.	N/A	N/A
2015/0225778	12/2014	Hindson et al.	N/A	N/A
2015/0247182	12/2014	Faham et al.	N/A	N/A
2015/0253237	12/2014	Castellarnau et al.	N/A	N/A
2015/0259734	12/2014	Asbury et al.	N/A	N/A
2015/0275295	12/2014	Wang et al.	N/A	N/A
2015/0298091	12/2014	Weitz	N/A	N/A
2015/0299784	12/2014	Fan et al.	N/A	N/A
2015/0307874	12/2014	Jaitin	N/A	N/A
2015/0329852	12/2014	Nolan	N/A	N/A
2015/0360193	12/2014	Fan et al.	N/A	N/A

2015/0376609	12/2014	Hindson et al.	N/A	N/A
2016/0017320	12/2015	Wang et al.	N/A	N/A
2016/0026758	12/2015	Jabara et al.	N/A	N/A
2016/0053253	12/2015	Salathia et al.	N/A	N/A
2016/0055632	12/2015	Fu et al.	N/A	N/A
2016/0060621	12/2015	Agresti et al.	N/A	N/A
2016/0060682	12/2015	Pregibon et al.	N/A	N/A
2016/0068889	12/2015	Gole et al.	N/A	N/A
2016/0122751	12/2015	LaBaer	N/A	N/A
2016/0122753	12/2015	Mikkelsen et al.	N/A	N/A
2016/0138091	12/2015	Chee et al.	N/A	N/A
2016/0145677	12/2015	Chee et al.	N/A	N/A
2016/0145683	12/2015	Fan et al.	N/A	N/A
2016/0153973	12/2015	Smith	N/A	N/A
2016/0201125	12/2015	Samuels et al.	N/A	N/A
2016/0208322	12/2015	Anderson et al.	N/A	N/A
2016/0222378	12/2015	Fodor et al.	N/A	N/A
2016/0232291	12/2015	Kyriazopoulou- Panagiotopoulou et al.	N/A	N/A
2016/0244742	12/2015	Linnarsson et al.	N/A	N/A
2016/0244828	12/2015	Mason	N/A	N/A
2016/0265027	12/2015	Sanches-Kuiper et al.	N/A	N/A
2016/0265069	12/2015	Fan et al.	N/A	N/A
2016/0266094	12/2015	Ankrum et al.	N/A	N/A
2016/0289669	12/2015	Fan et al.	N/A	N/A
2016/0289670	12/2015	Samuels et al.	N/A	N/A
2016/0298180	12/2015	Chee	N/A	N/A
2016/0312276	12/2015	Fu et al.	N/A	N/A
2016/0320720	12/2015	Murata et al.	N/A	N/A
2016/0355879	12/2015	Kamberov et al.	N/A	N/A
2016/0362730	12/2015	Alexander et al.	N/A	N/A
2017/0044525	12/2016	Kaper et al.	N/A	N/A
2017/0136458	12/2016	Dunne et al.	N/A	N/A
2017/0154421	12/2016	Fu et al.	N/A	N/A
2017/0192013	12/2016	Agresti et al.	N/A	N/A
2017/0260584	12/2016	Zheng et al.	N/A	N/A
2017/0275669	12/2016	Weissleder et al.	N/A	N/A
2017/0314067	12/2016	Shum et al.	N/A	N/A
2017/0342405	12/2016	Fu et al.	N/A	N/A
2017/0342465	12/2016	Shum et al.	N/A	N/A
2017/0342484	12/2016	Shum et al.	N/A	N/A
2017/0344866	12/2016	Fan et al.	N/A	N/A
2018/0002738	12/2017	Wang et al.	N/A	N/A
2018/0016634	12/2017	Hindson et al.	N/A	N/A
2018/0024139	12/2017	Peikon et al.	N/A	N/A
2018/0030522	12/2017	Kamberov et al.	N/A	N/A
2018/0037942	12/2017	Fu et al.	N/A	N/A
2018/0057873	12/2017	Zhou et al.	N/A	N/A

2018/0088112	12/2017	Fan et al.	N/A	N/A
2018/0094312	12/2017	Hindson et al.	N/A	N/A
2018/0094314	12/2017	Hindson et al.	N/A	N/A
2018/0094315	12/2017	Hindson et al.	N/A	N/A
2018/0105808	12/2017	Mikkelsen et al.	N/A	N/A
2018/0112266	12/2017	Hindson et al.	N/A	N/A
2018/0127743	12/2017	Vigneault et al.	N/A	N/A
2018/0142292	12/2017	Hindson et al.	N/A	N/A
2018/0163201	12/2017	Larson	N/A	N/A
2018/0179590	12/2017	Belgrader et al.	N/A	N/A
2018/0179591	12/2017	Belgrader et al.	N/A	N/A
2018/0201923	12/2017	LaBaer	N/A	N/A
2018/0201980	12/2017	Chee et al.	N/A	N/A
2018/0208975	12/2017	Peterson et al.	N/A	N/A
2018/0216174	12/2017	Shum et al.	N/A	N/A
2018/0230527	12/2017	Fang et al.	N/A	N/A
2018/0251825	12/2017	Stoeckius et al.	N/A	N/A
2018/0258482	12/2017	Hindson et al.	N/A	N/A
2018/0276332	12/2017	Fan et al.	N/A	N/A
2018/0282803	12/2017	Belgrader et al.	N/A	N/A
2018/0320241	12/2017	Nolan et al.	N/A	N/A
2018/0340170	12/2017	Belhocine et al.	N/A	N/A
2018/0346969	12/2017	Chang et al.	N/A	N/A
2018/0346970	12/2017	Chang et al.	N/A	N/A
2018/0371536	12/2017	Fu et al.	N/A	N/A
2019/0010552	12/2018	Xu et al.	N/A	N/A
2019/0025304	12/2018	Vigneault et al.	N/A	N/A
2019/0032129	12/2018	Hindson et al.	N/A	N/A
2019/0095578	12/2018	Shum et al.	N/A	N/A
2019/0119726	12/2018	Shum et al.	N/A	N/A
2019/0136316	12/2018	Hindson et al.	N/A	N/A
2019/0136317	12/2018	Hindson et al.	N/A	N/A
2019/0136319	12/2018	Hindson et al.	N/A	N/A
2019/0161743	12/2018	Church et al.	N/A	N/A
2019/0177788	12/2018	Hindson et al.	N/A	N/A
2019/0177800	12/2018	Boutet et al.	N/A	N/A
2019/0203270	12/2018	Amit et al.	N/A	N/A
2019/0203291	12/2018	Hindson et al.	N/A	N/A
2019/0211395	12/2018	Tsao et al.	N/A	N/A
2019/0218276	12/2018	Regev et al.	N/A	N/A
2019/0218607	12/2018	Love et al.	N/A	N/A
2019/0221287	12/2018	Tsujimoto	N/A	N/A
2019/0221292	12/2018	Tsujimoto	N/A	N/A
2019/0256888	12/2018	Weissleder et al.	N/A	N/A
2019/0256907	12/2018	Ryan et al.	N/A	N/A
2019/0292592	12/2018	Shum et al.	N/A	N/A
2019/0338353	12/2018	Belgrader et al.	N/A	N/A
2019/0338357	12/2018	Fan et al.	N/A	N/A
2019/0390253	12/2018	Kennedy et al.	N/A	N/A
2020/0102598	12/2019	Xie et al.	N/A	N/A

2020/0109437	12/2019	Chang et al.	N/A	N/A
2020/0115753	12/2019	Shalek et al.	N/A	N/A
2020/0149037	12/2019	Shum	N/A	N/A
2021/0039582	12/2020	Patton et al.	N/A	N/A
2021/0123044	12/2020	Zhang et al.	N/A	N/A
2021/0132078	12/2020	Peikon et al.	N/A	N/A
2021/0198754	12/2020	Fan et al.	N/A	N/A
2021/0213413	12/2020	Saligrama et al.	N/A	N/A
2021/0214770	12/2020	Prosen et al.	N/A	N/A
2021/0214784	12/2020	Prosen et al.	N/A	N/A
2021/0222163	12/2020	Wu et al.	N/A	N/A
2021/0222244	12/2020	Martin et al.	N/A	N/A
2021/0230582	12/2020	Fu et al.	N/A	N/A
2021/0230583	12/2020	Lam et al.	N/A	N/A
2021/0230666	12/2020	Wu et al.	N/A	N/A
2021/0246492	12/2020	Song et al.	N/A	N/A
2021/0263019	12/2020	Martin et al.	N/A	N/A
2021/0355484	12/2020	Jensen et al.	N/A	N/A
2021/0371909	12/2020	Lazaruk	N/A	N/A
2021/0371914	12/2020	Stoeckius et al.	N/A	N/A
2022/0010361	12/2021	Song et al.	N/A	N/A
2022/0010362	12/2021	Campbell	N/A	N/A
2022/0033810	12/2021	Song et al.	N/A	N/A
2022/0154288	12/2021	Mortimer	N/A	N/A
2022/0162695	12/2021	Sakofsky et al.	N/A	N/A
2022/0162773	12/2021	Sakofsky et al.	N/A	N/A
2022/0178909	12/2021	Huang et al.	N/A	N/A
2022/0214356	12/2021	Henikoff et al.	N/A	N/A
2022/0219170	12/2021	Khurana et al.	N/A	N/A
2022/0220549	12/2021	Shum et al.	N/A	N/A
2022/0267759	12/2021	Sanjana et al.	N/A	N/A
2022/0333185	12/2021	Fu et al.	N/A	N/A
2022/0348904	12/2021	Shum et al.	N/A	N/A
2023/0083422	12/2022	Fu et al.	N/A	N/A
2023/0109336	12/2022	Shum et al.	N/A	N/A
2023/0125113	12/2022	Fan et al.	N/A	N/A
2023/0193372	12/2022	Shum et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2474509	12/2002	CA	N/A
2961210	12/2015	CA	N/A
106460033	12/2016	CN	N/A
107208158	12/2016	CN	N/A
102008025656	12/2008	DE	N/A
1473080	12/2003	EP	N/A
1647600	12/2005	EP	N/A
1845160	12/2006	EP	N/A
2036989	12/2008	EP	N/A

1379693	12/2008	EP	N/A
2204456	12/2009	EP	N/A
2431465	12/2011	EP	N/A
2203749	12/2011	EP	N/A
2511708	12/2011	EP	N/A
2538220	12/2011	EP	N/A
2623613	12/2012	EP	N/A
1745155	12/2013	EP	N/A
2805769	12/2013	EP	N/A
2556171	12/2014	EP	N/A
2970958	12/2016	EP	N/A
3263715	12/2017	EP	N/A
2670863	12/2017	EP	N/A
3136103	12/2017	EP	N/A
2954102	12/2017	EP	N/A
3428290	12/2018	EP	N/A
2970957	12/2018	EP	N/A
3058092	12/2018	EP	N/A
3256606	12/2018	EP	N/A
3327123	12/2018	EP	N/A
2293238	12/1995	GB	N/A
H04108385	12/1991	JP	N/A
2001078768	12/2000	JP	N/A
2005233974	12/2004	JP	N/A
2007504831	12/2006	JP	N/A
2008256428	12/2007	JP	N/A
2013039275	12/2012	JP	N/A
2018509896	12/2017	JP	N/A
WO1989001050	12/1988	WO	N/A
WO1996024061	12/1995	WO	N/A
WO1997010365	12/1996	WO	N/A
WO1999015702	12/1998	WO	N/A
WO1999028505	12/1998	WO	N/A
WO2000058516	12/1999	WO	N/A
WO2001020035	12/2000	WO	N/A
WO2001048242	12/2000	WO	N/A
WO2001053539	12/2000	WO	N/A
WO2002018643	12/2001	WO	N/A
WO2002046472	12/2001	WO	N/A
WO2002056014	12/2001	WO	N/A
WO2002059355	12/2001	WO	N/A
WO2002070684	12/2001	WO	N/A
WO2002072772	12/2001	WO	N/A
WO2002079490	12/2001	WO	N/A
WO2002083922	12/2001	WO	N/A
WO2002101358	12/2001	WO	N/A
WO2003031591	12/2002	WO	N/A
WO2003035829	12/2002	WO	N/A
WO2004017374	12/2003	WO	N/A
WO2004021986	12/2003	WO	N/A

WO2004033669	12/2003	WO	N/A
WO2004066185	12/2003	WO	N/A
WO2004081225	12/2003	WO	N/A
WO2005017206	12/2004	WO	N/A
WO2005021731	12/2004	WO	N/A
WO2005042759	12/2004	WO	N/A
WO2005071110	12/2004	WO	N/A
WO2005080604	12/2004	WO	N/A
WO2005111242	12/2004	WO	N/A
WO2005111243	12/2004	WO	N/A
WO2006026828	12/2005	WO	N/A
WO2006071776	12/2005	WO	N/A
WO2006102264	12/2005	WO	N/A
WO2006137932	12/2005	WO	N/A
WO2007087310	12/2006	WO	N/A
WO2007087312	12/2006	WO	N/A
WO2007147079	12/2006	WO	N/A
WO2008047428	12/2007	WO	N/A
WO2008051928	12/2007	WO	N/A
WO2008057163	12/2007	WO	N/A
WO2008096318	12/2007	WO	N/A
WO2008104380	12/2007	WO	N/A
WO2008147428	12/2007	WO	N/A
WO2008150432	12/2007	WO	N/A
WO2009048530	12/2008	WO	N/A
WO2009148560	12/2008	WO	N/A
WO2009152928	12/2008	WO	N/A
WO2010048605	12/2009	WO	N/A
WO2010059820	12/2009	WO	N/A
WO2010117620	12/2009	WO	N/A
WO2011091393	12/2010	WO	N/A
WO2011106738	12/2010	WO	N/A
WO2011123246	12/2010	WO	N/A
WO2011127099	12/2010	WO	N/A
WO2011143659	12/2010	WO	N/A
WO2011155833	12/2010	WO	N/A
WO2012038839	12/2011	WO	N/A
WO2012041802	12/2011	WO	N/A
WO2012042374	12/2011	WO	N/A
WO2012047297	12/2011	WO	N/A
WO2012048341	12/2011	WO	N/A
WO2012083225	12/2011	WO	N/A
WO2012099896	12/2011	WO	N/A
WO2012103154	12/2011	WO	N/A
WO2012106385	12/2011	WO	N/A
WO2012106546	12/2011	WO	N/A
WO2012108864	12/2011	WO	N/A
WO2012112804	12/2011	WO	N/A
WO2012129363	12/2011	WO	N/A
WO2012140224	12/2011	WO	N/A

WO2012142213	12/2011	WO	N/A
WO2012148477	12/2011	WO	N/A
WO2012148497	12/2011	WO	N/A
WO2012149042	12/2011	WO	N/A
WO2012156744	12/2011	WO	N/A
WO2012162267	12/2011	WO	N/A
WO2012177639	12/2011	WO	N/A
WO2013019075	12/2012	WO	N/A
WO2013070990	12/2012	WO	N/A
WO2013096802	12/2012	WO	N/A
WO2013117595	12/2012	WO	N/A
WO2013130674	12/2012	WO	N/A
WO2013137737	12/2012	WO	N/A
WO2013148525	12/2012	WO	N/A
WO2013173394	12/2012	WO	N/A
WO2013176767	12/2012	WO	N/A
WO2013177206	12/2012	WO	N/A
WO2013188831	12/2012	WO	N/A
WO2013188872	12/2012	WO	N/A
WO2013191775	12/2012	WO	N/A
WO2014015084	12/2013	WO	N/A
WO2014015098	12/2013	WO	N/A
WO2014018093	12/2013	WO	N/A
WO2014018460	12/2013	WO	N/A
WO2014028537	12/2013	WO	N/A
WO2014031997	12/2013	WO	N/A
WO-2014031997	12/2013	WO	G01N 33/54306
WO2014065756	12/2013	WO	N/A
WO2014093676	12/2013	WO	N/A
WO2014108850	12/2013	WO	N/A
WO2014124046	12/2013	WO	N/A
WO2014124336	12/2013	WO	N/A
WO2014124338	12/2013	WO	N/A
WO2014126937	12/2013	WO	N/A
WO2014144495	12/2013	WO	N/A
WO2014145458	12/2013	WO	N/A
WO2014176575	12/2013	WO	N/A
WO2014200767	12/2013	WO	N/A
WO2014201273	12/2013	WO	N/A
WO2014204939	12/2013	WO	N/A
WO2014210223	12/2013	WO	N/A
WO2014210225	12/2013	WO	N/A
WO2014210353	12/2013	WO	N/A
WO2015002908	12/2014	WO	N/A
WO2018015365	12/2014	WO	N/A
WO2015017586	12/2014	WO	N/A
WO2015031691	12/2014	WO	N/A
WO2015035087	12/2014	WO	N/A
WO2015044428	12/2014	WO	N/A

WO2015047186	12/2014	WO	N/A
WO2015057985	12/2014	WO	N/A
WO2014071361	12/2014	WO	N/A
WO2015061844	12/2014	WO	N/A
WO2015103339	12/2014	WO	N/A
WO2015117163	12/2014	WO	N/A
WO2015134787	12/2014	WO	N/A
WO2015160439	12/2014	WO	N/A
WO2015168161	12/2014	WO	N/A
WO2015179339	12/2014	WO	N/A
WO2015200869	12/2014	WO	N/A
WO2015200893	12/2014	WO	N/A
WO2016044227	12/2015	WO	N/A
WO2016049418	12/2015	WO	N/A
WO2016061517	12/2015	WO	N/A
WO2016100976	12/2015	WO	N/A
WO2016118915	12/2015	WO	N/A
WO2016126871	12/2015	WO	N/A
WO2016130578	12/2015	WO	N/A
WO2016160965	12/2015	WO	N/A
WO2016138496	12/2015	WO	N/A
WO2016138500	12/2015	WO	N/A
WO2016145409	12/2015	WO	N/A
WO2016149418	12/2015	WO	N/A
WO2016160844	12/2015	WO	N/A
WO2016168825	12/2015	WO	N/A
WO2016172373	12/2015	WO	N/A
WO2016176091	12/2015	WO	N/A
WO2016190795	12/2015	WO	N/A
WO2016191272	12/2015	WO	N/A
WO2017032808	12/2016	WO	N/A
WO2017040306	12/2016	WO	N/A
WO2017044574	12/2016	WO	N/A
WO2017053905	12/2016	WO	N/A
WO2017079593	12/2016	WO	N/A
WO2017087873	12/2016	WO	N/A
WO2017096239	12/2016	WO	N/A
WO2017097939	12/2016	WO	N/A
WO2017117358	12/2016	WO	N/A
WO2017125508	12/2016	WO	N/A
WO2017139690	12/2016	WO	N/A
WO2017164936	12/2016	WO	N/A
WO2017173328	12/2016	WO	N/A
WO2017205691	12/2016	WO	N/A
WO2018017949	12/2017	WO	N/A
WO2018018008	12/2017	WO	N/A
WO2018020489	12/2017	WO	N/A
WO2018031631	12/2017	WO	N/A
WO2018058073	12/2017	WO	N/A

WO-2018058073	12/2017	WO	C12N 15/1006
WO2018064640	12/2017	WO	N/A
WO2018075693	12/2017	WO	N/A
WO2018111872	12/2017	WO	N/A
WO2018115852	12/2017	WO	N/A
WO2018119447	12/2017	WO	N/A
WO2018132635	12/2017	WO	N/A
WO2018140966	12/2017	WO	N/A
WO2018144240	12/2017	WO	N/A
WO2018144813	12/2017	WO	N/A
WO2018174827	12/2017	WO	N/A
WO2018217862	12/2017	WO	N/A
WO2018218222	12/2017	WO	N/A
WO2018222548	12/2017	WO	N/A
WO2018226293	12/2017	WO	N/A
WO2019055852	12/2018	WO	N/A
WO2019076768	12/2018	WO	N/A
WO2019084046	12/2018	WO	N/A
WO2019099906	12/2018	WO	N/A
WO2019113457	12/2018	WO	N/A
WO2019113499	12/2018	WO	N/A
WO2019113506	12/2018	WO	N/A
WO2019113533	12/2018	WO	N/A
WO2019118355	12/2018	WO	N/A
WO2019126789	12/2018	WO	N/A
WO2019157529	12/2018	WO	N/A
WO2019178164	12/2018	WO	N/A
WO2019213237	12/2018	WO	N/A
WO2019213294	12/2018	WO	N/A
WO2019218101	12/2018	WO	N/A
WO2020028266	12/2019	WO	N/A
WO2020033164	12/2019	WO	N/A
WO2020037065	12/2019	WO	N/A
WO2020046833	12/2019	WO	N/A
WO2020072380	12/2019	WO	N/A
WO2020097315	12/2019	WO	N/A
WO2020123384	12/2019	WO	N/A
WO2020131699	12/2019	WO	N/A
WO2020154247	12/2019	WO	N/A
WO2020159757	12/2019	WO	N/A
WO2020167920	12/2019	WO	N/A
WO2020214642	12/2019	WO	N/A
WO2020219721	12/2019	WO	N/A
WO2020242377	12/2019	WO	N/A
WO2021092386	12/2020	WO	N/A
WO2021142233	12/2020	WO	N/A
WO2021146207	12/2020	WO	N/A
WO2021146219	12/2020	WO	N/A
WO2021146636	12/2020	WO	N/A

WO2021155057	12/2020	WO	N/A
WO2021155284	12/2020	WO	N/A
WO2021163374	12/2020	WO	N/A
WO2021168015	12/2020	WO	N/A
WO2021168261	12/2020	WO	N/A
WO20210178199	12/2020	WO	N/A
WO2021247593	12/2020	WO	N/A
WO2022015667	12/2021	WO	N/A
WO2022026909	12/2021	WO	N/A
WO2022040453	12/2021	WO	N/A
WO2022143221	12/2021	WO	N/A
WO2022256324	12/2021	WO	N/A
WO2023/034739	12/2022	WO	N/A
WO2023/034789	12/2022	WO	N/A
WO2023/034790	12/2022	WO	N/A
WO2023/034794	12/2022	WO	N/A
WO2023/034872	12/2022	WO	N/A
WO2023/039433	12/2022	WO	N/A

OTHER PUBLICATIONS

Armbrecht et al (Microsyst Nanoeng. Nov. 4, 2019; 5:55) (Year: 2019). cited by examiner

Adey et al., "Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition," Genome Biology 2010, 11(R19), in 17 pages. cited by applicant

Ahern, "Biochemical, Reagent Kits Offer Scientists Good Return on Investment," The Scientist 1995, 9(15), in 5 pages. cited by applicant

Bolivar et al., "Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients," Modern Pathology 2019, 32(3), 405-414. cited by applicant

Brouillette et al., "A Simple and Novel Method for RNA-seq Library Preparation of Single Cell cDNA Analysis by Hyperactive Tn5 Transposase," Developmental Dynamics 2012, 241, 1584-1590. cited by applicant

Buenrosto et al., "Transposition of native chromatin for multimodal regulatory analysis and personal epigenomics," Nat Methods 2013, 10(12), 1213-1218. cited by applicant

Buenrosto et al., "ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide," Curr Protoc Mol Biol 2016, 109, 1-21. cited by applicant

Chang et al., "Single-cell protein and gene expression profiling of stem memory T cells by BD Ab-seq," Annual Joint Meeting of the American Society for Cell Biology and the European Molecular Biology Organization 2017, 28(26), p. 1896. cited by applicant

Chen et al., "High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell," Nature Biotechnology 2019, 37, 1452-1457. cited by applicant

Dengl et al., "Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery," Immunol Rev. 2016, 270, 165-177. cited by applicant

Examination Report dated Oct. 8, 2021 in European Patent Application No. 18716877.8. cited by applicant

Examination Report dated Nov. 18, 2021 in European Patent Application No. 19724003.9. cited by applicant

Examination Report dated Nov. 24, 2021 in European Patent Application No. 19762517.1. cited by applicant

Examination Report dated Dec. 6, 2021 in European Patent Application No. 18703156.2. cited by

applicant

Examination Report dated Dec. 9, 2021 in European Patent Application No. 19723988.2. cited by applicant

Examination Report dated Apr. 7, 2022 in Singapore Patent Application No. 10201806890V. cited by applicant

Examination Report dated Apr. 8, 2022 in Australian Patent Application No. 2018281745. cited by applicant

Extended European Search Report dated May 28, 2021 in European Patent Application No. 20209777.0. cited by applicant

Final Office Action dated Jun. 15, 2021 in U.S. Appl. No. 15/084,307. cited by applicant

Final Office Action dated Jul. 15, 2021 in U.S. Appl. No. 16/836,750. cited by applicant

Final Office Action dated Aug. 10, 2021 in U.S. Appl. No. 16/012,584. cited by applicant

Final Office Action dated Aug. 27, 2021 in U.S. Appl. No. 15/055,407. cited by applicant

Final Office Action dated Sep. 24, 2021 in U.S. Appl. No. 16/788,743. cited by applicant

Final Office Action dated Oct. 1, 2021 in U.S. Appl. No. 16/677,012. cited by applicant

Final Office Action dated Nov. 2, 2021 in U.S. Appl. No. 16/789,311. cited by applicant

Final Office Action dated Jan. 18, 2022 in U.S. Appl. No. 16/588,405. cited by applicant

Final Office Action dated Feb. 23, 2022 in U.S. Appl. No. 16/707,780. cited by applicant

Final Office Action dated Mar. 15, 2022 in U.S. Appl. No. 16/374,626. cited by applicant

Final Office Action dated Mar. 25, 2022 in U.S. Appl. No. 16/551,620. cited by applicant

Final Office Action dated Apr. 12, 2022 in U.S. Appl. No. 15/084,307. cited by applicant

Final Office Action dated May 26, 2022 in U.S. Appl. No. 16/747,737. cited by applicant

Final Office Action dated Jun. 14, 2022 in U.S. Appl. No. 15/055,407. cited by applicant

Final Office Action dated Aug. 23, 2022 in U.S. Appl. No. 16/012,584. cited by applicant

Final Office Action dated Nov. 15, 2022 in U.S. Appl. No. 16/525,054. cited by applicant

Fitzgerald and Grivel, "A Universal Nanoparticle Cell Secretion Capture Assay," Cytometry Part A 2012, 83A(2), 205-211. cited by applicant

Gertz et al., "Transposase mediated construction of RNA-seq libraries," Genome Research 2012, 22, 134-141. cited by applicant

Goodridge et al., "Synthesis of Albumin and Malic Enzyme in Wheat-Germ Lysates and *Xenopus laevis* Oocytes Programmed with Chicken-Liver Messenger RNA," Eur. J. Biochem. 1979, 96, 1-8. cited by applicant

Gratton et al., "Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo," Nature Medicine 2003, 9(3), 357-362. cited by applicant

International Search Report and Written Opinion dated May 4, 2021 in PCT Application No. PCT/US2021/013109. cited by applicant

International Search Report and Written Opinion dated May 11, 2021 in PCT Application No. PCT/US2021/013748. cited by applicant

International Search Report and Written Opinion dated Jul. 15, 2021 in PCT Application No. PCT/US2021/019475. cited by applicant

International Search Report and Written Opinion dated Jul. 20, 2021 in PCT Application No. PCT/US2021/015898. cited by applicant

International Search Report and Written Opinion dated Aug. 31, 2021 in PCT Application No. PCT/US2021/035270. cited by applicant

International Search Report and Written Opinion dated Sep. 22, 2021, in PCT Application No. PCT/US2021/013747. cited by applicant

International Search Report and Written Opinion dated Oct. 12, 2021, in PCT Application No. PCT/US2021/041327. cited by applicant

International Search Report and Written Opinion dated Oct. 29, 2021, in PCT Application No.

PCT/US2021/032319. cited by applicant
International Search Report and Written Opinion dated Nov. 12, 2021, in PCT Application No. PCT/US2021/044036. cited by applicant
International Search Report and Written Opinion dated Mar. 10, 2022, in PCT Application No. PCT/US2021/060206. cited by applicant
International Search Report and Written Opinion dated Apr. 12, 2022, in PCT Application No. PCT/US2021/059573. cited by applicant
International Search Report and Written Opinion dated Mar. 11, 2022, in PCT Application No. PCT/US2021/060197. cited by applicant
International Search Report and Written Opinion dated Apr. 5, 2022, in PCT Application No. PCT/US2021/062473. cited by applicant
International Search Report and Written Opinion dated Jun. 8, 2022, in PCT Application No. PCT/US2022/021015. cited by applicant
International Search Report and Written Opinion dated Jul. 29, 2022, in PCT Application No. PCT/US2022/029023. cited by applicant
International Search Report and Written Opinion dated Jul. 29, 2022, in PCT Application No. PCT/US2022/029057. cited by applicant
Invitation to Pay Fees dated May 25, 2021 in PCT Application No. PCT/US2021/015898. cited by applicant
Invitation to Pay Additional Search Fees dated Sep. 8, 2021 in PCT Application No. PCT/US2021/032319. cited by applicant
Invitation to Provide Informal Clarification dated Jun. 9, 2021 in PCT Application No. PCT/US2021/019475. cited by applicant
Jacobsen et al., "33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer," Journal for Immunotherapy of Cancer 2018, 6(S1), p. 56. cited by applicant
Janeway et al., "Structural variation in immunoglobulin constant regions," Immunology: The Immune System in Health and Disease 1999, 101-103. cited by applicant
Lake et al., "Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain," Nature Biotechnology 2018, 36(1), 70-80. cited by applicant
Lan et al., "Droplet barcoding for massively parallel single-molecule deep sequencing," Nature Communications 2016, 7(11784), in 10 pages. cited by applicant
Livingstone, "rRNA depletion, poly(A) enrichment, or exonuclease treatment?" Tebu-Bio Blog 2015, in 1 page. cited by applicant
Lutz et al., "Isolation and analysis of high quality nuclear DNA with reduced organellar DNA for plant genome sequencing and resequencing," BMC Biotechnology 2011, 11(54), in 9 pages. cited by applicant
Mair et al., "A Targeted Multi-omic Analysis Approach Measures Protein Expression and Low-Abundance Transcripts on the Single-Cell Level", Cell Reports 2020, 31(1), 107499, in 20 pages. cited by applicant
Minnoye et al., "Chromatin accessibility profiling methods," Nature Reviews Method Primers 2021, 1-24. cited by applicant
Monneron, "One-step Isolation and Characterization of Nuclear Membranes, 1974 Electron Microscopy and Composition of Biological Membranes and Envelops," The Royal Publishing Society 1974, 268, 101-108. cited by applicant
Non-Final Office Action dated May 18, 2021 in U.S. Appl. No. 16/535,080. cited by applicant
Non-Final Office Action dated Aug. 17, 2021 in U.S. Appl. No. 16/551,620. cited by applicant
Non-Final Office Action dated Aug. 19, 2021 in U.S. Appl. No. 16/781,814. cited by applicant
Non-Final Office Action dated Aug. 31, 2021 in U.S. Appl. No. 15/715,028. cited by applicant
Non-Final Office Action dated Sep. 1, 2021 in U.S. Appl. No. 16/789,358. cited by applicant

Non-Final Office Action dated Sep. 14, 2021 in U.S. Appl. No. 16/707,780. cited by applicant
Non-Final Office Action dated Sep. 28, 2021 in U.S. Appl. No. 16/400,885. cited by applicant
Non-Final Office Action dated Sep. 30, 2021 in U.S. Appl. No. 16/374,626. cited by applicant
Non-Final Office Action dated Oct. 1, 2021 in U.S. Appl. No. 16/677,012. cited by applicant
Non-Final Office Action dated Oct. 8, 2021 in U.S. Appl. No. 16/400,866. cited by applicant
Non-Final Office Action dated Dec. 15, 2021 in U.S. Appl. No. 15/875,816. cited by applicant
Non-Final Office Action dated Dec. 21, 2021 in U.S. Appl. No. 15/055,407. cited by applicant
Non-Final Office Action dated Jan. 6, 2022 in U.S. Appl. No. 15/084,307. cited by applicant
Non-Final Office Action dated Feb. 2, 2022 in U.S. Appl. No. 16/747,737. cited by applicant
Non-Final Office Action dated Feb. 9, 2022 in U.S. Appl. No. 16/525,054. cited by applicant
Non-Final Office Action dated Apr. 5, 2022 in U.S. Appl. No. 16/400,885. cited by applicant
Non-Final Office Action dated Apr. 8, 2022 in U.S. Appl. No. 16/232,287. cited by applicant
Non-Final Office Action dated May 3, 2022 in U.S. Appl. No. 16/012,584. cited by applicant
Non-Final Office Action dated May 11, 2022 in U.S. Appl. No. 16/588,405. cited by applicant
Non-Final Office Action dated May 19, 2022 in U.S. Appl. No. 16/459,444. cited by applicant
Non-Final Office Action dated Jul. 7, 2022 in U.S. Appl. No. 16/788,743. cited by applicant
Non-Final Office Action dated Jul. 7, 2022 in U.S. Appl. No. 16/677,012. cited by applicant
Non-Final Office Action dated Jul. 18, 2022 in U.S. Appl. No. 16/551,620. cited by applicant
Non-Final Office Action dated Jul. 27, 2022 in U.S. Appl. No. 16/747,737. cited by applicant
Non-Final Office Action dated Oct. 13, 2022 in U.S. Appl. No. 17/147,272. cited by applicant
Notice of Allowance dated Aug. 16, 2021 in Japanese Patent Application No. 2018-512152. cited by applicant
Notice of Allowance dated Nov. 16, 2021 in U.S. Appl. No. 16/836,750. cited by applicant
Notice of Allowance dated Jan. 24, 2022 in Korean Patent Application No. 16/836,750. cited by applicant
Notice of Allowance dated Feb. 9, 2022 in U.S. Appl. No. 16/781,814. cited by applicant
Notice of Allowance dated Feb. 11, 2022 in Chinese Patent Application No. 201680007351.2. cited by applicant
Notice of Allowance dated Feb. 16, 2022 in U.S. Appl. No. 15/875,816. cited by applicant
Notice of Allowance dated Feb. 21, 2022 in Korean Patent Application No. 10-2020-7033213. cited by applicant
Notice of Allowance dated Apr. 11, 2022 in U.S. Appl. No. 15/134,967. cited by applicant
Notice of Allowance dated Apr. 25, 2022 in Korean Patent Application No. 10-2018-7008560. cited by applicant
Notice of Allowance dated Apr. 27, 2022 in U.S. Appl. No. 16/400,886. cited by applicant
Notice of Allowance dated May 9, 2022 in Australian Patent Application No. 2018281745. cited by applicant
Notice of Allowance dated May 15, 2022 in Japanese Patent Application No. 2019-540515. cited by applicant
Notice of Allowance dated May 23, 2022 in U.S. Appl. No. 15/715,028. cited by applicant
Notice of Allowance dated May 26, 2022 in Korean Patent Application No. 10-2019-7038794. cited by applicant
Notice of Allowance dated Jun. 6, 2022 in U.S. Appl. No. 16/789,358. cited by applicant
Notice of Allowance dated Jul. 20, 2022 in U.S. Appl. No. 16/707,780. cited by applicant
Notice of Allowance dated Aug. 9, 2022 in U.S. Appl. No. 16/232,287. cited by applicant
Notice of Allowance dated Sep. 26, 2022, 2022 in U.S. Appl. No. 15/084,307. cited by applicant
Notice of Allowance dated Oct. 17, 2022, 2022 in U.S. Appl. No. 16/400,885. cited by applicant
Notice of Allowance dated Oct. 20, 2022 in Australian Patent Application No. 2019204928. cited by applicant
Notice of Allowance dated Oct. 21, 2022 in European Patent Application No. 19762517.1. cited by

applicant
Notice of Allowance dated Oct. 24, 2022 in European Patent Application No. 20708266.0. cited by applicant
Notice of Allowance dated Nov. 7, 2022 in U.S. Appl. No. 16/012,584. cited by applicant
Novus Biologicals, "Fixation and Permeability in ICC IF," Novus Biologicals 2021, 1-3. cited by applicant
Nowak et al., "Does the KIR2DS5 gene protect from some human diseases?," PLoS One 2010, 5(8), in 6 pages. cited by applicant
Office Action dated Jul. 26, 2021 in Korean Patent Application No. 10-2019-7011635. cited by applicant
Office Action dated Jul. 28, 2021 in Korean Patent Application No. 10-2020-7033213. cited by applicant
Office Action dated Aug. 13, 2021 in Chinese Patent Application No. 2017800587991. cited by applicant
Office Action dated Aug. 27, 2021 in Chinese Patent Application No. 2016800076525. cited by applicant
Office Action dated Aug. 30, 2021 in Japanese Patent Application No. 2019-540515. cited by applicant
Office Action dated Aug. 31, 2021, in Korean Patent Application No. 10-2019-7038794. cited by applicant
Office Action dated Sep. 14, 2021, in Chinese Patent Application No. 2016800523302. cited by applicant
Office Action dated Oct. 21, 2021, in Chinese Patent Application No. 2016800073512. cited by applicant
Office Action dated Nov. 2, 2021, in Japanese Patent Application No. 2017-549390. cited by applicant
Office Action dated Dec. 23, 2021, in Japanese Patent Application No. 2019-566787. cited by applicant
Office Action dated Dec. 17, 2021 in Korean Patent Application No. 10-2018-7008560. cited by applicant
Office Action dated Jan. 13, 2022 in Chinese Patent Application No. 2017800587991. cited by applicant
Office Action dated Feb. 9, 2022 in Japanese Patent Application No. 2019-540515. cited by applicant
Office Action dated Mar. 7, 2022 in Korean Patent Application No. 10-2022-7004715. cited by applicant
Office Action dated May 17, 2022 in Australian Patent Application No. 2019204928. cited by applicant
Office Action dated May 24, 2022 in European Patent Application No. 20708266.0. cited by applicant
Office Action dated Jun. 28, 2022 in European Patent Application No. 16719706.0. cited by applicant
Office Action dated Aug. 2, 2022 in European Patent Application No. 19765601.0. cited by applicant
Office Action dated Aug. 1, 2022 in Korean Patent Application No. 10-2022-7017261. cited by applicant
O'Shea et al., "Analysis of T Cell Receptor Beta Chain CDR3 Size Using RNA Extracted from Formalin Fixed Paraffin Wax Embedded Tissue," Journal of Clinical Pathology 1997, 50(10), 811-814. cited by applicant
Prevette et al., "Polycation-Induced Cell Membrane Permeability Does Not Enhance Cellular

Uptake or Expression Efficiency of Delivered DNA,” *Molecular Pharmaceutics* 2010, 7(3), 870-883. cited by applicant

Pringle et al., “In Situ Hybridization Demonstration of Poly-Adenylated RNA Sequences in Formalin-Fixed Paraffin Sections Using a Biotinylated Oligonucleotide Poly d(T) Probe,” *Journal of Pathology* 1989, 158, 279-286. cited by applicant

Quail et al., “SASI-Seq: sample assurance Spike-Ins, and highly differentiating 384 barcoding for Illumina sequencing,” *BMC Genomics* 2014, 15(110), in 13 pages. cited by applicant

Restriction Requirement dated Jun. 4, 2021 in U.S. Appl. No. 16/551,620. cited by applicant

Restriction Requirement dated Aug. 8, 2022 in U.S. Appl. No. 17/163,177. cited by applicant

Restriction Requirement dated Aug. 11, 2022 in U.S. Appl. No. 17/091,639. cited by applicant

Restriction Requirement dated Aug. 19, 2022 in U.S. Appl. No. 17/147,283. cited by applicant

Restriction Requirement dated Sep. 19, 2022 in U.S. Appl. No. 16/934,530. cited by applicant

Restriction Requirement dated Oct. 21, 2022 in U.S. Appl. No. 17/320,052. cited by applicant

Restriction Requirement dated Nov. 8, 2022 in U.S. Appl. No. 17/157,872. cited by applicant

Shapiro et al., “Single-cell sequencing-based technologies will revolutionize whole-organism science,” *Nature Reviews Genetics* 2013, 14, 618-629. cited by applicant

Song et al., DNase-seq: a high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells, *Cold Spring Harb Protoc* 2010, 2, in 13 pages. cited by applicant

Sos et al., “Characterization of chromatin accessibility with a transposome hypersensitive sites sequencing (THS-seq) assay,” *Genome Biology* 2016, 17(20), in 15 pages. cited by applicant

Takara Bio, “SMARTer Human BCR IgG IgM H/K/L Profiling Kit User Manual,” Takara Bio USA Inc. 2019, 1-22. cited by applicant

Trzupek et al., “Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis”, *Genome Medicine* 2020, 12(1), in 22 pages. cited by applicant

Wang et al., “Tagmentation-based whole-genome bisulfite sequencing,” *Nature Protocols* 2013, 8(10), 2022-2032. cited by applicant

Yang & Zhao, “Quantitative Analysis of Nonoxynol-9 in Blood,” *Contraception* 1991, 43(2), 161-166. cited by applicant

Zhang et al., “Immunoaffinity Purification of Plasma Membrane with Secondary Antibody Superparamagnetic Beads,” *Journal of Proteome* 2006, 6, 34-43. cited by applicant

Zhao et al., “Methylated DNA Immunoprecipitation and High-Throughput Sequencing (MeDIP-seq) Using Low Amounts of Genomic DNA,” *Cellular Reprogramming* 2014, 16(3), in 20 pages. cited by applicant

10X Genomics, Inc., 2019, User Guide: Visium Spatial Gene Expression Reagent Kits, www.10xGenomics.com, 76 pp. cited by applicant

2018 Top 10 Innovations, *The Scientist Magazine®* (2018). Available at: <https://www.thescientist.com/features/2018-top-10-innovations-65140>, 16 pp. cited by applicant

Achim et al., “High-throughput spatial mapping of single-cell RNA-seq data to tissue of origin,” *Nature Biotechnology* 2015, 33(5), 503-511. cited by applicant

Advisory Action dated Nov. 29, 2019 in U.S. Appl. No. 15/084,307. cited by applicant

Advisory Action dated Dec. 2, 2019 in U.S. Appl. No. 15/055,407. cited by applicant

Advisory Action dated Aug. 25, 2020 in U.S. Appl. No. 15/084,307. cited by applicant

Agasti et al., “Photocleavable DNA barcode-antibody conjugates allow sensitive and multiplexed protein analysis in single cell,” *J Am Chem Soc.* 2012, 134(45), 18499-18502. cited by applicant

Alexandra M. Ewing of Richards, Layton and Finger, P.A., Entry of Appearance dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 1 pp. cited by applicant

Alkan et al., “Personalized copy No. and segmental duplication maps using next-generation sequencing,” *Nat Genet.* 2009, 41(10):1061-1067. cited by applicant

Anderson, "Study Describes RNA Sequencing Applications for Molecular Indexing Methods," GenomeWeb 2014, 5 pp. cited by applicant

Ansorge, "Next-generation DNA sequencing techniques," New Biotechnology 2009, 25(4), 195-203. cited by applicant

Applied Biosystems, Apr. 2008, SOLiD™ System Barcoding, Application Note, 4 pp. cited by applicant

Argawal et al., "Counting Single Native Biomolecules and Intact Viruses with Color-Coded Nanoparticles," Analytical Chemistry 2006, 78, 1061-1070. cited by applicant

Arsalan et al., "An efficient algorithm for the stochastic simulation of the hybridization of DNA to microarrays," BMC Bioinformatics 2009, 10(411), 1-17. cited by applicant

Atanur et al., "The genome sequence of the spontaneously hypertensive rat: Analysis and functional significance." Genome Res. 2010, 20(6), 791-803. cited by applicant

Audic et al., "The Significance of Digital Gene Expression Profiles," Genome Res. 1997, 7, 986-995. cited by applicant

Baek et al., "Development of Hydrogel TentaGel Shell-Core Beads for Ultra-high Throughput Solution Phase Screening of Encoded OBOC Combinatorial Small Molecule Libraries," J. Comb Chem. 2009, 11(1), 91-102. cited by applicant

BD Life Sciences, 2018, BD AbSeq antibody-oligo conjugates, www.bd.com/genomics, 2 pp. cited by applicant

BD Life Sciences, 2018, BD AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mRNA and protein quantification, www.bd.com/genomics, 7 pp. cited by applicant

Bendall et al., "Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum," Science 2011, 332(6030), 687-696. cited by applicant

Bionumbers, Aug. 21, 2010, "Useful fundamental Nos. in molecular biology," <http://bionumbers.hms.harvard.edu/KeyNumbers.aspx>, 1-4. cited by applicant

Biosciences Product Catalogue, Dynal® Catalog 1999, Oslo, Norway, 49-51. cited by applicant

Bioscribe "Massively parallel sequencing technology for single-cell gene expression published" (press release), PhysOrg 2015, 1-2. cited by applicant

Blainey, "The future is now: single-cell genomics of bacteria and archaea," FEMS Microbiol Rev. 2013, 37(3), 407-427. cited by applicant

Bogdanova et al., "Normalization of full-length enriched cDNA," Molecular Biosystems 2008, 4(3), 205-212. cited by applicant

Bonaldo et al., "Normalization and Subtraction: Two Approaches to facilitate Gene Discovery," Genome Res. 1996, 6, 791-806. cited by applicant

Bontoux et al., "Integrating whole transcriptome assays on a lab-on-a-chip for single cell gene profiling", Lab on a Chip 2008, 8(3), 443-450. cited by applicant

Bose et al., "Scalable microfluidics for single-cell RNA printing and sequencing," Genome Biology 2015, 16(120), 1-16. cited by applicant

Brady et al., "Construction of cDNA libraries form single cells", Methods in Enzymology 1993, (225), 611-623. cited by applicant

Braha et al., "Simultaneous stochastic sensing of divalent metal ions," Nature Biotechnology 2000, 18, 1005-1007. cited by applicant

Bratke et al., "Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood," Eur J Immunol. 2005, 35, 2608-2616. cited by applicant

Brenner et al., "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays," Nature Biotechnology 2000, 18, 630-634. cited by applicant

Brenner et al., "In vitro cloning of complex mixtures of DNA on microbeads: Physical separation of differentially expressed cDNAs," PNAS 2000, 97(4), 1665-1670. cited by applicant

Brinza et al., "Detection of somatic mutations at 0.1% frequency from cfDNA in peripheral blood with a multiplex next-generation sequencing assay," Conference Poster, AACR 107th Annual Meeting, Apr. 16-20, 2016, 1 p. cited by applicant

Brisco et al., "Quantification of RNA integrity and its use for measurement of transcript number," *Nucleic Acids Research* 2012, 40(18), e144, 1-9. cited by applicant

Brodin et al., "Challenges with Using Primer IDs to Improve Accuracy of Next Generation Sequencing," *PLoS One* 2015, 19(3), 1-12. cited by applicant

Buggenum et al., "A covalent and cleavable antibody DNA conjugation strategy for sensitive protein detection via immunoPCR," *Scientific Reports* 2016, 6(22675), 1-12. cited by applicant

Bustin, "Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays," *Journal of Molecular Endocrinology* 2000, 25, 169-193. cited by applicant

Butkus, "Cellular research set to launch first gene expression platform using 'molecular indexing' technology," *GenomeWeb* 2014, 1-5. cited by applicant

Cai, "Turning single cells in microarrays by super-resolution bar-coding," *Briefings in Functional Genomics* 2012, 12(2), 75-80. cited by applicant

Cao et al., "Comprehensive single-cell transcriptional profiling of a multicellular organism," *Science* 2017, 357, 661-667. cited by applicant

Carr et al., "Inferring relative proportions of DNA variants from sequencing electropherograms," *Bioinformatics* 2009, 25(24), 3244-3250. cited by applicant

Caruccio et al., "Nextera (TM) Technology for NGS DNA Library Preparation: Simultaneous Fragmentation and Tagging by in Vitro Transposition," *EpiBio* 2009, 16(3), 4-6. cited by applicant

Casbon et al., "A method for counting PCR template molecules with application to next-generation sequencing," *Nucleic Acids Res.* 2011, 39(12), e81, 1-8. cited by applicant

Castellarnau et al., "Stochastic particle barcoding for single-cell tracking and multiparametric analysis," *Small* 2015, 11(4), 489-498. cited by applicant

Castle et al., "DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing," *BMC Genomics* 2010, 11(244), 1-11. cited by applicant

Chamberlain et al., "Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification," *Nucleic Acids Res.* 1988, 16(23), 11141-11156. cited by applicant

Chapin et al., "Rapid microRNA Profiling on Encoded Gel Microparticles," *Angew Chem Int Ed Engl.* 2011, 50(10), 2289-2293. cited by applicant

Chee et al., "Accessing genetic information with high-density DNA arrays," *Science* 1996, 274, 610-614. cited by applicant

Chee, "Enzymatic multiplex DNA sequencing," *Nucleic Acids Research* 1991, 19(12), 3301-3305. cited by applicant

Chen et al., "Spatially resolved, highly multiplexed RNA profiling in single cells," *Science Express* 2015, 348(6233), aaa6090, 1-36. cited by applicant

Church et al., "Multiplex DNA sequencing," *Science* 1988, 240(4849), 185-188. cited by applicant

Civil Cover Sheet filed Nov. 15, 2018 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Clontech Laboratories, Inc., "Smar™ PCR cDNA Synthesis Kit User Manual," Clontech 2007, 1-39. cited by applicant

Cloonan et al., "Stem cell transcriptome profiling via massive-scale mRNA sequencing", *Nature Methods* 2008, 5(7), 613-619. cited by applicant

Combined Search and Examination Report dated Aug. 6, 2014 in UK Patent Application No. 1408829.8. cited by applicant

Combined Search and Examination Report dated Feb. 21, 2017 in UK Patent Application No. 1609740.4. cited by applicant

Complaint filed in Becton, *Dickinson and Company and Cellular Research Inc. v. 10X Genomics, Inc.* dated Nov. 15, 2018 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 141 pp.

cited by applicant

Costa et al., "Single-Tube Nested Real-Time PCR as a New Highly Sensitive Approach to Trace Hazelnut," *Journal of Agricultural and Food Chemistry* 2012, 60, 8103-8110. cited by applicant

Costello et al., "Discovery and characterization of artefactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation," *Nucleic Acids Res* 2013, 41(6), e67, 1-12. cited by applicant

Cotten et al., "Selection of proteins with desired properties from natural proteome libraries using mRNA display," *Nature Protocols* 2011, 6, 1163-1182. cited by applicant

Cox, "Bar coding objects with DNA," *Analyst* 2001, 126, 545-547. cited by applicant

Craig et al., "Identification of genetic variants using bar-coded multiplexed sequencing," *Nat Methods* 2008, 5(10), 887-893. cited by applicant

Cusanovich et al., "Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing," *Science* 2015, 348(6237), 910-914. cited by applicant

Custom Antibody Services, Precision Antibody, accessed Apr. 16, 2014, 2 pp. cited by applicant

Daines et al., "High-throughput multiplex sequencing to discover copy No. variants in *Drosophila*," *Genetics* 2009, 182(4), 182, 935-941. cited by applicant

Dalerba et al., "Single-cell dissection of transcriptional heterogeneity in human colon tumors," *Nat Biotechnol.* 2011, 29(12), 1120-1127. cited by applicant

D'Antoni et al., "Rapid quantitative analysis using a single molecule counting approach," *Anal Biochem.* 2006, 352, 97-109. cited by applicant

Daser et al., "Interrogation of genomes by molecular copy-number counting (MCC)," *Nature Methods* 2006, 3(6), 447-453. cited by applicant

Day et al., "Immobilization of polynucleotides on magnetic particles," *Biochem. J.* 1991, 278, 735-740. cited by applicant

Decision of Refusal dated Aug. 21, 2017 in Japanese Patent Application No. 2014-558975. cited by applicant

Defendant 10X Genomics, Inc.'s Letter to Judge Andrews in Response to Plaintiff's Letter of Supplemental Authority, dated Jul. 11, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Defendant 10X Genomics Motion for Admission Pro Hac Vice of Paul Ehrlich, Azra Hadzimehmedovic and Aaron Nathan, Pursuant to Local Rule 83.5, dated May 1, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 5 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Motion for Admission Pro Hac Vice Pursuant to Local Rule 83.5, dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 5 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), dated Jan. 18, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Motion to Dismiss the First Amended Complaint Pursuant to Federal Rule of Civil Procedure 12(b)(6), dated Mar. 1, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Defendant 10X Genomics Notice of Service for Initial Disclosures served to Opposing Counsel, dated Jun. 7, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Defendant 10X Genomic Inc.'s Notice of Service for Initial Requests for Production and Interrogatories Served to Becton, Dickinson, and Company and Cellular Research, Inc., dated May 31, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Defendant 10X Genomics Inc.'s, Notice of Service of Technical Documents, dated Jul. 8, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Opening Brief in Support of Its Motion to Dismiss Pursuant to

Federal Rule of Civil Procedure 12(b)(6), dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 1:18-cv-01800-RGA, 25 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Opening Brief in Support of Its Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), dated Mar. 1, 2019 in the USDC District of Delaware, C.A. No. 18-1800 RGA, 26 pp. cited by applicant

Defendant 10X Genomics, Inc.'s [Proposed] Order for Partial Dismissal Pursuant to Federal Rules of Civil Procedure 12(b)(6), dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 1 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Proposed Order for Dismissal pursuant to Federal Rules of Civil Procedure 12(b)(6), filed Mar. 1, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Defendant 10X Genomics Reply Brief in Support of its Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6), dated Apr. 12, 2019 in the USDC for the District of Delaware, C.A. No. 18-1800-RGA, 15 pp. cited by applicant

Defendant 10X Genomics Request for Oral Argument Under D. Del. LR 7.1.4, dated Apr. 18, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA 2 pp. cited by applicant

Defendant 10X Genomics Response Letter to Judge Richard G. Andrews re Request for a Rule 16, dated Apr. 16, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Defendant 10X Genomics, Inc.'s Rule 7.1 Disclosure Statement, dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 1 pp. 1. cited by applicant

Delley et al., "Combined aptamer and transcriptome sequencing of single cells," bioRxiv 2017, 1-10. cited by applicant

De Saizieu et al., "Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays," Nature Biotechnology 1988, 16, 45-48. cited by applicant

Di Carlo et al., "Dynamic single-cell analysis for quantitative biology," Analytical Chemistry 2006, 78(23), 7918-7925. cited by applicant

Dirks et al., Triggered amplification by hybridization chain reaction., Proc Natl Acad Sci 2014, 101(43), 15275-15278. cited by applicant

Dube et al., "Mathematical Analysis of Copy Number Variation in a DNA Sample Using Digital PCR on a Nanofluidic Device," PLoS One 2008, 3(8) e2876. cited by applicant

Eberwine et al., "Analysis of gene expression in single live neurons," Proc. Natl. Acad. Sci. 1992, 89, 3010-3014. cited by applicant

Evanko et al., "Hybridization chain reaction," Nature Methods 2004, 1(3), 186-187. cited by applicant

Ex Parte David H Gelfand, Ivo Glynne Gut, Keith A. Bauer, and Florence Mauger, Appeal No. 2017-001917 (PTAB Aug. 6, 2018). cited by applicant

Ex Parte Olga Ornatsky, Appeal No. 2018-001623 (PTAB Jul. 29, 2019). cited by applicant

Ex Parte Brian Jon Peter, Appeal No. 2017-008386 (PTAB May 29, 2018). cited by applicant

Examination Report dated Oct. 24, 2017 in Australian Patent Application No. 2013226081. cited by applicant

Examination Report dated Jul. 20, 2018 in Australian Patent Application No. 2014312208. cited by applicant

Examination Report dated May 12, 2020 in Australian Patent Application No. 2018220004. cited by applicant

Examination Report dated Jul. 12, 2016 in European Patent Application No. 13755319.4. cited by applicant

Examination Report dated Apr. 10, 2017 in European Patent Application No. 14761937.3. cited by applicant

Examination Report dated Oct. 10, 2017 in European Patent Application No. 14761937.3. cited by applicant

applicant
Examination Report dated Mar. 16, 2018 in European Patent Application No. 13754428.4. cited by applicant
Examination Report dated Sep. 5, 2018 in European Patent Application No. 16710357.1. cited by applicant
Examination Report dated Sep. 26, 2018 in European Patent Application No. 16714081.3. cited by applicant
Examination Report dated Dec. 12, 2018 in European Patent Application No. 16719706.0. cited by applicant
Examination Report dated Jan. 2, 2019 in European Patent Application No. 16757986.1. cited by applicant
Examination Report dated Feb. 6, 2019 in European Patent Application No. 13754428.4. cited by applicant
Examination Report dated Apr. 26, 2019 in European Patent Application No. 16710357.1. cited by applicant
Examination Report dated Jun. 18, 2019 in European Patent Application No. 16710551.9. cited by applicant
Examination Report dated Jul. 24, 2019 in European Patent Application No. 16714081.3. cited by applicant
Examination Report dated Aug. 2, 2019 in European Patent Application No. 17202409.3. cited by applicant
Examination Report dated Oct. 11, 2019 in European Patent Application No. 16757986.1. cited by applicant
Examination Report dated Dec. 4, 2019 in European Patent Application No. 16719706.0. cited by applicant
Examination Report dated Feb. 19, 2020 in European Patent Application No. 16710551.9. cited by applicant
Examination Report dated Mar. 18, 2020 in European Patent Application No. 17202409.3. cited by applicant
Examination Report dated Jul. 6, 2020 in European Patent Application No. 17781265.8. cited by applicant
Examination Report dated Sep. 21, 2020 in European Patent Application No. 18703156.2. cited by applicant
Examination Report dated Nov. 12, 2020 in European Patent Application No. 18716877.8. cited by applicant
Examination Report dated Dec. 3, 2020 in European Patent Application No. 16719706.0. cited by applicant
Examination Report dated Mar. 25, 2021 in European Patent Application No. 17781265.8. cited by applicant
Examination Report dated Mar. 18, 2019 in Singapore Patent Application No. 11201405274W. cited by applicant
Examination Report dated Jan. 27, 2016 in United Kingdom Patent Application No. 1408829.8. cited by applicant
Examination Report dated Feb. 19, 2016 in United Kingdom Patent Application No. GB1511591.8. cited by applicant
Examination Report dated Jun. 8, 2016 in United Kingdom Patent Application No. 1408829.8. cited by applicant
Examination Report dated Jun. 15, 2016 in United Kingdom Patent Application No. GB1511591.8. cited by applicant
Examination Report dated Jan. 3, 2018 in United Kingdom Patent Application No. 1609740.4.

cited by applicant
Exhibit A filed Jul. 10, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 25 pp. cited by applicant
Exhibits 12-32 filed Feb. 8, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 795 pp. cited by applicant
Exhibits A-D filed Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 1:18-cv-01800-RGA, 47 pp. cited by applicant
Exhibits A-E filed Mar. 1, 2019 in the USDC District of Delaware, C.A. No. 18-1800 RGA, 75 pp. cited by applicant
Extended European Search Report dated Jul. 17, 2015 in European Patent Application No. 13755319.4. cited by applicant
Extended European Search Report dated Dec. 14, 2015 in European Patent Application No. 13754428.4. cited by applicant
Extended European Search Report dated Feb. 8, 2018 in European Patent Application No. 17202409.3. cited by applicant
Extended European Search Report dated Jun. 11, 2018 in European Patent Application No. 16740872.3. cited by applicant
Extended European Search Report dated Mar. 22, 2019 in European Patent Application No. 18195513.9. cited by applicant
Extended European Search Report dated May 6, 2021 in European Patent Application No. 20207621.2. cited by applicant
Fan et al., "Parallel Genotyping of Human SNPs Using Generic High-density Oligonucleotide Tag Arrays," Genome Research 2000, 10, 853-860. cited by applicant
Fan et al., "Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy," Am Obstet Gynecol. 2009, 200, 543e1-543e7. cited by applicant
Fan, "Molecular counting: from noninvasive prenatal diagnostics to whole-genome haplotyping," Doctoral Dissertation, Stanford University 2010, 1-185. cited by applicant
Fan et al., "Non-invasive Prenatal Measurement of the Fetal Genome," Nature 2012, 487(7407), 320-324. cited by applicant
Fan et al., "Combinatorial labeling of single cells for gene expression cytometry," Science 2015, 347(6222), 1258366-1258369. cited by applicant
Feldhaus et al., "Oligonucleotide-conjugated beads for transdominant genetic experiments," Nucleic Acids Res. 2000, 28(2), 534-543. cited by applicant
Final Office Action dated Sep. 1, 2015 for U.S. Appl. No. 14/540,029. cited by applicant
Final Office Action dated Sep. 24, 2015 for U.S. Appl. No. 14/540,007. cited by applicant
Final Office Action dated Oct. 6, 2015 in U.S. Appl. No. 14/540,018. cited by applicant
Final Office Action dated Apr. 11, 2016 for U.S. Appl. No. 14/800,526. cited by applicant
Final Office Action dated Jul. 20, 2016 for U.S. Appl. No. 14/281,706. cited by applicant
Final Office Action dated Aug. 12, 2016 in U.S. Appl. No. 14/381,488. cited by applicant
Final Office Action dated Feb. 13, 2017 in U.S. Appl. No. 14/381,488. cited by applicant
Final Office Action dated May 8, 2017 in U.S. Appl. No. 15/224,460. cited by applicant
Final Office Action dated Oct. 16, 2017 in U.S. Appl. No. 15/409,355. cited by applicant
Final Office Action dated Nov. 16, 2017 in U.S. Appl. No. 14/381,488. cited by applicant
Final Office Action dated Jan. 25, 2018 in U.S. Appl. No. 14/381,526. cited by applicant
Final Office Action dated May 3, 2018 in U.S. Appl. No. 15/046,225. cited by applicant
Final Office Action dated May 10, 2018 in U.S. Appl. No. 14/381,488. cited by applicant
Final Office Action dated Jul. 5, 2018 in U.S. Appl. No. 15/004,618. cited by applicant
Final Office Action dated Jul. 20, 2018 in U.S. Appl. No. 15/217,886. cited by applicant
Final Office Action dated Nov. 16, 2018 in U.S. Appl. No. 15/134,967. cited by applicant
Final Office Action dated Feb. 19, 2019 in U.S. Appl. No. 14/381,526. cited by applicant

Final Office Action dated Mar. 1, 2019 in U.S. Appl. No. 16/012,584. cited by applicant
Final Office Action dated Apr. 22, 2019 in U.S. Appl. No. 15/987,851. cited by applicant
Final Office Action dated May 2, 2019 in U.S. Appl. No. 16/012,635. cited by applicant
Final Office Action dated May 3, 2019 in U.S. Appl. No. 15/937,713. cited by applicant
Final Office Action dated Sep. 18, 2019 in U.S. Appl. No. 15/055,407. cited by applicant
Final Office Action dated Oct. 2, 2019 in U.S. Appl. No. 15/084,307. cited by applicant
Final Office Action dated Dec. 4, 2019 in U.S. Appl. No. 15/596,364. cited by applicant
Final Office Action dated Jan. 8, 2020 in U.S. Appl. No. 15/459,977. cited by applicant
Final Office Action dated Jan. 16, 2020 in U.S. Appl. No. 16/012,584. cited by applicant
Final Office Action dated Jan. 29, 2020 in U.S. Appl. No. 14/381,488. cited by applicant
Final Office Action dated Feb. 4, 2020 in U.S. Appl. No. 15/715,028. cited by applicant
Final Office Action dated Mar. 9, 2020 in U.S. Appl. No. 15/987,851. cited by applicant
Final Office Action dated Apr. 28, 2020 in U.S. Appl. No. 15/134,967. cited by applicant
Final Office Action dated Jun. 5, 2020 in U.S. Appl. No. 15/084,307. cited by applicant
Final Office Action dated Aug. 19, 2020 in U.S. Appl. No. 15/875,816. cited by applicant
Final Office Action dated Sep. 14, 2020 in U.S. Appl. No. 16/789,358. cited by applicant
Final Office Action dated Sep. 22, 2020 in U.S. Appl. No. 16/789,311. cited by applicant
Final Office Action dated Sep. 25, 2020 in U.S. Appl. No. 15/055,407. cited by applicant
Final Office Action dated Dec. 7, 2020 in U.S. Appl. No. 16/012,584. cited by applicant
Final Office Action dated Feb. 11, 2021 in U.S. Appl. No. 15/134,967. cited by applicant
Final Office Action dated Mar. 16, 2021 in U.S. Appl. No. 15/715,028. cited by applicant
Final Office Action dated Mar. 25, 2021 in U.S. Appl. No. 16/374,626. cited by applicant
First Action Interview Pilot Program Pre-Interview Communication dated Oct. 15, 2018 in U.S. Appl. No. 15/987,851. cited by applicant
First Action Interview Office Action Summary dated Jan. 25, 2019 in U.S. Appl. No. 15/987,851. cited by applicant
Flanigon et al., "Multiplex protein detection with DNA readout via mass spectrometry," N Biotechnol. 2013, 30(2), 153-158. cited by applicant
Forster et al., "A human gut bacterial genome and culture collection for improved metagenomic analyses," Nature Biotechnology 2019, 37, 186-192. cited by applicant
Fox-Walsh et al., "A multiplex RNA-seq strategy to profile poly(A+) RNA: application to analysis of transcription response and 3' end formation," Genomics 2011, 98, 266-721. cited by applicant
Fu et al., "Counting individual DNA molecules by the stochastic attachment of diverse labels," Proc Natl Acad Sci 2011, 108(22), 9026-9031. cited by applicant
Fu et al., Digital Encoding of Cellular mRNAs Enabling Precise and Absolute Gene Expression Measurement by Single-Molecule Counting. Anal Chem. 2014, 86, 2867-2870. cited by applicant
Fu et al., "Molecular indexing enables quantitative targeted RNA sequencing and reveals poor efficiencies in standard library preparation," PNAS 2014, 111(5), 1891-1896. cited by applicant
GenBank Accession No. NM_000518.5 for *Homo sapiens* hemoglobin subunit beta (HBB), mRNA. Mar. 22, 2021 [online], [retrieved on Apr. 27, 2021], retrieved from the Internet: <URL: www.ncbi.nlm.nih.gov/nuccore/NM_000518.5?report=Genbank (Year: 2021). cited by applicant
Gerry et al., "Universal DNA Microarray Method for Multiplex Detection of Low Abundance Point Mutations," Journal of Molecular Biology 1999, 292, 251-262. cited by applicant
Gillespie, "Exact Stochastic Simulation of Coupled Chemical Reactions," Journal of Physical Chemistry 1977, 81(25), 2340-2361. cited by applicant
Gong et al., "Massively parallel detection of gene expression in single cells using subnanolitre wells," Lab Chip 2010, 10, 2334-2337. cited by applicant
Gong et al., "Simple Method Prepare Oligonucleotide-Conjugated Antibodies and Its Application in Multiplex Protein Detection in Single Cells," Bioconjugate Chem. 2016, 27, 217-225. cited by applicant

Grant et al., "SNP genotyping on a genome-wide amplified DOP-PCR template," *Nucleic Acids Res* 2002, 30(22), e25, 1-6. cited by applicant

Grounds for Opposition dated Jul. 21, 2016 and filed in European Patent 2414548B1. cited by applicant

Gu et al., "Complete workflow for detection of low frequency somatic mutations from cell-free DNA using Ion Torrent™ platforms," Conference Poster, AACR 107th Annual Meeting, Apr. 16-20, 2016, 1 p. cited by applicant

Gu et al., "Depletion of abundant sequences by hybridization (DSH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications," *Genome Biology* 2016, 17(41) 1-13. cited by applicant

Gunderson et al., "Decoding Randomly Ordered DNA Arrays," *Genome Research* 2004, 14, 870-877. cited by applicant

Gundry et al., "Direct, genome-wide assessment of DNA mutations in single cells," *Nucleic Acids Research* 2011, 40(5), 2032-2040. cited by applicant

Gundry et al., "Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants," *Mutat Res.* 2012, 729(1-2), 1-15. cited by applicant

Hacia et al., "Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays," *Nature Genetics* 1999, 22, 164-167. cited by applicant

Haff, "Improved Quantitative PCR Using Nested Primers," *PCR Methods and Applications* 1994, 3, 332-337. cited by applicant

Hamady et al., "Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex," *Nat Methods* 2008, 5(3), 235-237. cited by applicant

Han et al., "An approach to multiplexing an immunosorbent assay with antibody-oligonucleotide conjugates," *Bioconjug Chem.* 2010, 21(12), 2190-2196. cited by applicant

Harbers, "The current status of cDNA cloning," *Genomics* 2008, 91, 232-242. cited by applicant

Harrington et al., Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course, *AIDS* 2009, 23(8), 907-915. cited by applicant

Hartmann, "Gene expression profiling of single cells on large-scale oligonucleotide arrays", *Nucleic Acids Research*, (Oct. 2006) vol. 34, No. 21, p. e143, 1-12. cited by applicant

Hashimshony et al., "CEL-Seq: Single-Cell RNA-Seq by Multiplexed Linear Amplification," *Cell Rep.* 2012, 2(3), 666-673. cited by applicant

Hensel et al., "Simultaneous identification of bacterial virulence genes by negative selection," *Science* 1995, 269(5222), 400-403. cited by applicant

Hiatt et al., "Parallel, tag-directed assembly of locally derived short sequence reads," *Nat Methods* 2010, 7(2), 119-122. cited by applicant

Hiatt et al., "Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation," *Genome Res.* 2013, 23(5), 843-854. cited by applicant

Holcomb et al., "Abstract 1853: Single-cell multiplexed profiling of protein-level changes induced by EGFR inhibitor gefitinib," *Cancer Res* 2016, 76(14 Suppl), Abstract 1853. cited by applicant

Hollas et al., "A stochastic approach to count RNA molecules using DNA sequencing methods," *Algorithms in Bioinformatics. WABI 2003, Lecture Notes in Computer Science*, 2812, 55-62. cited by applicant

How many species of bacteria are there? *WisegEEK.org*, accessed Jan. 21, 2014, 2 pp. cited by applicant

Hu et al., "Dissecting Cell-Type Composition and Activity-Dependent Transcriptional State in Mammalian Brains by Massively Parallel Single-Nucleus RNA-Seq," *Molecular Cell* 2017, 68, 1006-1015. cited by applicant

Hu et al., "Single Cell Multi-Omics Technology: Methodology and Application," *Frontiers in Cell and Developmental Biology* 2018, 6(28), 1-13. cited by applicant

Hug et al., Measure of the Number of Molecular of a Single mRNA Species in a Complex mRNA

Preparation, Journal of Theoretical Biology 2003, 221, 615-624. cited by applicant

Ingolia et al., Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling, Science 2009, 324(5924), 218-223. cited by applicant

International Preliminary Report on Patentability dated Mar. 26, 2019 in PCT Application No. PCT/US2017/053331. cited by applicant

International Preliminary Report on Patentability dated Aug. 6, 2019 in PCT Application No. PCT/US2018/014385. cited by applicant

International Preliminary Report on Patentability dated Nov. 3, 2020 in PCT Application No. PCT/US2019/030175. cited by applicant

International Preliminary Report on Patentability dated Nov. 3, 2020 in PCT Application No. PCT/US2019/030245. cited by applicant

International Preliminary Report on Patentability dated Feb. 9, 2021 in PCT Application No. PCT/US2019/043949. cited by applicant

International Preliminary Report on Patentability dated Feb. 23, 2021 in PCT Application No. PCT/US2019/046549. cited by applicant

International Preliminary Report on Patentability dated Mar. 2, 2021 in PCT Application No. PCT/US2019/048179. cited by applicant

International Search Report and Written Opinion dated May 7, 2012 for PCT Application No. PCT/IB2011/003160. cited by applicant

International Search Report and Written Opinion dated Jun. 6, 2012 in PCT Application No. PCT/US2011/065291. cited by applicant

International Search Report and Written Opinion dated Jun. 14, 2013 in PCT Application No. PCT/US2013/028103. cited by applicant

International Search Report and Written Opinion dated Aug. 16, 2013 for PCT Application No. PCT/US2013/027891. cited by applicant

International Search Report and Written Opinion dated Dec. 19, 2014 in PCT Application No. PCT/US2014/059542. cited by applicant

International Search Report and Written Opinion dated Feb. 3, 2015 in PCT Application No. PCT/US2014/053301. cited by applicant

International Search Report and Written Opinion dated May 3, 2016 in PCT Application No. PCT/US2016/018354. cited by applicant

International Search Report and Written Opinion dated Jun. 9, 2016 in PCT Application No. PCT/US2016/022712. cited by applicant

International Search Report and Written Opinion dated Jun. 17, 2016 in PCT Application No. PCT/US2016/019962. cited by applicant

International Search Report and Written Opinion dated Jun. 20, 2016 in PCT Application No. PCT/US2016/014612. cited by applicant

International Search Report and Written Opinion dated Aug. 9, 2016 in PCT Application No. PCT/US2016/019971. cited by applicant

International Search Report and Written Opinion dated Sep. 27, 2016 in PCT Application No. PCT/US2016/034473. cited by applicant

International Search Report and Written Opinion dated Sep. 28, 2016 in PCT Application No. PCT/US2016/028694. cited by applicant

International Search Report and Written Opinion dated Dec. 5, 2016 in PCT Application No. PCT/US2016/024783. cited by applicant

International Search Report and Written Opinion dated Jan. 31, 2017 in PCT Application No. PCT/US2016/050694. cited by applicant

International Search Report and Written Opinion dated Aug. 7, 2017 in PCT Application No. PCT/US2017/034576. cited by applicant

International Search Report and Written Opinion dated Sep. 8, 2017 in PCT Application No.

PCT/US2017/030097. cited by applicant
International Search Report and Written Opinion dated Mar. 20, 2018 in PCT Application No. PCT/US2017/053331. cited by applicant
International Search Report and Written Opinion dated Mar. 28, 2018 in PCT Application No. PCT/US2018/014385. cited by applicant
International Search Report and Written Opinion dated Jul. 16, 2018 in PCT Application No. PCT/US2018/024602. cited by applicant
International Search Report and Written Opinion dated Jun. 24, 2019 in PCT Application No. PCT/US2019/030175. cited by applicant
International Search Report and Written Opinion dated Oct. 8, 2019 in PCT Application No. PCT/US2019/043949. cited by applicant
International Search Report and Written Opinion dated Oct. 16, 2019 in PCT Application No. PCT/US2019/030245. cited by applicant
International Search Report and Written Opinion dated Nov. 27, 2019 in PCT Application No. PCT/US2019/046549. cited by applicant
International Search Report and Written Opinion dated Dec. 4, 2019 in PCT Application No. PCT/US2019/053868. cited by applicant
International Search Report and Written Opinion dated Jan. 27, 2020 in PCT Application No. PCT/US2019/048179. cited by applicant
International Search Report and Written Opinion dated Mar. 30, 2020 in PCT Application No. PCT/US2019/060243. cited by applicant
International Search Report and Written Opinion dated Mar. 30, 2020 in PCT Application No. PCT/US2019/065237. cited by applicant
International Search Report and Written Opinion dated May 18, 2020 in PCT Application No. PCT/US2020/014339. cited by applicant
International Search Report and Written Opinion dated Jun. 30, 2020 in PCT Application No. PCT/US2020/017890. cited by applicant
International Search Report and Written Opinion dated Nov. 12, 2020 in PCT Application No. PCT/US2020/042880. cited by applicant
International Search Report and Written Opinion dated Jan. 19, 2021 in PCT Application No. PCT/US2020/059419. cited by applicant
International Search Report and Written Opinion dated Apr. 9, 2021 in PCT Application No. PCT/US2021/013137. cited by applicant
International Search Report and Written Opinion dated Apr. 21, 2021 in PCT Application No. PCT/US2021/015571. cited by applicant
Invitation to Pay Fees dated Mar. 16, 2016 in PCT Application No. PCT/US2016/019971. cited by applicant
Invitation to Pay Fees dated May 16, 2018 in PCT Application No. PCT/US2018/024602. cited by applicant
Invitation to Pay Fees dated Nov. 26, 2019 in PCT Application No. PCT/US2019/048179. cited by applicant
Invitation to Pay Additional Search Fees dated May 7, 2020 in PCT Application No. PCT/US2020/017890. cited by applicant
Invitation to Respond to Written Opinion dated May 26, 2017 in Singapore Patent Application No. 11201405274W. cited by applicant
Islam et al., "Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq," Genome Research 2011, 21, 1160-1167. cited by applicant
Islam et al., "Highly multiplexed and strand specific single-cell RNA 5' end sequencing," Nature Protocols 2012, 7(5), 813-828. cited by applicant
Islam et al., "Quantitative single-cell RNA-seq with unique molecular identifiers," Nature Methods

2014, 11(2), 163-168. cited by applicant

Jabara, "Capturing the cloud: High throughput sequencing of multiple individual genomes from a retroviral population," Biology Lunch Bunch Series, Training Initiatives in Biomedical & Biological Sciences of the University of North Carolina at Chapel Hill 2010. cited by applicant
Jabara et al., "Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID," PNAS 2011, 108(50), 20166-20171. cited by applicant

Jason J. Rawnsley of Richards, Layton and Finger, P.A., Entry of Appearance dated Jan. 18, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 1 pp. cited by applicant

Jiang et al., "Synthetic spike-in standards for RNA-seq experiments," Genome Res. 2011, 21, 1543-1551. cited by applicant

Joint Stipulation and Order to Extend Time to Respond to Plaintiff's First Amended Complaint, dated Feb. 21, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Joint Stipulation and Order to Request Extended Time to File Opposition to Defendant's Motion to Dismiss dated, Mar. 8, 2019 in the USDC District of Delaware, C.A. No. 18-1800 RGA, 2 pp. cited by applicant

Joint Stipulation and Order to Request Extended Time to Submit a proposed Protective Order, dated Jun. 7, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Joint Stipulation and Order to Extended Time to Submit Agreed Document Production Protocol, filed Jun. 28, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 1 pp. cited by applicant

Joint Stipulation and Order to Request Extended Time to Submit Agreed Document Production Protocol, dated Jul. 11, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 1 pp. cited by applicant

Junker et al., "Single-Cell Transcriptomics Enters the Age of Mass Production," Molecular Cell 2015, 58, 563-564. cited by applicant

Kanagawa, "Bias and artifacts in multi-template polymerase chain reactions (PCR)," Journal of Bioscience and Bioengineering 2003, 96(4), 317-323. cited by applicant

Kang et al., "Targeted sequencing with enrichment PCR: a novel diagnostic method for the detection of EGFR mutations," Oncotarget 2015, 6(15), 13742-13749. cited by applicant

Kang et al., "Application of multi-omics in single cells," Ann Biotechnol. 2018, 2(1007), 1-8. cited by applicant

Karrer et al., "In situ isolation of mRNA from individual plant cells: creation of cell-specific cDNA libraries," Proc. Natl. Acad. Sci. USA 1995, 92, 3814-3818. cited by applicant

Kausch et al., "Organelle Isolation by Magnetic Immunoabsorption," BioTechniques 1999, 26(2), 336-343. cited by applicant

Kebschull et al., "Sources of PCR-induced distortions in high-throughput sequencing data sets," Nucleic Acids Research 2015, 1-15. cited by applicant

Keys et al., Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain, AIDS Research and Human Retroviruses 2015, 31(6), 658-668. cited by applicant

Kim et al., Polony Multiplex Analysis of Gene Expression (PMAGE) in Mouse Hypertrophic Cardiomyopathy, Science 2007, 316(5830), 1481-1484. cited by applicant

Kinde et al., "Detection and quantification of rare mutations with massively parallel sequencing," Proc. Natl Acad Sci 2011, 108(23), 9530-9535. cited by applicant

Kirsebom et al., "Stimuli-Responsive Polymers in the 21st Century: Elaborated Architecture to Achieve High Sensitivity, Fast Response, and Robust Behavior," Journal of Polymer Science: Part B: Polymer Physics 2011, 49, 173-178. cited by applicant

Kivioja et al., "Counting absolute Nos. of molecules using unique molecular identifiers," Nature

Proceedings 2011, 1-18. cited by applicant

Klein et al., Droplet Barcoding for Single-Cell Transcriptomics Applied to Embryonic Stem Cells, Cell 2015, 161, 1187-1201. cited by applicant

Ko et al., "RNA-conjugated template-switching RT-PCR method for generating an *Escherichia coli* cDNA library for small RNAs," Journal of Microbiological Methods 2006, 64, 297-304. cited by applicant

Koboldt et al., VarScan: variant detection in massively parallel sequencing of individual and pooled samples, Bioinformatics 2009, 25(17), 2283-2285. cited by applicant

Kolodziejczyk et al., The Technology and Biology of Single-Cell RNA Sequencing, Molecular Cell 2015, 58, 610-620. cited by applicant

Konig et al., "iCLIP reveals the function of hnRNAP particles in splicing at individual nucleotide resolution," Nature Structural & Molecular Biology 2010, 17(7), 909-916. cited by applicant

Kooiker & Xue, "cDNA Library Preparation," Cereal Genomics 2013, 1099, 29-40. cited by applicant

Kotake et al., "A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples," Journal of Immunological Methods 1996, 199, 193-203. cited by applicant

Kozarewa & Turner, "96-Plex Molecular Barcoding for the Illumina Genome Analyzer," High-Throughput Next Generation Sequencing. Methods in Molecular Biology (Methods and Applications) 2011, 733, 24 pp. DOI: 10.1007/978-1-61779-089-8_20. cited by applicant

Kozlov et al., "A high-complexity, multiplexed solution-phase assay for profiling protease activity on microarrays," Comb Chem High Throughput Screen 2008, 11(1), 24-35. cited by applicant

Kurimoto et al., "An improved single-cell cDNA amplification method for efficient high-density oligonucleotide microarray analysis," Nucleic Acids Res. 2006, 34(5), e42, 1-17. cited by applicant

Kurimoto et al., "Global single-cell cDNA amplification to provide a template for representative high-density oligonucleotide microarray analysis," Nature Protocols 2007, 2(3), 739-752. cited by applicant

Lamble et al., "Improved workflows for high throughput library preparation using the transposome-based nextera system," BMC Biotechnology 2013, 13, 104, 1-10. cited by applicant

Larson et al., "A single molecule view of gene expression," Trends Cell Biol. 2009, 19(11), 630-637. cited by applicant

Lass-Napiorkowska et al., "Detection methodology based on target molecule-induced sequence-specific binding to a single-stranded oligonucleotide," Anal Chem. 2012, 84(7), 3382-3389. cited by applicant

Leamon et al., A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions, Electrophoresis 2003, 24, 3769-3777. cited by applicant

Lee et al., "Large-scale arrays of picolitre chambers for single-cell analysis of large cell populations," Lab Chip 2010, 10, 2952-2958. cited by applicant

Lee et al., "Highly Multiplexed Subcellular RNA Sequencing in Situ," Science 2014, 343, 1360-1363. cited by applicant

Lee et al., "Universal process-inert encoding architecture for polymer microparticles," Nature Materials 2014, 13(5), 524-529. cited by applicant

Letter regarding the opposition procedure dated Jul. 22, 2015 for European Patent Application No. 11810645.9. cited by applicant

Letter to Judge Richard G. Andrews Requesting a Rule 16 Conference, dated Apr. 15, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 1 pp. cited by applicant

Letter to Judge Andrews regarding Agreement on Proposed Scheduling Order, dated May 7, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Letter to Judge Andrews regarding Notice of Supplemental Authority, dated Jul. 10, 2019 in the USDC for the District of Delaware, C.A. 18-1800(RGA), 2pp. cited by applicant

Lin et al., "Self-Assembled Combinatorial Encoding Nanoarrays for Multiplexed Biosensing," *Nano Lett.* 2007, 7 (2), 507-512. cited by applicant

Liu et al., "Single-cell transcriptome sequencing: recent advances and remaining challenges," *F1000Research* 2016, 5(F1000 Faculty Rev)(182), 1-9. cited by applicant

Lizardi et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," *Nat Genet.* 1998, 19, 225-232. cited by applicant

Lockhart et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," *Nature Biotechnology* 1996, 14, 1675-1680. cited by applicant

Lovatt et al., "Transcriptome in vivo analysis (TIVA) of spatially defined single cells in live tissue," *Nat Methods* 2014, 11(2), 190-196. cited by applicant

Loy et al., "A rapid library preparation method with custom assay designs for detection of variants at 0.1% allelic frequency in liquid biopsy samples," *ThermoFisher Scientific*, Oct. 2, 2018, 1 p. cited by applicant

Lucito et al., "Representational Oligonucleotide Microarray Analysis: A High-Resolution Method to Detect Genome Copy Number Variation," *Genome Research* 2003, 13, 2291-2305. cited by applicant

Lundberg et al., "Practical innovations for high-throughput amplicon sequencing," *Nature Methods* 2013, 10(10), 999-1007. cited by applicant

Lundberg et al., "Supplementary Information for: Practical innovations for high-throughput amplicon sequencing," *Nature Methods* 2013, 1-24. cited by applicant

Maamar et al., "Noise in Gene Expression Determines Cell Fate in *Bacillus subtilis*," *Science* 2007, 317, 526-529. cited by applicant

MacAulay et al., "Single Cell Genomics: Advances and Future Perspectives," *PLoS Genetics* 2014, 10(1), 1-9. cited by applicant

MacAulay et al., "G&T-seq: parallel sequencing of single-cell genomes and transcriptomes," *Nature Methods* 2015, 1-7. cited by applicant

MacOsco et al., "Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets," *Cell* 2015, 161, 1202-1214. cited by applicant

Maeda et al., "Development of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer," *BioTechniques* 2008, 45(1), 95-97. cited by applicant

Makrigiorgos et al., "A PCR-Based amplification method retaining quantities difference between two complex genomes," *Nature Biotech* 2002, 20(9), 936-939. cited by applicant

Marcus et al., "Microfluidic single-cell mRNA isolation and analysis," *Anal Chem.* 2006, 78, 3084-3089. cited by applicant

Mardis, "Next-generation DNA sequencing methods", *Annu. Rev. Genomics Hum. Genet.* 2008, 9, 387-402. cited by applicant

Marguerat et al., "Next-generation sequencing: applications beyond genomes," *Biochem. Soc. Trans.* 2008, 36(5), 1091-1096. cited by applicant

Marguiles et al., "Genome sequencing in microfabricated high-density picolitre reactors," *Nature* 2005, 437, 376-380. cited by applicant

Martinez et al., "A microfluidic approach to encapsulate living cells in uniform alginate hydrogel microparticles," *Macromol. Biosci* 2012, 12, 946-951. cited by applicant

Massachusetts General Hospital, Overview of Illumina Chemistry, <http://nextgen.mgh.harvard.edu/IlluminaChemistry.html>, downloaded Jan. 28, 2020, 2 pp. cited by applicant

McCloskey et al., "Encoding PCR products with batch-stamps and barcodes," *Biochem Genet.* 2007, 45(11-12), 761-767. cited by applicant

Medvedev et al., "Detecting copy number variation with mated short reads," *Genome Res.* 2010, 20, 1613-1622. cited by applicant

Mei et al., "Identification of recurrent regions of Copy-Number Variants across multiple individuals," BMC Bioinformatics 2010, 11, 147, 1-14. cited by applicant

Merriam-Webster, definition of associate: <http://www.merriam-webster.com/dictionary/associate>, accessed Apr. 5, 2016. cited by applicant

Meyer et al., "Parallel tagged sequencing on the 454 platform," Nature Protocols 2008, 3(2), 267-278. cited by applicant

Miller et al., Directed evolution by in vitro compartmentalization, Nature Methods 2006, 3(7), 561-570. cited by applicant

Miner et al., "Molecular barcodes detect redundancy and contamination in hairpin-bisulfite PCR," Nucleic Acids Research 2004, 32(17), e135, 1-4. cited by applicant

Mortazavi et al., "Mapping and quantifying mammalian transcriptomes by RNA-Seq," Nat. Methods 2008, 5(7), 621-628. cited by applicant

Motion and Order for Admission Pro Hac Vice Pursuant to Local Rule 83.5, dated Jan. 24, 2019 in the USDC District of Delaware, C.A. No. 18-1800-RGA, 7 pp. cited by applicant

Nadai et al., Protocol for nearly full-length sequencing of HIV-1 RNA from plasma, PLoS One 2008, 3(1), e1420, 1-6. cited by applicant

Nagai et al., "Development of a microchamber array for picoleter PCR," Anal. Chem. 2001, 73, 1043-1047. cited by applicant

Navin et al., "The first five years of single-cell cancer genomics and beyond," Genome Research 2015, 25, 1499-1507. cited by applicant

New COVID-19 Variants, Centers for Disease Control and Prevention 2021, accessed Jan. 21, 2021, 3 pp. cited by applicant

Newell et al., Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012, 36(1), 142-152. cited by applicant

Non-Final Office Action dated Oct. 3, 2013 in U.S. Appl. No. 12/969,581. cited by applicant

Non-Final Office Action dated Feb. 18, 2015 for U.S. Appl. No. 14/540,007. cited by applicant

Non-Final Office Action dated Feb. 26, 2015 for U.S. Appl. No. 14/540,029. cited by applicant

Non-Final Office Action dated Mar. 19, 2015 in U.S. Appl. No. 14/540,018. cited by applicant

Non-Final Office Action dated May 7, 2015 for U.S. Appl. No. 13/327,526. cited by applicant

Non-Final Office Action dated Dec. 3, 2015 for U.S. Appl. No. 14/281,706. cited by applicant

Non-Final Office Action dated Dec. 31, 2015 for U.S. Appl. No. 14/800,526. cited by applicant

Non-Final Office Action dated Apr. 11, 2016 in U.S. Appl. No. 14/472,363. cited by applicant

Non-Final Office Action dated May 10, 2016 in U.S. Appl. No. 14/381,488. cited by applicant

Non-Final Office Action dated May 13, 2016 in U.S. Appl. No. 14/508,911. cited by applicant

Non-Final Office Action dated Aug. 17, 2016 for U.S. Appl. No. 14/800,526. cited by applicant

Non-Final Office Action dated Sep. 26, 2016 in U.S. Appl. No. 15/167,807. cited by applicant

Non-Final Office Action dated Oct. 11, 2016 in U.S. Appl. No. 15/224,460. cited by applicant

Non-Final Office Action dated Jan. 19, 2017 in U.S. Appl. No. 15/055,445. cited by applicant

Non-Final Office Action dated Mar. 24, 2017 in U.S. Appl. No. 15/409,355. cited by applicant

Non-Final Office Action dated Jun. 2, 2017 in U.S. Appl. No. 14/381,526. cited by applicant

Non-Final Office Action dated Jun. 7, 2017 in U.S. Appl. No. 14/381,488. cited by applicant

Non-Final Office Action dated Jul. 28, 2017 in U.S. Appl. No. 14/975,441. cited by applicant

Non-Final Office Action dated Sep. 8, 2017 in U.S. Appl. No. 15/046,225. cited by applicant

Non-Final Office Action dated Sep. 8, 2017 in U.S. Appl. No. 15/134,967. cited by applicant

Non-Final Office Action dated Nov. 1, 2017 in U.S. Appl. No. 15/667,125. cited by applicant

Non-Final Office Action dated Nov. 9, 2017 in U.S. Appl. No. 15/004,618. cited by applicant

Non-Final Office Action dated Jan. 9, 2018 in U.S. Appl. No. 15/217,896. cited by applicant

Non-Final Office Action dated Jan. 12, 2018 in U.S. Appl. No. 15/217,886. cited by applicant

Non-Final Office Action dated Mar. 8, 2018 in U.S. Appl. No. 15/608,780. cited by applicant

Non-Final Office Action dated Apr. 6, 2018 in U.S. Appl. No. 15/603,239. cited by applicant
Non-Final Office Action dated Jul. 25, 2018 in U.S. Appl. No. 15/108,268. cited by applicant
Non-Final Office Action dated Oct. 4, 2018 in U.S. Appl. No. 15/260,106. cited by applicant
Non-Final Office Action dated Oct. 25, 2018 in U.S. Appl. No. 16/012,584. cited by applicant
Non-Final Office Action dated Nov. 5, 2018 in U.S. Appl. No. 16/038,790. cited by applicant
Non-Final Office Action dated Nov. 26, 2018 in U.S. Appl. No. 15/937,713. cited by applicant
Non-Final Office Action dated Jan. 7, 2019 in U.S. Appl. No. 15/055,407. cited by applicant
Non-Final Office Action dated Jan. 14, 2019 in U.S. Appl. No. 16/219,553. cited by applicant
Non-Final Office Action dated Mar. 19, 2019 in U.S. Appl. No. 15/046,225. cited by applicant
Non-Final Office Action dated May 15, 2019 in U.S. Appl. No. 15/084,307. cited by applicant
Non-Final Office Action dated May 23, 2019 in U.S. Appl. No. 15/459,977. cited by applicant
Non-Final Office Action dated Jun. 17, 2019 in U.S. Appl. No. 14/381,488. cited by applicant
Non-Final Office Action dated Jul. 9, 2019 in U.S. Appl. No. 15/596,364. cited by applicant
Non-Final Office Action dated Aug. 20, 2019 for U.S. Appl. No. 15/715,028. cited by applicant
Non-Final Office Action dated Sep. 18, 2019 in U.S. Appl. No. 16/194,819. cited by applicant
Non-Final Office Action dated Nov. 29, 2019 in U.S. Appl. No. 15/937,713. cited by applicant
Non-Final Office Action dated Jan. 17, 2020 in U.S. Appl. No. 15/084,307. cited by applicant
Non-Final Office Action dated Feb. 5, 2020 in U.S. Appl. No. 15/875,816. cited by applicant
Non-Final Office Action dated Mar. 12, 2020 in U.S. Appl. No. 16/789,358. cited by applicant
Non-Final Office Action dated Mar. 17, 2020 in U.S. Appl. No. 15/055,407. cited by applicant
Non-Final Office Action dated Mar. 26, 2020 in U.S. Appl. No. 16/012,635. cited by applicant
Non-Final Office Action dated Mar. 26, 2020 in U.S. Appl. No. 16/789,311. cited by applicant
Non-Final Office Action dated Jun. 8, 2020 in U.S. Appl. No. 15/715,028. cited by applicant
Non-Final Office Action dated Aug. 4, 2020 in U.S. Appl. No. 15/459,977. cited by applicant
Non-Final Office Action dated Aug. 19, 2020 in U.S. Appl. No. 16/374,626. cited by applicant
Non-Final Office Action dated Aug. 25, 2020 in U.S. Appl. No. 14/381,488. cited by applicant
Non-Final Office Action dated Dec. 4, 2020 in U.S. Appl. No. 16/677,012. cited by applicant
Non-Final Office Action dated Dec. 9, 2020 in U.S. Appl. No. 16/788,743. cited by applicant
Non-Final Office Action dated Jan. 19, 2021 in U.S. Appl. No. 16/836,750. cited by applicant
Non-Final Office Action dated Feb. 2, 2021 in U.S. Appl. No. 16/535,080. cited by applicant
Non-Final Office Action dated Feb. 25, 2021 in U.S. Appl. No. 15/055,407. cited by applicant
Non-Final Office Action dated Feb. 25, 2021 in U.S. Appl. No. 15/084,307. cited by applicant
Non-Final Office Action dated Mar. 29, 2021 in U.S. Appl. No. 16/789,358. cited by applicant
Non-Final Office Action dated Apr. 14, 2021 in U.S. Appl. No. 16/789,311. cited by applicant
Non-Final Office Action dated Apr. 20, 2021 in U.S. Appl. No. 15/875,816. cited by applicant
Notice of Allowability dated Jun. 19, 2014 for U.S. Appl. No. 12/969,581. cited by applicant
Notice of Allowance dated Mar. 21, 2014 for U.S. Appl. No. 12/969,581. cited by applicant
Notice of Allowance dated Aug. 22, 2014 for U.S. Appl. No. 12/969,581. cited by applicant
Notice of Allowance dated Dec. 15, 2015 for U.S. Appl. No. 14/540,007. cited by applicant
Notice of Allowance dated Dec. 21, 2015 in U.S. Appl. No. 14/540,018. cited by applicant
Notice of Allowance dated Jan. 21, 2016 for U.S. Appl. No. 13/327,526. cited by applicant
Notice of Allowance dated Jan. 9, 2019 in U.S. Appl. No. 15/603,239. cited by applicant
Notice of Allowance dated Mar. 20, 2019 in U.S. Appl. No. 16/219,553. cited by applicant
Notice of Allowance dated Mar. 21, 2019 in U.S. Appl. No. 15/993,468. cited by applicant
Notice of Allowance dated May 28, 2019 in U.S. Appl. No. 16/219,553. cited by applicant
Notice of Allowance dated Sep. 24, 2019 in U.S. Appl. No. 15/217,886. cited by applicant
Notice of Allowance dated Nov. 11, 2019 in Japanese Patent Application No. 2017-245295. cited by applicant
Notice of Allowance dated Nov. 29, 2019 in U.S. Appl. No. 16/012,635. cited by applicant
Notice of Allowance dated Dec. 27, 2019 in U.S. Appl. No. 15/260,106. cited by applicant

Notice of Allowance dated Mar. 5, 2020 in U.S. Appl. No. 15/217,886. cited by applicant

Notice of Allowance dated Mar. 27, 2020 in U.S. Appl. No. 15/596,364. cited by applicant

Notice of Allowance dated Mar. 30, 2020 in U.S. Appl. No. 15/937,713. cited by applicant

Notice of Allowance dated Apr. 15, 2020 in U.S. Appl. No. 16/012,635. cited by applicant

Notice of Allowance dated Sep. 23, 2020 in Korean Patent Application No. 10-2016-7008144. cited by applicant

Notice of Allowance dated Oct. 29, 2020 in U.S. Appl. No. 15/987,851. cited by applicant

Notice of Allowance dated Jan. 13, 2021 in U.S. Appl. No. 14/381,488. cited by applicant

Notice of Allowance dated Jan. 13, 2021 in U.S. Appl. No. 15/459,977. cited by applicant

Notice of Allowance dated Apr. 26, 2021 in Japanese Patent Application No. 2019-014564. cited by applicant

Notice, Consent, and Reference of a Civil Action to a Magistrate Judge (Rule 73.1), filed Nov. 15, 2018 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 3 pp. cited by applicant

Notice of Opposition dated Jul. 9, 2015 for European Patent Application No. 11810645.9. cited by applicant

Notice of Opposition dated Jul. 27, 2016 for European Patent Application No. 10762102.1. cited by applicant

Notice of Reasons for Rejection dated Dec. 28, 2016 in Japanese Patent Application No. 2014-558975. cited by applicant

Notice of Reasons for Rejection dated Apr. 2, 2018 in Japanese Patent Application No. 2014-558975. cited by applicant

Notice of Reasons for Rejection dated Jul. 30, 2018 in Japanese Patent Application No. 2016-537867. cited by applicant

Notice of Reasons for Rejection dated Aug. 31, 2018 in Japanese Patent Application No. 2016-520632. cited by applicant

Notice of Reasons for Rejection dated Dec. 5, 2018 in Japanese Patent Application No. 2017-245295. cited by applicant

Notice of Reason for Rejection dated Nov. 21, 2019 in Korean Patent Application No. 10-2016-7008144. cited by applicant

Notice of Reasons for Rejection dated Feb. 25, 2020 in Japanese Patent Application No. 2019-014564. cited by applicant

Notice of Reasons for Rejection dated May 11, 2020 in Japanese Patent Application No. 2017-549390. cited by applicant

Notice of Service of Disclosures to Opposing Counsel, dated Jun. 10, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 3 pp. cited by applicant

Notice of Service of Interrogatories and First Request of Documents and Things to Defendant 10X Genomics, Inc., dated Jul. 5, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 3 pp. cited by applicant

Notification Prior to Examination dated Nov. 27, 2019 in Israeli Patent Application No. 265478. cited by applicant

Novak et al., "Single-Cell Multiplex Gene Detection and Sequencing with Microfluidically Generated Agarose Emulsions," *Angew. Chem. Int. Ed.* 2011, 50, 390-395. cited by applicant

Office Action dated Jun. 6, 2016 in Chinese Patent Application No. 201380022187.9. cited by applicant

Office Action dated Dec. 27, 2016 in Chinese Patent Application No. 201380022187.9. cited by applicant

Office Action dated Feb. 17, 2017 in Canadian Patent Application No. 2,865,575. cited by applicant

Office Action dated Jul. 14, 2017 in Chinese Patent Application No. 201380022187.9. cited by applicant

Office Action dated Dec. 19, 2017 in Chinese Patent Application No. 201480061859.1. cited by

applicant
Office Action dated Feb. 15, 2018 in Canadian Patent Application No. 2,865,575. cited by applicant
Office Action dated Sep. 7, 2018 in Chinese Patent Application No. 201480061859.1. cited by applicant
Office Action dated Dec. 13, 2018 in Canadian Patent Application No. 2,865,575. cited by applicant
Office Action dated Jan. 2, 2019 in Chinese Patent Application No. 201480059505.3. cited by applicant
Office Action dated Mar. 4, 2020 in Canadian Patent Application No. 2,865,575. cited by applicant
Office Action dated Jun. 22, 2020 in Chinese Patent Application No. 201680007351.2. cited by applicant
Office Action dated Jun. 22, 2020 in Chinese Patent Application No. 201680007652.5. cited by applicant
Office Action dated Jun. 23, 2020 in Chinese Patent Application No. 2016800157452. cited by applicant
Office Action dated Jul. 20, 2020 in Japanese Patent Application No. 2018-512152. cited by applicant
Office Action dated Oct. 29, 2020 in Chinese Patent Application No. 2018800377201. cited by applicant
Office Action dated Jan. 4, 2021 in Japanese Patent Application No. 2017-549390. cited by applicant
Office Action dated Jan. 6, 2021 in Chinese Patent Application No. 201680052330.2. cited by applicant
Office Action dated Jan. 14, 2021 in Japanese Patent Application No. 2019-014564. cited by applicant
Office Action dated Jan. 15, 2021 in Korean Patent Application No. 10-2020-7033213. cited by applicant
Office Action dated Jan. 26, 2021 in Chinese Patent Application No. 201680007351.2. cited by applicant
Office Action dated Feb. 4, 2021 in Canadian Patent Application No. 2,865,575. cited by applicant
Office Action dated Feb. 20, 2021 in Chinese Patent Application No. 201680022865.5. cited by applicant
Office Action dated Mar. 1, 2021 in Chinese Patent Application No. 201680007652.5. cited by applicant
Office Action dated Mar. 2, 2021 in Chinese Patent Application No. 2016800157452. cited by applicant
Office Action dated Mar. 8, 2021 in Japanese Patent Application No. 2018-512152. cited by applicant
Office Action dated Mar. 16, 2021 in Chinese Patent Application No. 2018800377201. cited by applicant
Office Action dated May 10, 2021 in Japanese Patent Application No. 2019-566787. cited by applicant
Ogino et al., "Quantification of PCR bias caused by a single nucleotide polymorphism in SMN gene dosage analysis," J Mol Diagn. 2002, 4(4), 185-190. cited by applicant
Opposition to Defendant's Motion to Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(6) dated Feb. 15, 2019, in the USDC for the District of Delaware, C.A. 18-800-RGA, 3 pp. cited by applicant
Oral Order by Judge Andrews Canceling Scheduling Conference set for May 8, 2019. cited by applicant
Order Setting Rule 16(b) Conference as Ordered by Judge Andrews Pursuant to Fed. R. Civ. P.

16(b), ruling dated Apr. 17, 2019 in the USDC District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Order Scheduling ADR Mediation Teleconference, filed May 13, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 4pp. cited by applicant

Ozkumur et al., “Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells,” *Science Translational Medicine* 2013, 5(179), 1-20. cited by applicant

Parameswaran et al., “A pyrosequencing-tailored nucleotide barcode design unveils opportunities for large-scale sample multiplexing,” *Nucleic Acids Res.* 2007, 35(19), e130, 1-9. cited by applicant

Park et al., “Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing,” *Nat Genet.* 2010, 42(5), 400-405. cited by applicant

Patanjali et al., “Construction of a uniform-abundance (normalized) CNDA library,” *Proceedings of the National Academy of Sciences* 1991, 88(5), 1943-1947. cited by applicant

Peng et al., “Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes,” *BMC Genomics* 2015, 16(589), 1-12. cited by applicant

Pérez-Rentero et al., “Synthesis of Oligonucleotides Carrying Thiol Groups Using a Simple Reagent Derived from Threoninol,” *Molecules* 2012, 17, 10026-10045. cited by applicant

Peterson et al., “Multiplexed quantification of proteins and transcripts in single cells,” *Nature Biotechnology* 2017, 35, 936-939. cited by applicant

Picelli et al., “Tn5 transposase and tagmentation procedures for massively scaled sequencing projects,” *Genome Research* 2014, 24(12), 2033-2040. cited by applicant

Picelli et al., “Single-cell RNA-sequencing: The future of genome biology is now,” *RNA Biology* 2017, 14(5), 637-650. cited by applicant

Pihlak et al., “Rapid genome sequencing with short universal tiling probes,” *Nature Biotechnology* 2008, 26, 1-9. cited by applicant

Pinkel et al., “Comparative Genomic Hybridization,” *Annual Review of Genomics and Human Genetics* 2005, 6, 331-354. cited by applicant

Plaintiff's Brief in Opposition to Defendant's Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b) (6), filed Mar. 29, 2019 in the USDC District of Delaware, C.A. No. 18-1800 (RGA), 27 pp. cited by applicant

Plaintiff's First Amended Complaint filed on Feb. 8, 2019, in the USDC for the District of Delaware, C.A. 18-1800-RGA, 178 pp. cited by applicant

Pleasance et al., “A small-cell lung cancer genome with complex signatures of tobacco exposure,” *Nature* 2010, 463(7278), 184-190. cited by applicant

Plessy et al., “Population transcriptomics with single-cell resolution: a new field made possible by microfluidics: a technology for high throughput transcript counting and data-driven definition of cell types,” *Bioessays* 2012, 35, 131-140. cited by applicant

Pre-interview communication dated Nov. 27, 2018 in U.S. Appl. No. 16/012,635. cited by applicant

Preissl et al., “Single-nucleus analysis of accessible chromatin in developing mouse forebrain reveals cell-type-specific transcriptional regulation,” *Nature Neuroscience* 2018, 21(3), 432-439. cited by applicant

Proposed Stipulated Protective Order Pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, filed Jun. 20, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 26 pp. cited by applicant

Qiu et al., “DNA Sequence-Based “Bar Codes” for Tracking the Origins of Expressed Sequence Tags from a Maize cDNA Library Constructed Using Multiple mRNA Sources,” *Plant Physiol.* 2003, 133, 475-481. cited by applicant

Raj et al., “Stochastic mRNA synthesis in mammalian cells,” *PLoS Biol.* 2006, 4(10) 1707-1719. cited by applicant

Raj et al., "Imaging individual mRNA molecules using multiple singly labeled probes," *Nature Methods* 2008, 5(10), 877-879. cited by applicant

Raj et al., "Single-Molecule Approaches to Stochastic Gene Expression," *Annu Rev Biophys* 2009, 38, 255-270. cited by applicant

Rajeevan et al., "Global amplification of sense RNA: a novel method to replicate and archive mRNA for gene expression analysis," *Genomics* 2003, 82, 491-497. cited by applicant

Report on the Filing or Determination of an Action Regarding a Patent or Trademark filed Nov. 15, 2018 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Restriction Requirement dated Mar. 15, 2016 in U.S. Appl. No. 14/381,488. cited by applicant

Restriction Requirement dated Mar. 17, 2016 in U.S. Appl. No. 14/472,363. cited by applicant

Restriction Requirement dated Mar. 29, 2019 in U.S. Appl. No. 15/715,028. cited by applicant

Restriction Requirement dated Jun. 19, 2019 in U.S. Appl. No. 15/596,364. cited by applicant

Restriction Requirement dated Sep. 20, 2019 in U.S. Appl. No. 15/875,816. cited by applicant

Rhee et al., "Simultaneous detection of mRNA and protein stem cell markers in live cells," *BMC Biotechnology* 2009, 9(30), 1-10. cited by applicant

Roche Diagnostics GmbH, "Genome Sequencer 20 System: First to the Finish," 2006, 1-40. cited by applicant

Rule 7.1 Disclosure Statement dated Nov. 15, 2018 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 1 pp. cited by applicant

Sah et al., "Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal," *Microbiol Resour Announc.* 2020, 9(11), e00169-20, 3 pp. cited by applicant

Sano et al., "Immuno-PCR: Very Sensitive Antigen Detection by Means of Specific Antibody-DNA Conjugates," *Science* 1992, 258, 120-122. cited by applicant

Sasagawa et al., "Quartz-Seq: a highly reproducible and sensitive single-cell RNA sequencing method, reveals non-genetic gene-expression heterogeneity," *Genome Biology* 2013, 14, R31. cited by applicant

Sasuga et al., Single-cell chemical lysis method for analyses of intracellular molecules using an array of picoliter-scale microwells, *Anal Chem* 2008, 80(23), 9141-9149. cited by applicant

Satija et al., Spatial reconstruction of single-cell gene expression data, *Nature Biotechnology* 2015, 33(5), 495-508. cited by applicant

Scheduling Order pursuant to Local Rule 16.1(b), filed May 7, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 10 pp. cited by applicant

Scheduling Order Signed by Judge Andrews, dated May 8, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 10 pp. cited by applicant

Schmitt et al., "Detection of ultra-rare mutations by next-generation sequencing," *Proc Natl Acad Sci* 2012, 109(36), 1-6. cited by applicant

Search and Examination Report dated Aug. 26, 2015 in United Kingdom Patent Application No. 1511591.8. cited by applicant

Search Report and Written Opinion dated Jan. 26, 2016 in Singapore Patent Application No. 1120140527W. cited by applicant

Search Report and Written Opinion dated Aug. 26, 2020 in Singapore Patent Application No. 10201806890V. cited by applicant

Sebat et al., "Large-Scale Copy Number Polymorphism in the Human Genome," *Science* 2004, 305, 525-528. cited by applicant

Shahi et al., "Abseq: ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding," *Scientific Reports* 2017, 7(44447), 1-10. cited by applicant

Shalek et al., "Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells," *Nature* 2013, 498(7453), 236-240. cited by applicant

Shendure et al., "Next-generation DNA sequencing," *Nature Biotechnology* 2008, 26(10), 1135-1145. cited by applicant

Shirotguchi et al., "Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes," *Proc Natl Acad Sci* 2012, 109(4):1347-1352. cited by applicant

S.H.KO, "An 'equalized cDNA library' by the reassociation of short double-stranded cDNAs," *Nucleic Acids Res.* 1990, 18(19), 5705-5711. cited by applicant

Shoemaker et al., "Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy," *Nature Genetics* 1996, 14, 450-456. cited by applicant

Shortreed et al., "A thermodynamic approach to designing structure-free combinatorial DNA word sets," *Nucleic Acids Res.* 2005, 33(15), 4965-4977. cited by applicant

Shum et al., "Quantitation of mRNA Transcripts and Proteins Using the BD Rhapsody™ Single-Cell Analysis System," *Adv Exp Med Biol.* 2019, 1129, 63-79. cited by applicant

Simpson et al., "Copy number variant detection in inbred strains from short read sequence data," *Bioinformatics* 2010, 26(4), 565-567. cited by applicant

Smith et al., "Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples," *Nucleic Acids Research* 2010, 38(13), e142, 1-7. cited by applicant

Soares et al., "Construction and characterization of a normalized cDNA library," *Proc. Natl., Acad. Sci.* 1994, 91, 9228-9232. cited by applicant

Sogin et al., "Microbial diversity in the deep sea and the underexplored "rare biosphere"," *PNAS* 2008, 103(32), 12115-12120. cited by applicant

Sommer et al., "Minimal homology requirements for PCR primers," *Nucleic Acids Research* 1989, 17(16), 6749. cited by applicant

Song et al., "Design rules for size-based cell sorting and sheathless cell focusing by hydrophoresis," *Journal of Chromatography A* 2013, 1302, 191-196. cited by applicant

Soumillon et al., "Characterization of directed differentiation by high-throughput single-cell RNA-Seq," *bioRxiv* 2014, 1-13. cited by applicant

Speicher et al., "The new cytogenetics: blurring the boundaries with molecular biology," *Nature Reviews Genetics* 2005, 6(10), 782-792. cited by applicant

Statement of Opposition of Strawman Limited filed against European Patent No. EP2414548B1 on Jul. 19, 2016. cited by applicant

Statement of Opposition dated Jul. 21, 2016 filed against European Patent No. EP2414548B1. cited by applicant

Statement of Opposition filed against European Patent No. EP2414548B1 on Jul. 26, 2016. cited by applicant

Statement regarding Third-Party Submission filed on Jun. 6, 2018 for U.S. Appl. No. 15/847,752. cited by applicant

Stipulated Protective Order Pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, dated Jun. 21, 2019 in the USDC for the District of Delaware, C.A. 18-1800 (RGA), 26 pp. cited by applicant

Stipulation and Order to Extend Time to File Opposition to Motion to Dismiss, and Reply in Support of the Motion, dated Jan. 28, 2019 in the USDC for the District of Delaware, C.A. 18-1800-RGA, 2 pp. cited by applicant

Stoeckius et al., "Large-scale simultaneous measurement of epitopes and transcriptomes in single cells," *Nature Methods* 2017, 14(9), 865-868. cited by applicant

Stoeckius et al., "Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics," *Genome Biology* 2018, 19(224), 1-12. cited by applicant

Stratagene 1988 Catalog, Gene Characterization Kits, 39. cited by applicant

Subkhankulova et al., "Comparative evaluation of linear and exponential amplification techniques for expression profiling at the single cell level," *Genome Biology* 2006, 7(3), 1-16. cited by applicant

Submission dated Jan. 15, 2018 in preparation for upcoming oral proceedings in opposition against

European Patent No. EP2414548B1. cited by applicant

Summons in a Civil Action to Defendant 10X Genomics, Inc. filed Nov. 16, 2018 in the USDC for the District of Delaware, Civil Action No. 18-1800, 2 pp. cited by applicant

Summons to Attend Oral Proceedings dated Nov. 16, 2020 in European Patent Application No. 17202409.3. cited by applicant

Sun et al., "Ultra-deep profiling of alternatively spliced *Drosophila* Dscam isoforms by circularization-assisted multi-segment sequencing," EMBO J. 2013, 32(14), 2029-2038. cited by applicant

Takahashi et al., "Novel technique of quantitative nested real-time PCR assay for *Mycobacterium tuberculosis* DNA," Journal of Clinical Microbiology 2006, 44, 1029-1039. cited by applicant

Tan et al., "Genome-wide comparison of DNA hydroxymethylation in mouse embryonic stem cells and neural progenitor cells by a new comparative hMeDIP-seq method," Nucleic Acids Res. 2013, 41(7), e84, 1-12. cited by applicant

Tang et al., "RNA-Seq analysis to capture the transcriptome landscape of a single cell," Nature Protocols 2010, 5(3), 516-535. cited by applicant

Taudien et al., "Haplotyping and copy number estimation of the highly polymorphic human beta-defensin locus on 8p23 by 454 amplicon sequencing," BMC Genomics 2010, 11, 252, 1-14. cited by applicant

The Tibbs Times, UNC bioscience newsletter, Apr. 2010, 1-17. cited by applicant

Third-Party Submission filed on May 21, 2018 for U.S. Appl. No. 15/847,752. cited by applicant

Tomaz et al., "Differential methylation as a cause of allele dropout at the imprinted GNAS locus," Genet Test Mol Biomarkers 2010, 14(4), 455-460. cited by applicant

TotalSeq™—A0251 anti-human Hashtag 1 Antibody, BioLegend®, Jul. 2018, 1-10. cited by applicant

Treutlein et al., Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq, Nature 2014, 509, 371-375. cited by applicant

Ullal et al., "Cancer cell profiling by barcoding allows multiplexed protein analysis in fine needle aspirates," Sci Transl Med. 2014, 6(219), 22 pp. cited by applicant

Unopposed Motion to Extend Time for Defendant's Response, dated Dec. 4, 2018 in the USDC for the District of Delaware, C.A. 18-1800-(RGA), 2 pp. cited by applicant

Vandesompele et al., "Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes," Genome Biology 2002, 3(7), 1-12. cited by applicant

Velculescu et al., "Serial Analysis of Gene Expression," Science 1995, 270(5235), 484-487. cited by applicant

Velculescu et al., "Characterization of the Yeast Transcriptome," Cell 1997, 88, 243-251. cited by applicant

Vestheim et al., "Application of Blocking Oligonucleotides to Improve Signal-to-Noise Ratio in a PCR," Methods in Molecular Biology 2011, 687, 265-274. cited by applicant

Vogelstein et al., "Digital PCR," Proc. Natl. Acad. Sci. 1999, 96, 9236-9241. cited by applicant

Vollbrecht et al., "Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients," Oncotarget 2018, 9(26), 18529-18539. cited by applicant

Walker et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system," Proc Natl Acad Sci 1992, 89, 392-396. cited by applicant

Walsh et al., "Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing," Proc Natl Acad Sci 2010, 107(28), 12629-12633. cited by applicant

Wang et al., "Combining Gold Nanoparticles with Real-Time Immuno-PCR for Analysis of HIV p24 Antigens," Proceedings of ICBBE 2007, 1198-1201. cited by applicant

Wang et al., "RNA-Seq: a revolutionary tool for transcriptomics," Nature Reviews Genetics 2009,

10(1), 57-63. cited by applicant

Wang et al., "iCLIP predicts the dual splicing effects of TIA-RNA interactions," PLoS Biol 2010, 8(10), e1000530, 1-16. cited by applicant

Wang et al., "Advances and applications of single-cell sequencing technologies," Molecular Cell 2015, 58, 598-609. cited by applicant

Warren et al., "Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR," PNAS 2006, 103(47), 17807-17812. cited by applicant

Weber et al., "A real-time polymerase chain reaction assay for quantification of allele ratios and correction of amplification bias," Anal Biochem. 2003, 320, 252-258. cited by applicant

Weibrecht et al., "Proximity ligation assays: a recent addition to the proteomics toolbox," Expert Rev. Proteomics 2010, 7(3), 401-409. cited by applicant

Weiner et al., "Kits and their unique role in molecular biology: a brief retrospective," BioTechniques 2008, 44(5), 701-704. cited by applicant

White et al., "High-throughput microfluidic single-cell RT-qPCR," PNAS 2011, 108(34), 13999-14004. cited by applicant

Wittes et al., "Searching for Evidence of Altered Gene Expression: a Comment on Statistical Analysis of Microarray Data," Journal of the National Cancer Institute 1999, 91(5), 400-401. cited by applicant

Wodicka et al., "Genome-wide expression monitoring in *Saccharomyces cerevisiae*," Nature Biotechnology 1997, 15, 1359-1367. cited by applicant

Wojdacz et al., "Primer design versus PCR bias in methylation independent PCR amplifications," Epigenetics 2009, 4(4), 231-234. cited by applicant

Wood et al., "Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens," Nucleic Acids Res. 2010, 38(14), 1-14. cited by applicant

Written Submission of Publications dated Jun. 14, 2018 in Japanese Patent Application No. 2016-537867. cited by applicant

Wu et al., "Quantitative assessment of single-cell RNA-sequencing methods," Nat Methods 2014, 11(1), 41-46. cited by applicant

Yandell et al., "A probabilistic disease-gene finder for personal genomes," Genome Res. 2011, 21(9), 1529-1542. cited by applicant

Ye et al., "Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification," Human Mutation 2001, 17(4), 305-316. cited by applicant

Yoon et al., "Sensitive and accurate detection of copy number variants using read depth of coverage," Genome Res. 2009, 19, 1586-1592. cited by applicant

Zeberg et al., "The major genetic risk factor for severe COVID-19 is inherited from Neanderthals," Nature 2020, 587(7835), 1-13. cited by applicant

Zagordi et al., "Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies," Nucleic Acids Research 2010, 38(21), 7400-7409. cited by applicant

Zhang et al., "The impact of next-generation sequencing on genomics," J Genet Genomics 2011, 38(3), 95-109. cited by applicant

Zhang et al., "DNA-based hybridization chain reaction for amplified bioelectronic signal and ultrasensitive detection of proteins," Anal Chem. 2012, 84, 5392-5399. cited by applicant

Zhao et al., "Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis," Cancer Research 2005, 65(13), 5561-5570. cited by applicant

Zheng et al., "Haplotyping germline and cancer genomes with high-throughput linked-read sequencing," Nature Biotechnology 2016, 34(3), 303-311. cited by applicant

Zhou et al., "Counting alleles reveals a connection between chromosome 18q loss and vascular

invasion,” *Nature Biotechnology* 2001, 19, 78-81. cited by applicant

Zhou et al., “Photocleavable Peptide-Oligonucleotide Conjugates for Protein Kinase Assays by MALDI-TOF MS,” *Mol. BioSyst.* 2012, 8, 2395-2404. cited by applicant

Zhu et al., “Reverse Transcriptase Template Switching: A SMART Approach for Full-Length cDNA Library Construction,” *BioTechniques* 2001, 30(4), 892-897. cited by applicant

10X Genomics, Inc., 2022, “Chromium Fixed RNA Profiling Reagent Kits,” 10xGenomics.com, User Guide, in 95 pages. cited by applicant

Advisory Action dated May 31, 2023 in U.S. Appl. No. 16/789,311. cited by applicant

Arguel et al., “A cost effective 5' selective single cell transcriptome profiling approach with improved UMI design,” *Nucleic Acids Research* 2017, 45(7), e48, in 11 pages. cited by applicant

Chang et al., “Detection of Allelic Imbalance in Ascitic Supernatant by Digital Single Nucleotide Polymorphism Analysis,” *Clinical Cancer Research* 2002, 8, 2580-2585. cited by applicant

De Simone et al., “Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges,” *Frontiers in Immunology* 2018, 9(1638), 1-7. cited by applicant

Dovgan et al., “Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents,” *Bioconjugate Chem.* 2019, 30, 2483-2501. cited by applicant

Erickson et al., “AbSeq Protocol Using the Nano-Well Cartridge-Based Rhapsody Platform to Generate Protein and Transcript Expression Data on the Single-Cell Level,” *STAR Protocols* 2020, in 31 pages. cited by applicant

Final Office Action dated Nov. 16, 2022 in U.S. Appl. No. 16/588,405. cited by applicant

Final Office Action dated Jan. 25, 2023 in U.S. Appl. No. 16/789,311. cited by applicant

Final Office Action dated Jan. 26, 2023 in U.S. Appl. No. 16/459,444. cited by applicant

Final Office Action dated Feb. 21, 2023 in U.S. Appl. No. 16/551,620. cited by applicant

Final Office Action dated Apr. 25, 2023 in U.S. Appl. No. 16/525,054. cited by applicant

Final Office Action dated May 15, 2023 in U.S. Appl. No. 16/551,638. cited by applicant

Final Office Action dated May 19, 2023 in U.S. Appl. No. 17/163,177. cited by applicant

Final Office Action dated May 31, 2023 in U.S. Appl. No. 16/934,530. cited by applicant

Final Office Action dated Jun. 8, 2023 in U.S. Appl. No. 17/147,283. cited by applicant

International Search Report and Written Opinion dated Sep. 27, 2021, in PCT Application No. PCT/US2021/013747. cited by applicant

International Search Report and Written Opinion dated Dec. 5, 2022, in PCT Application No. PCT/US2022/075774. cited by applicant

International Search Report and Written Opinion dated Dec. 15, 2022, in PCT Application No. PCT/US2022/075655. cited by applicant

International Search Report and Written Opinion dated Dec. 20, 2022, in PCT Application No. PCT/US2022/075661. cited by applicant

International Search Report and Written Opinion dated Dec. 22, 2022, in PCT Application No. PCT/US2022/075577. cited by applicant

International Search Report and Written Opinion dated Jan. 9, 2023, in PCT Application No. PCT/US2022/076366. cited by applicant

International Search Report and Written Opinion dated Jan. 17, 2023, in PCT Application No. PCT/US2022/076056. cited by applicant

International Search Report and Written Opinion dated Feb. 13, 2023, in PCT Application No. PCT/US2022/075656. cited by applicant

Lee et al., “Comparison of Surface Markers between Human and Rabbit Mesenchymal Stem Cells,” *PLoS ONE* 2014, 9(11), in 10 pages. cited by applicant

Mayer et al., “Obtaining deeper insights into microbiome diversity using a simple method to block host and nontargets in amplicon sequencing,” *Molecular Ecology Resources* 2021, 21(6), 1952-1965. cited by applicant

Non-Final Office Action dated Jun. 9, 2021 in U.S. Appl. No. 16/588,405. cited by applicant

Non-Final Office Action dated Nov. 17, 2022 in U.S. Appl. No. 16/551,638. cited by applicant
Non-Final Office Action dated Dec. 8, 2022 in U.S. Appl. No. 16/934,530. cited by applicant
Non-Final Office Action dated Dec. 21, 2022 in U.S. Appl. No. 15/055,407. cited by applicant
Non-Final Office Action dated Jan. 10, 2023 in U.S. Appl. No. 17/163,177. cited by applicant
Non-Final Office Action dated Jan. 19, 2023 in U.S. Appl. No. 17/091,639. cited by applicant
Non-Final Office Action dated Jan. 23, 2023 in U.S. Appl. No. 17/183,840. cited by applicant
Non-Final Office Action dated Jan. 24, 2023 in U.S. Appl. No. 17/157,872. cited by applicant
Non-Final Office Action dated Feb. 10, 2023 in U.S. Appl. No. 17/390,640. cited by applicant
Non-Final Office Action dated Feb. 23, 2023 in U.S. Appl. No. 17/408,374. cited by applicant
Non-Final Office Action dated Mar. 13, 2023 in U.S. Appl. No. 17/151,050. cited by applicant
Non-Final Office Action dated Apr. 26, 2023 in U.S. Appl. No. 16/540,971. cited by applicant
Non-Final Office Action dated Apr. 26, 2023 in U.S. Appl. No. 16/374,626. cited by applicant
Notice of Allowance dated Apr. 26, 2022 in Chinese Patent Application No. 201780058799.1. cited by applicant
Notice of Allowance dated Oct. 25, 2022 in European Patent Application No. 19724003.9. cited by applicant
Notice of Allowance dated Jan. 10, 2023 in U.S. Appl. No. 16/588,405. cited by applicant
Notice of Allowance dated Jan. 19, 2023 in Korean Patent Application No. 10-2022-7004715. cited by applicant
Notice of Allowance dated Jan. 31, 2023 in U.S. Appl. No. 16/747,737. cited by applicant
Notice of Allowance dated Feb. 1, 2023 in U.S. Appl. No. 17/147,272. cited by applicant
Notice of Allowance dated Feb. 21, 2023 in Korean Patent Application No. 10-2022-7017261. cited by applicant
Notice of Allowance dated Mar. 1, 2023 in U.S. Appl. No. 17/192,814. cited by applicant
Notice of Allowance dated Mar. 10, 2023 in European Patent Application No. 19762517.1. cited by applicant
Notice of Allowance dated Mar. 10, 2023 in European Patent Application No. 20708266.0. cited by applicant
Notice of Allowance dated Mar. 10, 2023 in European Patent Application No. 19724003.9. cited by applicant
Notice of Allowance dated Mar. 13, 2023 in European Patent Application No. 17781265.8. cited by applicant
Notice of Allowance dated Apr. 4, 2023 in Australian Patent Application No. 2017331459. cited by applicant
Notice of Allowance dated Jun. 8, 2023 in Australian Patent Application No. 16/459,444. cited by applicant
Office Action dated May 21, 2021 in Chinese Patent Application No. 201680007351.2. cited by applicant
Office Action dated May 5, 2022 in European Patent Application No. 19787547.9. cited by applicant
Office Action dated Sep. 21, 2022 in Israel Patent Application No. 265478. cited by applicant
Office Action dated Jan. 30, 2023 in European Patent Application No. 19752792.2. cited by applicant
Office Action dated Feb. 8, 2023 in Australian Patent Application No. 2017331459. cited by applicant
Office Action dated Feb. 20, 2023 in European Patent Application No. 19723988.2. cited by applicant
Office Action dated Feb. 23, 2023 in European Patent Application No. 20816802.1. cited by applicant
Office Action dated Feb. 28, 2023 in Chinese Patent Application No. 2019111653930. cited by applicant

applicant
Office Action dated Mar. 15, 2023 in European Patent Application No. 19787547.9. cited by applicant
Office Action dated Mar. 27, 2023 in European Patent Application No. 19836036.4. cited by applicant
Office Action dated Mar. 29, 2023 in Chinese Patent Application No. 2020800144092. cited by applicant
Office Action dated Apr. 10, 2023 in Japanese Patent Application No. 2022-030956. cited by applicant
Office Action dated Apr. 14, 2023 in Chinese Patent Application No. 201980082680.7. cited by applicant
Office Action dated Apr. 24, 2023 in Japanese Patent Application No. 2020-561800. cited by applicant
Office Action dated Apr. 24, 2023 in European Patent Application No. 21714995.4. cited by applicant
Office Action dated Apr. 26, 2023 in European Patent Application No. 18703156.2. cited by applicant
Office Action dated May 16, 2023 in European Patent Application No. 21707112.5. cited by applicant
Office Action dated May 26, 2023 in Chinese Patent Application No. 2019800373421. cited by applicant
Pfaffl et al., “Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper—Excel-based tool using pair-wise correlations,” *Biotechnology Letters* 2004, 26(6), 505-515. cited by applicant
Restriction Requirement dated Dec. 23, 2022 in U.S. Appl. No. 17/531,618. cited by applicant
Restriction Requirement dated Jan. 20, 2023 in U.S. Appl. No. 17/373,519. cited by applicant
Restriction Requirement dated Feb. 27, 2023 in U.S. Appl. No. 17/151,058. cited by applicant
Restriction Requirement dated Apr. 4, 2023 in U.S. Appl. No. 17/161,558. cited by applicant
Schouten et al., “Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification,” *Nucleic Acids Research* 2002, 30(12), e57. cited by applicant
Uellendahl-Werth et al., “A benchmark of hemoglobin blocking during library preparation for mRNA Sequencing of human blood samples,” *Scientific Reports* 2020, 10(1), 5630. cited by applicant
Wangsanuwat et al., “Efficient and cost-effective bacterial mRNA sequencing from low input samples through ribosomal RNA depletion,” *BMC Genomics* 2020, 21(1), 1-12. cited by applicant
Wu & Lambowitz, “Facile single-stranded DNA sequencing of human plasma DNA via thermostable group II intron reverse transcriptase template switching,” *Scientific Reports* 2017, 7(8421), 1-14. cited by applicant
Armbrecht, et al. “Single-cell protein profiling in microchambers with barcoded beads”, *Microsystems & Nanoengineering*, 2019, 5:55. cited by applicant
Buschmann et al., Enhancing the detection of barcoded reads in high throughput DNA sequencing DNA by controlling the false discovery rate, *BMC Bioinformatics*, 2014, 15(1), 264, 1-16. cited by applicant
Decision of Grant dated Aug. 21, 2023 in Japanese Patent Application 2020-561800. cited by applicant
Delebecque et al. “Designing and using RNA scaffolds to assemble proteins in vivo”. *Nature protocols*, 2012, 7(10), 1797-1807. cited by applicant
Dickey and Giangrande. “Oligonucleotide Aptamers: A Next-Generation Technology for the Capture and Detection of Circulating Tumor Cells.” *Methods*, 2016 97:94-103. cited by applicant
Dua, et al. “Patents on SELEX and therapeutic aptamers. Recent patents on DNA & gene

sequences,” 2008, 2(3), 172-186. cited by applicant

Eulberg, et al. “Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist,” *Nucleic acids research*, 2005, 33(4), e45. <https://doi.org/10.1093/nar/gni044>. cited by applicant

Examination Report dated Oct. 31, 2023 in European Patent Application 20753616.0. cited by applicant

Examination Report dated Nov. 9, 2023 in European Patent Application 20711394.5. cited by applicant

Extended European Search Report Dated Oct. 4, 2023 in European Patent Application No. 23166582.9. cited by applicant

Fathi,, P. Design and Characterization of SSDNA Aptamer Candidates to Bind *Bacteroides Fragilis* Toxin Subtypes BFT-1 and BFT-2 (Doctoral dissertation, Johns Hopkins University).2017. cited by applicant

Final Office Action dated Oct. 5, 2023 in U.S. Appl. No. 17/151,050. cited by applicant

Final Office Action dated Oct. 13, 2023 in U.S. Appl. No. 15/055,407. cited by applicant

Final Office Action dated Oct. 23, 2023 in U.S. Appl. No. 16/540,971. cited by applicant

Hoinka and Przytycka. “AptaPLEX—A Dedicated, Multithreaded Demultiplexer for HT-SE LEX Data.” *Methods*, 2016, 106:82-85 cited by applicant

Illumina, “Data Processing of Nextera Mate Pair Reads on Illumina Sequencing Platforms”, Data Processing Technical Note from 2012. cited by applicant

International Search Report and Written Opinion dated Jun. 5, 2023, in PCT Application No. PCT/US2023/061980. cited by applicant

International Search Report and Written Opinion dated Jun. 23, 2023 in PCT Application No. PCT/US2023/062070. cited by applicant

Invitrogen, “The attraction is simply magnetisk, Dynabeads® Streptavidin products and applications” Invitrogen, 2010, 1-8. cited by applicant

Ku, et al. “Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing.” *Sensors*, 2015, 15, 16281-16313. cited by applicant

Ko, “An ‘equalized cDNA library’ by the reassociation of short double-stranded cDNAs,” *Nucleic Acids Res.* 1990, 18(19), 5705-5711. cited by applicant

Livingstone, “rRNA depletion, poly(A) enrichment, or exonuclease treatment?” *Tebu-Bio Blog* 2015,. 5 pgs. cited by applicant

Mairal et al. “Aptamers: Molecular Tools for Analytical Applications.” *Analytical and bioanalytical chemistry* 2008,390: 989-1007. cited by applicant

Non-Final Office Action dated Jun. 14, 2023 in U.S. Appl. No. 17/174,249. cited by applicant

Non-Final Office Action dated Jun. 30, 2023 in U.S. Appl. No. 17/684,289. cited by applicant

Non-Final Office Action dated Jul. 27, 2023 in U.S. Appl. No. 17/373,519. cited by applicant

Non-Final Office Action dated Sep. 21, 2023 in Canadian Patent Application No. 3,034,924. cited by applicant

Non-Final Office Action dated Sep. 28, 2023 in U.S. Appl. No. 16/789,311. cited by applicant

Non-Final Office Action Dated Sep. 28, 2023 in U.S. Appl. No. 17/184,405. cited by applicant

Non-Final Office Action Dated Oct. 5, 2023 in U.S. Appl. No. 16/848,241. cited by applicant

Non-Final Office Action Dated Nov. 7, 2023 in U.S. Appl. No. 17/528,104. cited by applicant

Notice of Allowance dated Aug. 23, 2023 in Canadian Patent Application No. 2,865,575. cited by applicant

Notice of Allowance dated Aug. 25, 2023 in European Patent Application No. 22 200 785.8. cited by applicant

Notice of Allowance dated Aug. 28, 2023 in U.S. Appl. No. 16/374,626. cited by applicant

Notice of Allowance dated Sep. 14, 2023 in Canada Application No. 2982467. cited by applicant

Notice of Allowance dated Sep. 29, 2023 in European Application No. 22165594.7. cited by

applicant
Notice of Allowance dated Oct. 2, 2023 in European Application 21735067.8. cited by applicant
Notice of Allowance dated Oct. 25, 2023 in European Application 20816802.1. cited by applicant
Office Action dated Nov. 24, 2022 in Chinese Patent Application No. 2018800147939. cited by applicant
Office Action dated Aug. 31, 2021 in Chinese Patent Application No. 2016800157452. cited by applicant
Office Action dated Jun. 16, 2023 in Chinese Patent Application No. 2019800708938. cited by applicant
Office Action dated Jun. 22, 2023 in Japanese Patent Application No. 2022-071002. cited by applicant
Office Action dated Jun. 28, 2023 in European Patent Application 19836239.4. cited by applicant
Office Action dated Jul. 12, 2023 in Chinese Patent Application No. 2020800212600. cited by applicant
Office Action dated Jul. 12, 2023 in Canadian Patent Application No. 3,059,559. cited by applicant
Office Action dated Aug. 11, 2023 in European Patent Application 19752792.2. cited by applicant
Office Action dated Aug. 21, 2023 in Japanese Patent Application No. 2021-507836. cited by applicant
Office Action dated Sep. 21, 2023 in Japanese Patent Application 2022-030956. cited by applicant
Office Action dated Sep. 21, 2023 in Israel Patent Application 265478. cited by applicant
Office Action dated Oct. 10, 2023 in European Patent Application 16719706.0. cited by applicant
Office Action dated Oct. 13, 2023 in Chinese Patent Application 202080014409.2. cited by applicant
Office Action dated Oct. 19, 2023 in Japanese Patent Application 2019-566787. cited by applicant
Office Action dated Oct. 23, 2023 in Japanese Patent Application 2021-517856. cited by applicant
Office Action dated Oct. 26, 2023 in Japanese Patent Application 2022-525692. cited by applicant
Office Action Dated Oct. 30, 2023 in Japanese Patent Application 2021-523956. cited by applicant
Office Action Dated Nov. 9, 2023 in Japanese Patent Application 2017-549390. cited by applicant
Ogawa, T. et al., "The Efficacy and further functional advantages of random-base molecular barcodes for absolute and digital quantification of nucleic acid molecules", Sci Rep 7, 2017 12576. cited by applicant
Restriction Requirement dated Jun. 28, 2023 in U.S. Appl. No. 17/336,055. cited by applicant
Restriction Requirement dated Oct. 5, 2023 in U.S. Appl. No. 17/373,653. cited by applicant
Restriction Requirement dated Oct. 11, 2023 in U.S. Appl. No. 17/531,555. cited by applicant
Spanova et al., "Magnetic hydrophilic methacrylate-based polymer microspheres designed for polymerase chain reaction applications", Journal of Chromatography vol. 800, 2004, 27-32. cited by applicant
Summons to Attend Oral Proceedings Dated Aug. 8, 2023 in European Patent Application No. 14749671.5. cited by applicant
Wang et al., "Development of Multicolor Flow Cytometry Calibration Standards: Assignment of Equivalent Reference Fluorophores (ERF) Unit" J. Res. Natl. Inst. Stand. Technol. 2011 116, 671-683. cited by applicant
Zheng, et al. "Aptamer-Functionalized Barcode Particles for the Capture and Detection of Multiple Types of Circulating Tumor Cells." Advanced materials (Weinheim), 2014, 26, 7333-7338. cited by applicant
Zhou and Rossi. "Aptamers as Targeted Therapeutics: Current Potential and Challenges." Nature reviews. Drug discovery, 2017, 16:181-202. cited by applicant
Zhulidov et al., "Simple cDNA normalization using kamchatka crab duplex-specific nuclease," Nucleic Acids Research. 2004, 32(3)e37. cited by applicant

Primary Examiner: Gangle; Brian

Assistant Examiner: McCollum; Andrea K

Attorney, Agent or Firm: Dickinson Wright PLLC

Background/Summary

RELATED APPLICATIONS (1) This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 63/125,629, filed Dec. 15, 2020, the content of this related application is incorporated herein by reference in its entirety for all purposes.

BACKGROUND

Field

(1) The present disclosure relates generally to the field of molecular biology, for example determining the secreted molecule profiles of cells using molecular barcoding.

Description of the Related Art

(2) Current technology allows measurement of gene expression of single cells in a massively parallel manner (e.g., >10000 cells) by attaching cell specific oligonucleotide barcodes to poly(A) mRNA molecules from individual cells as each of the cells is co-localized with a barcoded reagent bead in a compartment. Gene expression may affect protein expression and the secretion of molecules. Protein-protein interaction may affect gene expression and protein expression as well as secretion of molecules by cells. Cytokines and other molecules released by the cell are of keen interest to immunologists and other cell biologists. Traditional methods for detecting and measuring secreted proteins are typically measured in bulk (rather than at the single cell level). For example, currently available methods include bead-based assays and ELISA for studying secreted factors in bulk. Therefore, single cell quantification and cellular phenotype analysis are missing in the data. As with the comparison of flow cytometry to traditional western blots, there is tremendous value in studying the individual cells from a heterogenous mixture of cells. There is an increasing need to correlate specific secretion activity with complex cell phenotype. Currently available methods for detecting secreted proteins have a limitation on the number of proteins that can be detected due to the number of fluorescence markers that can be used in the microscope or flow cytometry analysis. Moreover, such methods are less quantitative than desired due to limitations in measuring fluorescence intensity differences. There is a need for systems and methods that can quantitatively analyze the number of copies of a secreted factor secreted by a single cell. There is a need for systems and methods that can quantitatively analyze the number of copies of a secreted factor secreted by a single cell and simultaneously measure protein expression and/or gene expression.

SUMMARY

(3) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell. The method can comprise: contacting one or more single cells with a first plurality of first solid supports, the one or more single cells are capable of secreting a plurality of secreted factors, each first solid support comprises a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the first solid support with a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with

the secreted factor-binding reagent specific oligonucleotides for hybridization, the oligonucleotide barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.

(4) In some embodiments, contacting one or more single cells with a first plurality of first solid supports comprises: partitioning the one or more single cells and the first plurality of first solid supports to a plurality of first partitions, a first partition of the plurality of first partitions comprises a single cell of the one or more single cells and a single first solid support of the first plurality of first solid supports. In some embodiments, the method comprises, prior to contacting the first solid support with a plurality of secreted factor-binding reagents: pooling the single first solid supports from each first partition of the plurality of first partitions to generate a second plurality of first solid supports. In some embodiments, contacting the first solid support with a plurality of secreted factor-binding reagents comprises contacting the second plurality of first solid supports with the plurality of secreted factor-binding reagents. In some embodiments, the method comprises, after contacting the second plurality of first solid supports with the plurality of secreted factor-binding reagents, removing one or more secreted factor-binding reagents of the plurality of secreted factor-binding reagents that are not contacted with the second plurality of first solid supports to generate a third plurality of first solid supports. In some embodiments, removing the one or more secreted factor-binding reagents not contacted with the second plurality of first solid supports comprises: removing the one or more secreted factor-binding reagents not contacted with the respective at least one of the secreted factor bound by a capture probe. In some embodiments, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization comprises: partitioning the third plurality of first solid supports to a plurality of second partitions, a second partition of the plurality of second partitions comprises a single first solid support from the third plurality of first solid supports; and in the second partition comprising the single first solid support, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization.

(5) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell and the number of copies of a nucleic acid target in a single cell. The method can comprise: contacting one or more single cells with a first plurality of second solid supports to form one or more single cells associated with a second solid support, the one or more single cells comprise a surface cellular target and copies of a nucleic acid target, the one or more single cells are capable of secreting a plurality of secreted factors, each second solid support comprises a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to the surface cellular target, and the capture probe is capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization, the oligonucleotide

barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the copies of a nucleic acid target to generate a plurality of barcoded nucleic acid molecules each comprising a sequence complementary to at least a portion of the nucleic acid target and the first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded nucleic acid molecules, or products thereof, to determine the copy number of the nucleic acid target in each of the one or more single cells. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells (e.g., T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof).

(6) In some embodiments, contacting one or more single cells with a first plurality of second solid supports to form one or more single cells associated with a second solid support comprises: partitioning the one or more single cells and the plurality of second solid supports to a plurality of first partitions, a first partition of the plurality of first partitions comprises a single cell of the one or more single cells and a single second solid support of the plurality of second solid supports, the single cell is capable of becoming associated with a second solid support via the anchor probe binding to the surface cellular target. In some embodiments, the method comprises, prior to contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents: pooling the single cells associated with a second solid support from each first partition of the plurality of first partitions to generate a first plurality of single cells associated with a second solid support.

(7) In some embodiments, contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents comprises contacting the first plurality of single cells associated with a second solid support with the plurality of secreted factor-binding reagents. In some embodiments, the method comprises, after contacting the first plurality of single cells associated with a second solid support with the plurality of secreted factor-binding reagents, removing one or more secreted factor-binding reagents of the plurality of secreted factor-binding reagents that are not contacted with the first plurality of single cells associated with a second solid support to generate a second plurality of single cells associated with a second solid support. In some embodiments, removing the one or more secreted factor-binding reagents not contacted with the first plurality of single cells associated with a second solid support comprises: removing the one or more secreted factor-binding reagents not contacted with the respective at least one of the secreted factor bound by a capture probe.

(8) The method can comprise: prior to contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization: partitioning the second plurality of single cells associated with a second solid support to a plurality of second partitions, a second partition of the plurality of second partitions comprises a single cell and a single second solid support from the second plurality of single cells associated with a second solid support; in the second partition comprising the single cell and the single second solid support, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization. In some embodiments, the method comprises lysing the single cell in the second partition. Lysing the single cell can comprise heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.

(9) The at least one secreted factor can comprise a lymphokine, an interleukin, a chemokine, or any

combination thereof. For example, the secreted factor can be a cytokine, a hormone, a molecular toxin, or any combination thereof. In some embodiments, the at least one secreted factor comprises a nerve growth factor, a hepatic growth factor, a fibroblast growth factor, a vascular endothelial growth factor, a platelet-derived growth factor, a transforming growth factor, an osteoinductive factor, an interferon, a colony stimulating factor, or any combination thereof. The at least one secreted factor can comprise angiogenin, angiopoietin-1, angiopoietin-2, bNGF, cathepsin S, Galectin-7, GCP-2, G-CSF, GM-CSF, PAI-1, PDGF-AA, PDGF-BB, PDGF-AB, PlGF, PlGF-2, SDF-1, Tie2, VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3, 6Ckine, angiopoietin-1, angiopoietin-2, BLC, BRAK, CD186, ENA-78, Eotaxin-1, Eotaxin-2, Eotaxin-3, EpCAM, GDF-15, GM-CSF, GRO, HCC-4, I-309, IFN- γ , IL-1 α , IL-1 β , IL-1R4 (ST2), IL-2, IL-2R, IL-3, IL-3R α , IL-5, IL-6, IL-6R, IL-7, IL-8, IL-8 RB, IL-11, IL-12, IL-12p40, IL-12p70, IL-13, IL-13 R1, IL-13R2, IL-15, IL-15R α , IL-16, IL-17, IL-17C, IL-17E, IL-17F, IL-17R, IL-18, IL-18BP α , IL-18 R α , IL-20, IL-23, IL-27, IL-28, IL-31, IL-33, IP-10, I-TAC, LIF, LIX, LRP6, MadCAM-1, MCP-1, MCP-2, MCP-3, MCP-4, M-CSF, MIF, MIG, MIP-1 gamma, MIP-1 α , MIP-1 β , MIP-1 δ , MIP-3 α , MIP-3 β , MPIF-1, PARC, PF4, RANTES, Resistin, SCF, SCYB16, TACI, TARC, TSLP, TNF- α , TNF-R1, TRAIL-R4, TREM-1, Activin A, Amphiregulin, Axl, BDNF, BMP4, cathepsin S, EGF, FGF-1, FGF-2, FGF-7, FGF-21, Follistatin, Galectin-7, Gas6, GDF-15, HB-EGF, HGF, IGFBP-1, IGFBP-3, LAP, NGF R, NrCAM, NT-3, NT-4, PAI-1, TGF- α , TGF- β , TGF- β 3, TRAIL-R4, ADAMTS1, cathepsin S, FGF-2, Follistatin, Galectin-7, GCP-2, GDF-15, IGFBP-6, LIF, MMP-9, pro-MMP9, RANK, RANKL, RANTES, SDF-1, CXCR4, or any combination thereof.

(10) In some embodiments, the secreted factor-binding reagent and the capture probe are capable of binding to distinct epitopes of the same secreted factor. In some embodiments, one or more of the secreted factor-binding reagents, the capture probe, and the anchor probe comprise an antibody or fragment thereof. In some embodiments, the antibody or fragment thereof comprises a monoclonal antibody. In some embodiments, the antibody or fragment thereof comprises a Fab, a Fab', a F(ab')₂, a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, a multispecific antibody formed from antibody fragments, a single-domain antibody (sdAb), a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, an aptamer, an affibody, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPIn, a Fynomer, a Kunitz domain peptide, a monobody, or any combination thereof. In some embodiments, the capture probe and/or the anchor probe is conjugated to the first solid support and/or the second solid support by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, an addition to carbon-carbon multiple bond, an oxidation reaction, a click reaction, or any combination thereof.

(11) The surface cellular target can comprise a carbohydrate, a lipid, a protein, an extracellular protein, a cell-surface protein, a cell marker, a B-cell receptor, a T-cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an intracellular protein, or any combination thereof. For example, the surface cellular target can comprise a carbohydrate, a lipid, a protein, or any combination thereof. In some embodiments, the surface cellular target comprises CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD15u, CD15s, CD15su, CD16, CD16b, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD75s, CD77, CD79a, CD79b,

CD80, CD81, CD82, CD83, CD84, CD85a, CD85d, CD85j, CD85k, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107a, CD107b, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD118, CD119, CD120a, CD120b, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD129, CD130, CD131, CD132, CD133, CD134, CD135, CD136, CD137, CD138, CD139, CD140a, CD140b, CD141, CD142, CD143, CD144, CDw145, CD146, CD147, CD148, CDw149, CD150, CD151, CD152, CD153, CD154, CD155, CD156a, CD156b, CD156c, CD157, CD158e, CD158i, CD158k, CD159a, CD159c, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167a, CD167b, CD168, CD169, CD170, CD171, CD172a, CD172b, CD172g, CD173, CD174, CD175, CD175s, CD176, CD177, CD178, CD179a, CD179b, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CD199, CD200, CD201, CD202b, CD203c, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CDw210b, CD212, CD213a1, CD213a2, CD215, CD217a, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235a, CD235b, CD236, CD236R, CD238, CD239, CD240CE, CD240DCE, CD240D, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD252, CD253, CD254, CD256, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD286, CD289, CD290, CD292, CDw293, CD294, CD295, CD296, CD297, CD298, CD299, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD304, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD308, CD309, CD312, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD324, CD325, CD326, CD327, CD328, CD329, CD331, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD339, CD340, CD344, CD349, CD350, CD351, CD352, CD353, CD354, CD355, CD357, CD358, CD360, CD361, CD362, CD363, CD364, CD365, CD366, CD367, CD368, CD369, CD370, CD371, BCMA, a HLA protein, β 2-microglobulin, or any combination thereof.

(12) In some embodiments, the plurality of oligonucleotide barcodes are associated with a third solid support, and a second partition of the plurality of second partitions comprises a single third solid support. In some embodiments, the first partition and/or second partition is a well or a droplet. In some embodiments, each oligonucleotide barcode comprises a first universal sequence. In some embodiments, the oligonucleotide barcode comprises a target-binding region comprising a capture sequence. In some embodiments, the target-binding region comprises a poly(dT) region. In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises a sequence complementary to the capture sequence configured to capture the secreted factor-binding reagent specific oligonucleotide. In some embodiments, the sequence complementary to the capture sequence comprises a poly(dA) region. In some embodiments, the plurality of barcoded secreted factor-binding reagent specific oligonucleotides comprise a complement of the first universal sequence. In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises a second universal sequence.

(13) In some embodiments, obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, comprises: amplifying the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, using a primer capable of hybridizing to the first universal sequence, or a complement thereof, and a primer capable of hybridizing to the second universal sequence, or a complement thereof, to generate a plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides; and obtaining sequencing data of the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof.

(14) The secreted factor-binding reagent specific oligonucleotide can comprise a second molecular label. In some embodiments, at least ten of the plurality of secreted factor-binding reagent specific

oligonucleotides comprise different second molecular label sequences. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are identical. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are different.

(15) In some embodiments, the number of unique first molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the number of unique second molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the method comprises determining the number of copies of the at least one secreted factor secreted by each of the one or more single cells based on the number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof.

(16) In some embodiments, the method comprises determining the number of copies of the at least one secreted factor secreted by each of the one or more single cells based on the number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof. In some embodiments, obtaining the sequence information comprises attaching sequencing adaptors to the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof.

(17) In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises an alignment sequence adjacent to the poly(dA) region. The alignment sequence can be, one or more nucleotides in length, or two or more nucleotides in length. For example, the alignment sequence can (a) comprises a guanine, a cytosine, a thymine, a uracil, or a combination thereof; (b) comprises a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, a poly(dU) sequence, or a combination thereof; and/or (c) is 5' to the poly(dA) region.

(18) In some embodiments, the secreted factor-binding reagent specific oligonucleotide is associated with the secreted factor-binding reagent through a linker. In some embodiments, the linker comprises a carbon chain. The carbon chain can comprise 2-30 carbons (e.g., 12 carbons). In some embodiments, the linker comprises 5' amino modifier C12 (5AmMC12), or a derivative thereof. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is configured to be detachable from the secreted factor-binding reagent. For example, the method can comprise dissociating the secreted factor-binding reagent specific oligonucleotide from the secreted factor-binding reagent.

(19) In some embodiments, determining the copy number of the nucleic acid target in each of the one or more single cells comprises determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences, complements thereof, or a combination thereof, associated with the plurality of barcoded nucleic acid molecules, or products thereof.

(20) In some embodiments, the method comprises: contacting random primers with the plurality of barcoded nucleic acid molecules, each of the random primers comprises a third universal sequence, or a complement thereof; and extending the random primers hybridized to the plurality of barcoded nucleic acid molecules to generate a plurality of extension products. In some embodiments, the method comprises amplifying the plurality of extension products using primers capable of

hybridizing to the first universal sequence or complements thereof, and primers capable of hybridizing the third universal sequence or complements thereof, thereby generating a first plurality of barcoded amplicons. In some embodiments, amplifying the plurality of extension products comprises adding sequences of binding sites of sequencing primers and/or sequencing adaptors, complementary sequences thereof, and/or portions thereof, to the plurality of extension products. In some embodiments, the method comprises determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the first plurality of barcoded amplicons, or products thereof.

(21) In some embodiments, determining the copy number of the nucleic acid target in each of the one or more single cells comprises determining the number of each of the plurality of nucleic acid targets in each of the one or more single cells based on the number of the first molecular labels with distinct sequences associated with barcoded amplicons of the first plurality of barcoded amplicons comprising a sequence of the each of the plurality of nucleic acid targets. In some embodiments, the sequence of the each of the plurality of nucleic acid targets comprises a subsequence of the each of the plurality of nucleic acid targets. In some embodiments, the sequence of the nucleic acid target in the first plurality of barcoded amplicons comprises a subsequence of the nucleic acid target.

(22) In some embodiments, the method comprises amplifying the first plurality of barcoded amplicons using primers capable of hybridizing to the first universal sequence or complements thereof, and primers capable of hybridizing the third universal sequence or complements thereof, thereby generating a second plurality of barcoded amplicons. In some embodiments, amplifying the first plurality of barcoded amplicons comprises adding sequences of binding sites of sequencing primers and/or sequencing adaptors, complementary sequences thereof, and/or portions thereof, to the first plurality of barcoded amplicons. In some embodiments, the method comprises determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the second plurality of barcoded amplicons, or products thereof. In some embodiments, the first plurality of barcoded amplicons and/or the second plurality of barcoded amplicons comprise whole transcriptome amplification (WTA) products.

(23) In some embodiments, the method comprises synthesizing a third plurality of barcoded amplicons using the plurality of barcoded nucleic acid molecules as templates to generate a third plurality of barcoded amplicons. In some embodiments, synthesizing a third plurality of barcoded amplicons comprises performing (1) PCR amplification of the plurality of the barcoded nucleic acid molecules; (2) PCR amplification using primers capable of hybridizing to the first universal sequence, or a complement thereof, and a target-specific primer; or both. In some embodiments, the method comprises obtaining sequence information of the third plurality of barcoded amplicons, or products thereof. Obtaining the sequence information can comprise attaching sequencing adaptors to the third plurality of barcoded amplicons, or products thereof. The method can comprise determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the third plurality of barcoded amplicons, or products thereof.

(24) In some embodiments, the nucleic acid target comprises a nucleic acid molecule. In some embodiments, the nucleic acid molecule comprises ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation product, RNA comprising a poly(A) tail, a sample indexing oligonucleotide, a cellular component-binding reagent specific oligonucleotide, or any combination thereof. In some embodiments, extending the plurality of oligonucleotide barcodes comprising extending the plurality of oligonucleotide barcodes using a reverse transcriptase and/or a DNA polymerase lacking at least one of 5' to 3' exonuclease activity and 3' to 5' exonuclease activity. In some embodiments, the DNA polymerase comprises a Klenow

Fragment. In some embodiments, the reverse transcriptase comprises a viral reverse transcriptase (e.g., a murine leukemia virus (MLV) reverse transcriptase or a Moloney murine leukemia virus (MMLV) reverse transcriptase).

(25) In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence are the same. In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence are different. In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence comprise the binding sites of sequencing primers and/or a sequencing adaptor, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing adaptors comprise a P5 sequence, a P7 sequence, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing primers comprise a Read 1 sequencing primer, a Read 2 sequencing primer, complementary sequences thereof, and/or portions thereof. In some embodiments, at least 10 of the plurality of oligonucleotide barcodes comprise different first molecular label sequences. In some embodiments, the plurality of oligonucleotide barcodes each comprise a cell label. In some embodiments, each cell label of the plurality of oligonucleotide barcodes comprises at least 6 nucleotides. In some embodiments, oligonucleotide barcodes associated with the same third solid support comprise the same cell label. In some embodiments, oligonucleotide barcodes associated with different third solid supports comprise different cell labels.

(26) In some embodiments, the first solid support, second solid support, and/or third solid support comprises a synthetic particle or a planar surface. In some embodiments, at least one of the plurality of oligonucleotide barcodes is immobilized or partially immobilized on the synthetic particle, or the at least one of the plurality of oligonucleotide barcodes is enclosed or partially enclosed in the synthetic particle. The synthetic particle can be disruptable. The synthetic particle can comprise a bead. The bead can comprise: a sepharose bead, a streptavidin bead, an agarose bead, a magnetic bead, a conjugated bead, a protein A conjugated bead, a protein G conjugated bead, a protein A/G conjugated bead, a protein L conjugated bead, an oligo(dT) conjugated bead, a silica bead, a silica-like bead, an anti-biotin microbead, an anti-fluorochrome microbead, or any combination thereof; a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic, ceramic, plastic, glass, methylstyrene, acrylic polymer, titanium, latex, sepharose, cellulose, nylon, silicone, and any combination thereof; or a disruptable hydrogel particle.

(27) In some embodiments, each of the plurality of oligonucleotide barcodes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(28) In some embodiments, each of the plurality of anchor probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(29) In some embodiments, each of the plurality of capture probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(30) In some embodiments, the first solid support and/or the second solid support is sized and shaped to approximate a cell. In some embodiments, the first solid support and/or the second solid

support has the dimensions of a cell. In some embodiments, the cell is a mammalian cell, a yeast cell, an insect cell, a plant cell, a bacterial cell, or any combination thereof.

(31) Disclosed herein include compositions (e.g., kits). The composition can comprise: a first solid support comprising a plurality of capture probes capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

(32) Disclosed herein include compositions (e.g., kits). The composition can comprise: a second solid support comprising a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to a surface cellular target, and the capture probe is capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

(33) In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises a second molecular label sequence (e.g., 2-20 nucleotides in length). In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are identical. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are different.

(34) In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises a second universal sequence. In some embodiments, the second universal sequence comprises a binding site of a sequencing primers and/or a sequencing adaptor, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing adaptor comprises a P5 sequence, a P7 sequence, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing primer comprises a Read 1 sequencing primer, a Read 2 sequencing primer, complementary sequences thereof, and/or portions thereof.

(35) In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises a poly(dA) region. In some embodiments, the secreted factor-binding reagent specific oligonucleotide comprises an alignment sequence adjacent to the poly(dA) region. The alignment sequence can be one or more nucleotides in length, or two or more nucleotides in length. The alignment sequence can (a) comprises a guanine, a cytosine, a thymine, a uracil, or a combination thereof; (b) comprises a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, a poly(dU) sequence, or a combination thereof; and/or (c) is 5' to the poly(dA) region.

(36) In some embodiments, the secreted factor-binding reagent specific oligonucleotide is associated with the secreted factor-binding reagent through a linker. In some embodiments, the linker comprises a carbon chain. The carbon chain can comprise 2-30 carbons (e.g., 12 carbons). In some embodiments, the linker comprises 5' amino modifier C12 (5AmMC12), or a derivative thereof. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is attached to the secreted factor-binding reagent. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is covalently attached to the secreted factor-binding reagent. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is non-covalently attached to the secreted factor-binding reagent. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is conjugated to the secreted factor-binding reagent. In some embodiments, the secreted factor-binding reagent specific oligonucleotide is conjugated to the

secreted factor-binding reagent through a chemical group, such as a UV photocleavable group, a streptavidin, a biotin, an amine, or a combination thereof.

(37) The secreted factor can comprise a lymphokine, an interleukin, a chemokine, or any combination thereof. For example, the secreted factor can comprise a cytokine, a hormone, a molecular toxin, or any combination thereof. In some embodiments, the secreted factor comprises a nerve growth factor, a hepatic growth factor, a fibroblast growth factor, a vascular endothelial growth factor, a platelet-derived growth factor, a transforming growth factor, an osteoinductive factor, an interferon, a colony stimulating factor, or any combination thereof.

(38) In some embodiments, the secreted factor-binding reagents and the capture probe are capable of binding to distinct epitopes of the same secreted factor. In some embodiments, one or more of the secreted factor-binding reagents, the capture probe, and the anchor probe comprise an antibody or fragment thereof. In some embodiments, the antibody or fragment thereof comprises a monoclonal antibody. In some embodiments, the antibody or fragment thereof comprises a Fab, a Fab', a F(ab').sub.2, a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, a multispecific antibody formed from antibody fragments, a single-domain antibody (sdAb), a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, an aptamer, an affibody, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPin, a Fynomer, a Kunitz domain peptide, a monobody, or any combination thereof. In some embodiments, the capture probe and/or the anchor probe is conjugated to the first solid support and/or the second solid support by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, an addition to carbon-carbon multiple bond, an oxidation reaction, a click reaction, or any combination thereof.

(39) In some embodiments, the surface cellular target comprises a carbohydrate, a lipid, a protein, an extracellular protein, a cell-surface protein, a cell marker, a B-cell receptor, a T-cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an intracellular protein, or any combination thereof. For example, the surface cellular target can comprise a carbohydrate, a lipid, a protein, or any combination thereof.

(40) In some embodiments, the composition comprises a DNA polymerase (e.g., a Klenow Fragment) lacking at least one of 5' to 3' exonuclease activity and 3' to 5' exonuclease activity. In some embodiments, the composition comprises a reverse transcriptase, such as a viral reverse transcriptase. The composition can comprise a buffer, a cartridge, or both.

(41) In some embodiments, the composition comprises a plurality of oligonucleotide barcodes, each oligonucleotide barcode of the plurality of oligonucleotide barcodes comprises a target-binding region. The target-binding region can comprise a poly(dA) region, a poly(dT) region, a random sequence, a gene-specific sequence, or any combination thereof. In some embodiments, the plurality of oligonucleotide barcodes each comprise a molecular label. The molecular label can comprise at least 6 nucleotides. In some embodiments, at least 10 of the plurality of oligonucleotide barcodes comprise different molecular label sequences. In some embodiments, the plurality of oligonucleotide barcodes are associated with a third solid support. In some embodiments, the plurality of oligonucleotide barcodes each comprise a cell label. In some embodiments, oligonucleotide barcodes of the plurality of oligonucleotide barcodes associated with the same third solid support comprise the same cell label. In some embodiments, oligonucleotide barcodes of the plurality of oligonucleotide barcodes associated with different third solid supports comprise different cell labels.

(42) In some embodiments, the first solid support, second solid support, and/or third solid support comprises a synthetic particle or a planar surface. The at least one of the plurality of oligonucleotide barcodes can be immobilized or partially immobilized on the synthetic particle, or the at least one of the plurality of oligonucleotide barcodes is enclosed or partially enclosed in the synthetic particle. The synthetic particle can be disruptable, e.g., a disruptable hydrogel particle.

(43) In some embodiments, each of the plurality of oligonucleotide barcodes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(44) In some embodiments, each of the plurality of anchor probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(45) In some embodiments, each of the plurality of capture probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(46) In some embodiments, the first solid support and/or the second solid support is sized and shaped to approximate a cell. In some embodiments, the first solid support and/or the second solid support has the dimensions of a cell. In some embodiments, the cell is a mammalian cell, a yeast cell, an insect cell, a plant cell, a bacterial cell, or any combination thereof.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 illustrates a non-limiting exemplary barcode.

(2) FIG. 2 shows a non-limiting exemplary workflow of barcoding and digital counting.

(3) FIG. 3 is a schematic illustration showing a non-limiting exemplary process for generating an indexed library of targets barcoded at the 3'-ends from a plurality of targets.

(4) FIGS. 4A-4C show a schematic illustration of a non-limiting exemplary workflow for measurement of the number of copies of one or more secreted factors secreted by a single cell.

(5) FIGS. 5A-5C show a schematic illustration of a non-limiting exemplary workflow for simultaneous measurement of secreted factors and gene expression of single cells.

(6) FIG. 6 shows a non-limiting exemplary design of a secreted factor-binding reagent specific oligonucleotide (antibody oligonucleotide illustrated here) that is associated with a secreted factor-binding reagent (antibody illustrated here).

(7) FIGS. 7A-7D show a schematic illustration of a non-limiting exemplary workflow for simultaneous measurement of the number of copies of a secreted factor and a nucleic acid target.

(8) FIG. 8 shows a schematic illustration of a non-limiting exemplary workflow of barcoding of a binding reagent oligonucleotide (antibody oligonucleotide illustrated here) that is associated with a binding reagent (antibody illustrated here).

DETAILED DESCRIPTION

(9) In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated

herein and made part of the disclosure herein.

(10) All patents, published patent applications, other publications, and sequences from GenBank, and other databases referred to herein are incorporated by reference in their entirety with respect to the related technology.

(11) Quantifying small numbers of nucleic acids, for example messenger ribonucleotide acid (mRNA) molecules, is clinically important for determining, for example, the genes that are expressed in a cell at different stages of development or under different environmental conditions. However, it can also be very challenging to determine the absolute number of nucleic acid molecules (e.g., mRNA molecules), especially when the number of molecules is very small. One method to determine the absolute number of molecules in a sample is digital polymerase chain reaction (PCR). Ideally, PCR produces an identical copy of a molecule at each cycle. However, PCR can have disadvantages such that each molecule replicates with a stochastic probability, and this probability varies by PCR cycle and gene sequence, resulting in amplification bias and inaccurate gene expression measurements. Stochastic barcodes with unique molecular labels (also referred to as molecular indexes (MIs)) can be used to count the number of molecules and correct for amplification bias. Stochastic barcoding, such as the Precise™ assay (Cellular Research, Inc. (Palo Alto, CA)) and Rhapsody™ assay (Becton, Dickinson and Company (Franklin Lakes, NJ)), can correct for bias induced by PCR and library preparation steps by using molecular labels (MLs) to label mRNAs during reverse transcription (RT).

(12) The Precise™ assay can utilize a non-depleting pool of stochastic barcodes with large number, for example 6561 to 65536, unique molecular label sequences on poly(T) oligonucleotides to hybridize to all poly(A)-mRNAs in a sample during the RT step. A stochastic barcode can comprise a universal PCR priming site. During RT, target gene molecules react randomly with stochastic barcodes. Each target molecule can hybridize to a stochastic barcode resulting to generate stochastically barcoded complementary ribonucleotide acid (cDNA) molecules). After labeling, stochastically barcoded cDNA molecules from microwells of a microwell plate can be pooled into a single tube for PCR amplification and sequencing. Raw sequencing data can be analyzed to produce the number of reads, the number of stochastic barcodes with unique molecular label sequences, and the numbers of mRNA molecules.

(13) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell. The method can comprise: contacting one or more single cells with a first plurality of first solid supports, the one or more single cells are capable of secreting a plurality of secreted factors, each first solid support comprises a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the first solid support with a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization, the oligonucleotide barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.

(14) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell and the number of copies of a nucleic acid target in a single cell. The method can comprise: contacting one or more single cells with a first plurality of second solid supports to form one or more single cells associated with a second solid support, the one or more single cells comprise a surface cellular target and copies of a nucleic acid target, the one or more single cells are capable of secreting a plurality of secreted factors, each second solid support comprises a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to the surface cellular target, and the capture probe is capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization, the oligonucleotide barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the copies of a nucleic acid target to generate a plurality of barcoded nucleic acid molecules each comprising a sequence complementary to at least a portion of the nucleic acid target and the first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded nucleic acid molecules, or products thereof, to determine the copy number of the nucleic acid target in each of the one or more single cells. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.

(15) Disclosed herein include compositions (e.g., kits). The composition can comprise: a first solid support comprising a plurality of capture probes capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

(16) Disclosed herein include compositions (e.g., kits). The composition can comprise: a second solid support comprising a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to a surface cellular target, and the capture probe is capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

Definitions

(17) Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. See, e.g., Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley &

Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press (Cold Spring Harbor, NY 1989). For purposes of the present disclosure, the following terms are defined below.

(18) As used herein, the term “adaptor” can mean a sequence to facilitate amplification or sequencing of associated nucleic acids. The associated nucleic acids can comprise target nucleic acids. The associated nucleic acids can comprise one or more of spatial labels, target labels, sample labels, indexing label, or barcode sequences (e.g., molecular labels). The adaptors can be linear. The adaptors can be pre-adenylated adaptors. The adaptors can be double- or single-stranded. One or more adaptor can be located on the 5' or 3' end of a nucleic acid. When the adaptors comprise known sequences on the 5' and 3' ends, the known sequences can be the same or different sequences. An adaptor located on the 5' and/or 3' ends of a polynucleotide can be capable of hybridizing to one or more oligonucleotides immobilized on a surface. An adaptor can, in some embodiments, comprise a universal sequence. A universal sequence can be a region of nucleotide sequence that is common to two or more nucleic acid molecules. The two or more nucleic acid molecules can also have regions of different sequence. Thus, for example, the 5' adaptors can comprise identical and/or universal nucleic acid sequences and the 3' adaptors can comprise identical and/or universal sequences. A universal sequence that may be present in different members of a plurality of nucleic acid molecules can allow the replication or amplification of multiple different sequences using a single universal primer that is complementary to the universal sequence. Similarly, at least one, two (e.g., a pair) or more universal sequences that may be present in different members of a collection of nucleic acid molecules can allow the replication or amplification of multiple different sequences using at least one, two (e.g., a pair) or more single universal primers that are complementary to the universal sequences. Thus, a universal primer includes a sequence that can hybridize to such a universal sequence. The target nucleic acid sequence-bearing molecules may be modified to attach universal adaptors (e.g., non-target nucleic acid sequences) to one or both ends of the different target nucleic acid sequences. The one or more universal primers attached to the target nucleic acid can provide sites for hybridization of universal primers. The one or more universal primers attached to the target nucleic acid can be the same or different from each other.

(19) As used herein the term “associated” or “associated with” can mean that two or more species are identifiable as being co-located at a point in time. An association can mean that two or more species are or were within a similar container. An association can be an informatics association. For example, digital information regarding two or more species can be stored and can be used to determine that one or more of the species were co-located at a point in time. An association can also be a physical association. In some embodiments, two or more associated species are “tethered”, “attached”, or “immobilized” to one another or to a common solid or semisolid surface. An association may refer to covalent or non-covalent means for attaching labels to solid or semi-solid supports such as beads. An association may be a covalent bond between a target and a label. An association can comprise hybridization between two molecules (such as a target molecule and a label).

(20) As used herein, the term “complementary” can refer to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a given position of a nucleic acid is capable of hydrogen bonding with a nucleotide of another nucleic acid, then the two nucleic acids are considered to be complementary to one another at that position. Complementarity between two single-stranded nucleic acid molecules may be “partial,” in which only some of the nucleotides bind, or it may be complete when total complementarity exists between the single-stranded molecules. A first nucleotide sequence can be said to be the “complement” of a second sequence if the first nucleotide sequence is complementary to the second nucleotide sequence. A first nucleotide sequence can be said to be the “reverse complement” of a second sequence, if the first nucleotide sequence is complementary to a sequence that is the reverse (i.e., the order of the

nucleotides is reversed) of the second sequence. As used herein, a “complementary” sequence can refer to a “complement” or a “reverse complement” of a sequence. It is understood from the disclosure that if a molecule can hybridize to another molecule it may be complementary, or partially complementary, to the molecule that is hybridizing.

(21) As used herein, the term “digital counting” can refer to a method for estimating a number of target molecules in a sample. Digital counting can include the step of determining a number of unique labels that have been associated with targets in a sample. This methodology, which can be stochastic in nature, transforms the problem of counting molecules from one of locating and identifying identical molecules to a series of yes/no digital questions regarding detection of a set of predefined labels.

(22) As used herein, the term “label” or “labels” can refer to nucleic acid codes associated with a target within a sample. A label can be, for example, a nucleic acid label. A label can be an entirely or partially amplifiable label. A label can be entirely or partially sequenceable label. A label can be a portion of a native nucleic acid that is identifiable as distinct. A label can be a known sequence. A label can comprise a junction of nucleic acid sequences, for example a junction of a native and non-native sequence. As used herein, the term “label” can be used interchangeably with the terms, “index”, “tag,” or “label-tag.” Labels can convey information. For example, in various embodiments, labels can be used to determine an identity of a sample, a source of a sample, an identity of a cell, and/or a target.

(23) As used herein, the term “non-depleting reservoirs” can refer to a pool of barcodes (e.g., stochastic barcodes) made up of many different labels. A non-depleting reservoir can comprise large numbers of different barcodes such that when the non-depleting reservoir is associated with a pool of targets each target is likely to be associated with a unique barcode. The uniqueness of each labeled target molecule can be determined by the statistics of random choice, and depends on the number of copies of identical target molecules in the collection compared to the diversity of labels. The size of the resulting set of labeled target molecules can be determined by the stochastic nature of the barcoding process, and analysis of the number of barcodes detected then allows calculation of the number of target molecules present in the original collection or sample. When the ratio of the number of copies of a target molecule present to the number of unique barcodes is low, the labeled target molecules are highly unique (i.e., there is a very low probability that more than one target molecule will have been labeled with a given label).

(24) As used herein, the term “nucleic acid” refers to a polynucleotide sequence, or fragment thereof. A nucleic acid can comprise nucleotides. A nucleic acid can be exogenous or endogenous to a cell. A nucleic acid can exist in a cell-free environment. A nucleic acid can be a gene or fragment thereof. A nucleic acid can be DNA. A nucleic acid can be RNA. A nucleic acid can comprise one or more analogs (e.g., altered backbone, sugar, or nucleobase). Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to the sugar), thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queuosine, and wyosine. “Nucleic acid”, “polynucleotide”, “target polynucleotide”, and “target nucleic acid” can be used interchangeably.

(25) A nucleic acid can comprise one or more modifications (e.g., a base modification, a backbone modification), to provide the nucleic acid with a new or enhanced feature (e.g., improved stability). A nucleic acid can comprise a nucleic acid affinity tag. A nucleoside can be a base-sugar combination. The base portion of the nucleoside can be a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides can be nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be

linked to the 2', the 3', or the 5' hydroxyl moiety of the sugar. In forming nucleic acids, the phosphate groups can covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound; however, linear compounds are generally suitable. In addition, linear compounds may have internal nucleotide base complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within nucleic acids, the phosphate groups can commonly be referred to as forming the internucleoside backbone of the nucleic acid. The linkage or backbone can be a 3' to 5' phosphodiester linkage.

(26) A nucleic acid can comprise a modified backbone and/or modified internucleoside linkages. Modified backbones can include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Suitable modified nucleic acid backbones containing a phosphorus atom therein can include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonate such as 3'-alkylene phosphonates, 5'-alkylene phosphonates, chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkyl phosphoramidates, phosphorodiamidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', a 5' to 5' or a 2' to 2' linkage.

(27) A nucleic acid can comprise polynucleotide backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These can include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

(28) A nucleic acid can comprise a nucleic acid mimetic. The term "mimetic" can be intended to include polynucleotides wherein only the furanose ring or both the furanose ring and the internucleotide linkage are replaced with non-furanose groups, replacement of only the furanose ring can also be referred as being a sugar surrogate. The heterocyclic base moiety or a modified heterocyclic base moiety can be maintained for hybridization with an appropriate target nucleic acid. One such nucleic acid can be a peptide nucleic acid (PNA). In a PNA, the sugar-backbone of a polynucleotide can be replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleotides can be retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. The backbone in PNA compounds can comprise two or more linked aminoethylglycine units which gives PNA an amide containing backbone. The heterocyclic base moieties can be bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

(29) A nucleic acid can comprise a morpholino backbone structure. For example, a nucleic acid can comprise a 6-membered morpholino ring in place of a ribose ring. In some of these embodiments, a phosphorodiamidate or other non-phosphodiester internucleoside linkage can replace a phosphodiester linkage.

(30) A nucleic acid can comprise linked morpholino units (e.g., morpholino nucleic acid) having heterocyclic bases attached to the morpholino ring. Linking groups can link the morpholino monomeric units in a morpholino nucleic acid. Non-ionic morpholino-based oligomeric compounds can have less undesired interactions with cellular proteins. Morpholino-based polynucleotides can be nonionic mimics of nucleic acids. A variety of compounds within the morpholino class can be joined using different linking groups. A further class of polynucleotide

mimetic can be referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in a nucleic acid molecule can be replaced with a cyclohexenyl ring. CeNA DMT protected phosphoramidite monomers can be prepared and used for oligomeric compound synthesis using phosphoramidite chemistry. The incorporation of CeNA monomers into a nucleic acid chain can increase the stability of a DNA/RNA hybrid. CeNA oligoadenylates can form complexes with nucleic acid complements with similar stability to the native complexes. A further modification can include Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C, 4'-C-oxymethylene linkage thereby forming a bicyclic sugar moiety. The linkage can be a methylene ($-\text{CH}_2-$), group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNA and LNA analogs can display very high duplex thermal stabilities with complementary nucleic acid ($T_m = +3$ to $+10^\circ \text{C}$.), stability towards 3'-exonucleolytic degradation and good solubility properties.

(31) A nucleic acid may also include nucleobase (often referred to simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases can include the purine bases, (e.g., adenine (A) and guanine (G)), and the pyrimidine bases, (e.g., thymine (T), cytosine (C) and uracil (U)). Modified nucleobases can include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-\text{C}\equiv\text{C}-\text{CH}_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Modified nucleobases can include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo[2,3-d]pyrimidin-2-one).

(32) As used herein, the term "sample" can refer to a composition comprising targets. Suitable samples for analysis by the disclosed methods, devices, and systems include cells, tissues, organs, or organisms.

(33) As used herein, the term "sampling device" or "device" can refer to a device which may take a section of a sample and/or place the section on a substrate. A sample device can refer to, for example, a fluorescence activated cell sorting (FACS) machine, a cell sorter machine, a biopsy needle, a biopsy device, a tissue sectioning device, a microfluidic device, a blade grid, and/or a microtome.

(34) As used herein, the term "solid support" can refer to discrete solid or semi-solid surfaces to which a plurality of barcodes (e.g., stochastic barcodes) may be attached. A solid support may encompass any type of solid, porous, or hollow sphere, ball, bearing, cylinder, or other similar configuration composed of plastic, ceramic, metal, or polymeric material (e.g., hydrogel) onto which a nucleic acid may be immobilized (e.g., covalently or non-covalently). A solid support may comprise a discrete particle that may be spherical (e.g., microspheres) or have a non-spherical or irregular shape, such as cubic, cuboid, pyramidal, cylindrical, conical, oblong, or disc-shaped, and the like. A bead can be non-spherical in shape. A plurality of solid supports spaced in an array may not comprise a substrate. A solid support may be used interchangeably with the term "bead."

(35) As used herein, the term “stochastic barcode” can refer to a polynucleotide sequence comprising labels of the present disclosure. A stochastic barcode can be a polynucleotide sequence that can be used for stochastic barcoding. Stochastic barcodes can be used to quantify targets within a sample. Stochastic barcodes can be used to control for errors which may occur after a label is associated with a target. For example, a stochastic barcode can be used to assess amplification or sequencing errors. A stochastic barcode associated with a target can be called a stochastic barcode-target or stochastic barcode-tag-target.

(36) As used herein, the term “gene-specific stochastic barcode” can refer to a polynucleotide sequence comprising labels and a target-binding region that is gene-specific. A stochastic barcode can be a polynucleotide sequence that can be used for stochastic barcoding. Stochastic barcodes can be used to quantify targets within a sample. Stochastic barcodes can be used to control for errors which may occur after a label is associated with a target. For example, a stochastic barcode can be used to assess amplification or sequencing errors. A stochastic barcode associated with a target can be called a stochastic barcode-target or stochastic barcode-tag-target.

(37) As used herein, the term “stochastic barcoding” can refer to the random labeling (e.g., barcoding) of nucleic acids. Stochastic barcoding can utilize a recursive Poisson strategy to associate and quantify labels associated with targets. As used herein, the term “stochastic barcoding” can be used interchangeably with “stochastic labeling.”

(38) As used here, the term “target” can refer to a composition which can be associated with a barcode (e.g., a stochastic barcode). Exemplary suitable targets for analysis by the disclosed methods, devices, and systems include oligonucleotides, DNA, RNA, mRNA, microRNA, tRNA, and the like. Targets can be single or double stranded. In some embodiments, targets can be proteins, peptides, or polypeptides. In some embodiments, targets are lipids. As used herein, “target” can be used interchangeably with “species.”

(39) As used herein, the term “reverse transcriptases” can refer to a group of enzymes having reverse transcriptase activity (i.e., that catalyze synthesis of DNA from an RNA template). In general, such enzymes include, but are not limited to, retroviral reverse transcriptase, retrotransposon reverse transcriptase, retroplasmid reverse transcriptases, retron reverse transcriptases, bacterial reverse transcriptases, group II intron-derived reverse transcriptase, and mutants, variants or derivatives thereof. Non-retroviral reverse transcriptases include non-LTR retrotransposon reverse transcriptases, retroplasmid reverse transcriptases, retron reverse transcriptases, and group II intron reverse transcriptases. Examples of group II intron reverse transcriptases include the *Lactococcus lactis* LI.LtrB intron reverse transcriptase, the *Thermosynechococcus elongatus* Tel4c intron reverse transcriptase, or the *Geobacillus stearothermophilus* GsI-IIC intron reverse transcriptase. Other classes of reverse transcriptases can include many classes of non-retroviral reverse transcriptases (i.e., retrons, group II introns, and diversity-generating retroelements among others).

(40) The terms “universal adaptor primer,” “universal primer adaptor” or “universal adaptor sequence” are used interchangeably to refer to a nucleotide sequence that can be used to hybridize to barcodes (e.g., stochastic barcodes) to generate gene-specific barcodes. A universal adaptor sequence can, for example, be a known sequence that is universal across all barcodes used in methods of the disclosure. For example, when multiple targets are being labeled using the methods disclosed herein, each of the target-specific sequences may be linked to the same universal adaptor sequence. In some embodiments, more than one universal adaptor sequences may be used in the methods disclosed herein. For example, when multiple targets are being labeled using the methods disclosed herein, at least two of the target-specific sequences are linked to different universal adaptor sequences. A universal adaptor primer and its complement may be included in two oligonucleotides, one of which comprises a target-specific sequence and the other comprises a barcode. For example, a universal adaptor sequence may be part of an oligonucleotide comprising a target-specific sequence to generate a nucleotide sequence that is complementary to a target nucleic

acid. A second oligonucleotide comprising a barcode and a complementary sequence of the universal adaptor sequence may hybridize with the nucleotide sequence and generate a target-specific barcode (e.g., a target-specific stochastic barcode). In some embodiments, a universal adaptor primer has a sequence that is different from a universal PCR primer used in the methods of this disclosure.

(41) Barcodes

(42) Barcoding, such as stochastic barcoding, has been described in, for example, Fu et al., *Proc Natl Acad Sci U.S.A.*, 2011 May 31, 108(22):9026-31; U.S. Patent Application Publication No. US2011/0160078; Fan et al., *Science*, 2015 Feb. 6, 347(6222):1258367; US Patent Application Publication No. US2015/0299784; and PCT Application Publication No. WO2015/031691; the content of each of these, including any supporting or supplemental information or material, is incorporated herein by reference in its entirety. In some embodiments, the barcode disclosed herein can be a stochastic barcode which can be a polynucleotide sequence that may be used to stochastically label (e.g., barcode, tag) a target. Barcodes can be referred to stochastic barcodes if the ratio of the number of different barcode sequences of the stochastic barcodes and the number of occurrence of any of the targets to be labeled can be, or be about, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or a range between any two of these values. A target can be an mRNA species comprising mRNA molecules with identical or nearly identical sequences. Barcodes can be referred to as stochastic barcodes if the ratio of the number of different barcode sequences of the stochastic barcodes and the number of occurrence of any of the targets to be labeled is at least, or is at most, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. Barcode sequences of stochastic barcodes can be referred to as molecular labels.

(43) A barcode, for example a stochastic barcode, can comprise one or more labels. Exemplary labels can include a universal label, a cell label, a barcode sequence (e.g., a molecular label), a sample label, a plate label, a spatial label, and/or a pre-spatial label. FIG. 1 illustrates an exemplary barcode **104** with a spatial label. The barcode **104** can comprise a 5' amine that may link the barcode to a solid support **105**. The barcode can comprise a universal label, a dimension label, a spatial label, a cell label, and/or a molecular label. The order of different labels (including but not limited to the universal label, the dimension label, the spatial label, the cell label, and the molecule label) in the barcode can vary. For example, as shown in FIG. 1, the universal label may be the 5'-most label, and the molecular label may be the 3'-most label. The spatial label, dimension label, and the cell label may be in any order. In some embodiments, the universal label, the spatial label, the dimension label, the cell label, and the molecular label are in any order. The barcode can comprise a target-binding region. The target-binding region can interact with a target (e.g., target nucleic acid, RNA, mRNA, DNA) in a sample. For example, a target-binding region can comprise an oligo(dT) sequence which can interact with poly(A) tails of mRNAs. In some instances, the labels of the barcode (e.g., universal label, dimension label, spatial label, cell label, and barcode sequence) may be separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides.

(44) A label, for example the cell label, can comprise a unique set of nucleic acid sub-sequences of defined length, e.g., seven nucleotides each (equivalent to the number of bits used in some Hamming error correction codes), which can be designed to provide error correction capability. The set of error correction sub-sequences comprise seven nucleotide sequences can be designed such that any pairwise combination of sequences in the set exhibits a defined "genetic distance" (or number of mismatched bases), for example, a set of error correction sub-sequences can be designed to exhibit a genetic distance of three nucleotides. In this case, review of the error correction sequences in the set of sequence data for labeled target nucleic acid molecules (described more fully below) can allow one to detect or correct amplification or sequencing errors. In some

embodiments, the length of the nucleic acid sub-sequences used for creating error correction codes can vary, for example, they can be, or be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 31, 40, 50, or a number or a range between any two of these values, nucleotides in length. In some embodiments, nucleic acid sub-sequences of other lengths can be used for creating error correction codes.

(45) The barcode can comprise a target-binding region. The target-binding region can interact with a target in a sample. The target can be, or comprise, ribonucleic acids (RNAs), messenger RNAs (mRNAs), microRNAs, small interfering RNAs (siRNAs), RNA degradation products, RNAs each comprising a poly(A) tail, or any combination thereof. In some embodiments, the plurality of targets can include deoxyribonucleic acids (DNAs).

(46) In some embodiments, a target-binding region can comprise an oligo(dT) sequence which can interact with poly(A) tails of mRNAs. One or more of the labels of the barcode (e.g., the universal label, the dimension label, the spatial label, the cell label, and the barcode sequences (e.g., molecular label)) can be separated by a spacer from another one or two of the remaining labels of the barcode. The spacer can be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or more nucleotides. In some embodiments, none of the labels of the barcode is separated by spacer.

(47) Universal Labels

(48) A barcode can comprise one or more universal labels. In some embodiments, the one or more universal labels can be the same for all barcodes in the set of barcodes attached to a given solid support. In some embodiments, the one or more universal labels can be the same for all barcodes attached to a plurality of beads. In some embodiments, a universal label can comprise a nucleic acid sequence that is capable of hybridizing to a sequencing primer. Sequencing primers can be used for sequencing barcodes comprising a universal label. Sequencing primers (e.g., universal sequencing primers) can comprise sequencing primers associated with high-throughput sequencing platforms. In some embodiments, a universal label can comprise a nucleic acid sequence that is capable of hybridizing to a PCR primer. In some embodiments, the universal label can comprise a nucleic acid sequence that is capable of hybridizing to a sequencing primer and a PCR primer. The nucleic acid sequence of the universal label that is capable of hybridizing to a sequencing or PCR primer can be referred to as a primer binding site. A universal label can comprise a sequence that can be used to initiate transcription of the barcode. A universal label can comprise a sequence that can be used for extension of the barcode or a region within the barcode. A universal label can be, or be about, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. For example, a universal label can comprise at least about 10 nucleotides. A universal label can be at least, or be at most, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides in length. In some embodiments, a cleavable linker or modified nucleotide can be part of the universal label sequence to enable the barcode to be cleaved off from the support.

(49) Dimension Labels

(50) A barcode can comprise one or more dimension labels. In some embodiments, a dimension label can comprise a nucleic acid sequence that provides information about a dimension in which the labeling (e.g., stochastic labeling) occurred. For example, a dimension label can provide information about the time at which a target was barcoded. A dimension label can be associated with a time of barcoding (e.g., stochastic barcoding) in a sample. A dimension label can be activated at the time of labeling. Different dimension labels can be activated at different times. The dimension label provides information about the order in which targets, groups of targets, and/or samples were barcoded. For example, a population of cells can be barcoded at the G0 phase of the cell cycle. The cells can be pulsed again with barcodes (e.g., stochastic barcodes) at the G1 phase of the cell cycle. The cells can be pulsed again with barcodes at the S phase of the cell cycle, and so on. Barcodes at each pulse (e.g., each phase of the cell cycle), can comprise different dimension labels. In this way, the dimension label provides information about which targets were labelled at

which phase of the cell cycle. Dimension labels can interrogate many different biological times. Exemplary biological times can include, but are not limited to, the cell cycle, transcription (e.g., transcription initiation), and transcript degradation. In another example, a sample (e.g., a cell, a population of cells) can be labeled before and/or after treatment with a drug and/or therapy. The changes in the number of copies of distinct targets can be indicative of the sample's response to the drug and/or therapy.

(51) A dimension label can be activatable. An activatable dimension label can be activated at a specific time point. The activatable label can be, for example, constitutively activated (e.g., not turned off). The activatable dimension label can be, for example, reversibly activated (e.g., the activatable dimension label can be turned on and turned off). The dimension label can be, for example, reversibly activatable at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The dimension label can be reversibly activatable, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. In some embodiments, the dimension label can be activated with fluorescence, light, a chemical event (e.g., cleavage, ligation of another molecule, addition of modifications (e.g., pegylated, sumoylated, acetylated, methylated, deacetylated, demethylated), a photochemical event (e.g., photocaging), and introduction of a non-natural nucleotide.

(52) The dimension label can, in some embodiments, be identical for all barcodes (e.g., stochastic barcodes) attached to a given solid support (e.g., a bead), but different for different solid supports (e.g., beads). In some embodiments, at least 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99% or 100%, of barcodes on the same solid support can comprise the same dimension label. In some embodiments, at least 60% of barcodes on the same solid support can comprise the same dimension label. In some embodiments, at least 95% of barcodes on the same solid support can comprise the same dimension label.

(53) There can be as many as $10^{sup.6}$ or more unique dimension label sequences represented in a plurality of solid supports (e.g., beads). A dimension label can be, or be about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. A dimension label can be at least, or be at most, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300, nucleotides in length. A dimension label can comprise between about 5 to about 200 nucleotides. A dimension label can comprise between about 10 to about 150 nucleotides. A dimension label can comprise between about 20 to about 125 nucleotides in length.

(54) Spatial Labels

(55) A barcode can comprise one or more spatial labels. In some embodiments, a spatial label can comprise a nucleic acid sequence that provides information about the spatial orientation of a target molecule which is associated with the barcode. A spatial label can be associated with a coordinate in a sample. The coordinate can be a fixed coordinate. For example, a coordinate can be fixed in reference to a substrate. A spatial label can be in reference to a two or three-dimensional grid. A coordinate can be fixed in reference to a landmark. The landmark can be identifiable in space. A landmark can be a structure which can be imaged. A landmark can be a biological structure, for example an anatomical landmark. A landmark can be a cellular landmark, for instance an organelle. A landmark can be a non-natural landmark such as a structure with an identifiable identifier such as a color code, bar code, magnetic property, fluorescents, radioactivity, or a unique size or shape. A spatial label can be associated with a physical partition (e.g., A well, a container, or a droplet). In some embodiments, multiple spatial labels are used together to encode one or more positions in space.

(56) The spatial label can be identical for all barcodes attached to a given solid support (e.g., a bead), but different for different solid supports (e.g., beads). In some embodiments, the percentage of barcodes on the same solid support comprising the same spatial label can be, or be about, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or a range between any two of these values. In some embodiments, the percentage of barcodes on the same solid support comprising the same spatial label can be at least, or be at most, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or

100%. In some embodiments, at least 60% of barcodes on the same solid support can comprise the same spatial label. In some embodiments, at least 95% of barcodes on the same solid support can comprise the same spatial label.

(57) There can be as many as 10^6 or more unique spatial label sequences represented in a plurality of solid supports (e.g., beads). A spatial label can be, or be about, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. A spatial label can be at least or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides in length. A spatial label can comprise between about 5 to about 200 nucleotides. A spatial label can comprise between about 10 to about 150 nucleotides. A spatial label can comprise between about 20 to about 125 nucleotides in length.

(58) Cell Labels

(59) A barcode (e.g., a stochastic barcode) can comprise one or more cell labels. In some embodiments, a cell label can comprise a nucleic acid sequence that provides information for determining which target nucleic acid originated from which cell. In some embodiments, the cell label is identical for all barcodes attached to a given solid support (e.g., a bead), but different for different solid supports (e.g., beads). In some embodiments, the percentage of barcodes on the same solid support comprising the same cell label can be, or be about 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or a range between any two of these values. In some embodiments, the percentage of barcodes on the same solid support comprising the same cell label can be, or be about 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or 100%. For example, at least 60% of barcodes on the same solid support can comprise the same cell label. As another example, at least 95% of barcodes on the same solid support can comprise the same cell label.

(60) There can be as many as 10^6 or more unique cell label sequences represented in a plurality of solid supports (e.g., beads). A cell label can be, or be about, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. A cell label can be at least, or be at most, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides in length. For example, a cell label can comprise between about 5 to about 200 nucleotides. As another example, a cell label can comprise between about 10 to about 150 nucleotides. As yet another example, a cell label can comprise between about 20 to about 125 nucleotides in length.

(61) Barcode Sequences

(62) A barcode can comprise one or more barcode sequences. In some embodiments, a barcode sequence can comprise a nucleic acid sequence that provides identifying information for the specific type of target nucleic acid species hybridized to the barcode. A barcode sequence can comprise a nucleic acid sequence that provides a counter (e.g., that provides a rough approximation) for the specific occurrence of the target nucleic acid species hybridized to the barcode (e.g., target-binding region).

(63) In some embodiments, a diverse set of barcode sequences are attached to a given solid support (e.g., a bead). In some embodiments, there can be, or be about, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , or a number or a range between any two of these values, unique molecular label sequences. For example, a plurality of barcodes can comprise about 6561 barcode sequences with distinct sequences. As another example, a plurality of barcodes can comprise about 65536 barcode sequences with distinct sequences. In some embodiments, there can be at least, or be at most, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , or 10^9 , unique barcode sequences. The unique molecular label sequences can be attached to a given solid support (e.g., a bead). In some embodiments, the unique molecular label sequence is partially or entirely encompassed by a particle (e.g., a hydrogel bead).

(64) The length of a barcode can be different in different implementations. For example, a barcode can be, or be about, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. As another example, a barcode can be at least, or be

at most, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides in length.

(65) Molecular Labels

(66) A barcode (e.g., a stochastic barcode) can comprise one or more molecular labels. Molecular labels can include barcode sequences. In some embodiments, a molecular label can comprise a nucleic acid sequence that provides identifying information for the specific type of target nucleic acid species hybridized to the barcode. A molecular label can comprise a nucleic acid sequence that provides a counter for the specific occurrence of the target nucleic acid species hybridized to the barcode (e.g., target-binding region).

(67) In some embodiments, a diverse set of molecular labels are attached to a given solid support (e.g., a bead). In some embodiments, there can be, or be about, 10.sup.2, 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9, or a number or a range between any two of these values, of unique molecular label sequences. For example, a plurality of barcodes can comprise about 6561 molecular labels with distinct sequences. As another example, a plurality of barcodes can comprise about 65536 molecular labels with distinct sequences. In some embodiments, there can be at least, or be at most, 10.sup.2, 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, 10.sup.8, or 10.sup.9, unique molecular label sequences. Barcodes with unique molecular label sequences can be attached to a given solid support (e.g., a bead).

(68) For barcoding (e.g., stochastic barcoding) using a plurality of stochastic barcodes, the ratio of the number of different molecular label sequences and the number of occurrence of any of the targets can be, or be about, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or a range between any two of these values. A target can be an mRNA species comprising mRNA molecules with identical or nearly identical sequences. In some embodiments, the ratio of the number of different molecular label sequences and the number of occurrence of any of the targets is at least, or is at most, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.

(69) A molecular label can be, or be about, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. A molecular label can be at least, or be at most, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, or 300 nucleotides in length.

(70) Target-Binding Region

(71) A barcode can comprise one or more target binding regions, such as capture probes. In some embodiments, a target-binding region can hybridize with a target of interest. In some embodiments, the target binding regions can comprise a nucleic acid sequence that hybridizes specifically to a target (e.g., target nucleic acid, target molecule, e.g., a cellular nucleic acid to be analyzed), for example to a specific gene sequence. In some embodiments, a target binding region can comprise a nucleic acid sequence that can attach (e.g., hybridize) to a specific location of a specific target nucleic acid. In some embodiments, the target binding region can comprise a nucleic acid sequence that is capable of specific hybridization to a restriction enzyme site overhang (e.g., an EcoRI sticky-end overhang). The barcode can then ligate to any nucleic acid molecule comprising a sequence complementary to the restriction site overhang.

(72) In some embodiments, a target binding region can comprise a non-specific target nucleic acid sequence. A non-specific target nucleic acid sequence can refer to a sequence that can bind to multiple target nucleic acids, independent of the specific sequence of the target nucleic acid. For example, target binding region can comprise a random multimer sequence, a poly(dA) sequence, a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, or a combination thereof. For example, the target binding region can be an oligo(dT) sequence that hybridizes to the poly(A) tail on mRNA molecules. A random multimer sequence can be, for example, a random dimer, trimer, quatramer, pentamer, hexamer, septamer, octamer, nonamer, decamer, or higher multimer sequence of any length. In some embodiments, the target binding region is the same for all barcodes attached

to a given bead. In some embodiments, the target binding regions for the plurality of barcodes attached to a given bead can comprise two or more different target binding sequences. A target binding region can be, or be about, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or a number or a range between any two of these values, nucleotides in length. A target binding region can be at most about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides in length. For example, an mRNA molecule can be reverse transcribed using a reverse transcriptase, such as Moloney murine leukemia virus (MMLV) reverse transcriptase, to generate a cDNA molecule with a poly(dC) tail. A barcode can include a target binding region with a poly(dG) tail. Upon base pairing between the poly(dG) tail of the barcode and the poly(dC) tail of the cDNA molecule, the reverse transcriptase switches template strands, from cellular RNA molecule to the barcode, and continues replication to the 5' end of the barcode. By doing so, the resulting cDNA molecule contains the sequence of the barcode (such as the molecular label) on the 3' end of the cDNA molecule.

(73) In some embodiments, a target-binding region can comprise an oligo(dT) which can hybridize with mRNAs comprising polyadenylated ends. A target-binding region can be gene-specific. For example, a target-binding region can be configured to hybridize to a specific region of a target. A target-binding region can be, or be about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or a number or a range between any two of these values, nucleotides in length. A target-binding region can be at least, or be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, nucleotides in length. A target-binding region can be about 5-30 nucleotides in length. When a barcode comprises a gene-specific target-binding region, the barcode can be referred to herein as a gene-specific barcode.

(74) Orientation Property

(75) A stochastic barcode (e.g., a stochastic barcode) can comprise one or more orientation properties which can be used to orient (e.g., align) the barcodes. A barcode can comprise a moiety for isoelectric focusing. Different barcodes can comprise different isoelectric focusing points. When these barcodes are introduced to a sample, the sample can undergo isoelectric focusing in order to orient the barcodes into a known way. In this way, the orientation property can be used to develop a known map of barcodes in a sample. Exemplary orientation properties can include, electrophoretic mobility (e.g., based on size of the barcode), isoelectric point, spin, conductivity, and/or self-assembly. For example, barcodes with an orientation property of self-assembly, can self-assemble into a specific orientation (e.g., nucleic acid nanostructure) upon activation.

(76) Affinity Property

(77) A barcode (e.g., a stochastic barcode) can comprise one or more affinity properties. For example, a spatial label can comprise an affinity property. An affinity property can include a chemical and/or biological moiety that can facilitate binding of the barcode to another entity (e.g., cell receptor). For example, an affinity property can comprise an antibody, for example, an antibody specific for a specific moiety (e.g., receptor) on a sample. In some embodiments, the antibody can guide the barcode to a specific cell type or molecule. Targets at and/or near the specific cell type or molecule can be labeled (e.g., stochastically labeled). The affinity property can, in some embodiments, provide spatial information in addition to the nucleotide sequence of the spatial label because the antibody can guide the barcode to a specific location. The antibody can be a therapeutic antibody, for example a monoclonal antibody or a polyclonal antibody. The antibody can be humanized or chimeric. The antibody can be a naked antibody or a fusion antibody.

(78) The antibody can be a full-length (i.e., naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes) immunoglobulin molecule (e.g., an IgG antibody) or an immunologically active (i.e., specifically binding) portion of an immunoglobulin molecule, like an antibody fragment.

(79) The antibody fragment can be, for example, a portion of an antibody such as F(ab')₂, Fab', Fab, Fv, sFv and the like. In some embodiments, the antibody fragment can bind with the same

antigen that is recognized by the full-length antibody. The antibody fragment can include isolated fragments consisting of the variable regions of antibodies, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains and recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). Exemplary antibodies can include, but are not limited to, antibodies for cancer cells, antibodies for viruses, antibodies that bind to cell surface receptors (CD8, CD34, CD45), and therapeutic antibodies.

(80) Universal Adaptor Primer

(81) A barcode can comprise one or more universal adaptor primers. For example, a gene-specific barcode, such as a gene-specific stochastic barcode, can comprise a universal adaptor primer. A universal adaptor primer can refer to a nucleotide sequence that is universal across all barcodes. A universal adaptor primer can be used for building gene-specific barcodes. A universal adaptor primer can be, or be about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or a number or a range between any two of these nucleotides in length. A universal adaptor primer can be at least, or be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. A universal adaptor primer can be from 5-30 nucleotides in length.

(82) Linker

(83) When a barcode comprises more than one of a type of label (e.g., more than one cell label or more than one barcode sequence, such as one molecular label), the labels may be interspersed with a linker label sequence. A linker label sequence can be at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides in length. A linker label sequence can be at most about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides in length. In some instances, a linker label sequence is 12 nucleotides in length. A linker label sequence can be used to facilitate the synthesis of the barcode. The linker label can comprise an error-correcting (e.g., Hamming) code.

(84) Solid Supports

(85) Barcodes, such as stochastic barcodes, disclosed herein can, in some embodiments, be associated with a solid support. The solid support can be, for example, a synthetic particle. In some embodiments, some or all of the barcode sequences, such as molecular labels for stochastic barcodes (e.g., the first barcode sequences) of a plurality of barcodes (e.g., the first plurality of barcodes) on a solid support differ by at least one nucleotide. The cell labels of the barcodes on the same solid support can be the same. The cell labels of the barcodes on different solid supports can differ by at least one nucleotide. For example, first cell labels of a first plurality of barcodes on a first solid support can have the same sequence, and second cell labels of a second plurality of barcodes on a second solid support can have the same sequence. The first cell labels of the first plurality of barcodes on the first solid support and the second cell labels of the second plurality of barcodes on the second solid support can differ by at least one nucleotide. A cell label can be, for example, about 5-20 nucleotides long. A barcode sequence can be, for example, about 5-20 nucleotides long. The synthetic particle can be, for example, a bead.

(86) The bead can be, for example, a silica gel bead, a controlled pore glass bead, a magnetic bead, a Dynabead, a Sephadex/Sepharose bead, a cellulose bead, a polystyrene bead, or any combination thereof. The bead can comprise a material such as polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic, ceramic, plastic, glass, methylstyrene, acrylic polymer, titanium, latex, Sepharose, cellulose, nylon, silicone, or any combination thereof.

(87) In some embodiments, the bead can be a polymeric bead, for example a deformable bead or a gel bead, functionalized with barcodes or stochastic barcodes (such as gel beads from 10× Genomics (San Francisco, CA)). In some implementation, a gel bead can comprise a polymer based gels. Gel beads can be generated, for example, by encapsulating one or more polymeric precursors into droplets. Upon exposure of the polymeric precursors to an accelerator (e.g.,

tetramethylethylenediamine (TEMED)), a gel bead may be generated.

(88) In some embodiments, the particle can be disruptable (e.g., dissolvable, degradable). For example, the polymeric bead can dissolve, melt, or degrade, for example, under a desired condition. The desired condition can include an environmental condition. The desired condition may result in the polymeric bead dissolving, melting, or degrading in a controlled manner. A gel bead may dissolve, melt, or degrade due to a chemical stimulus, a physical stimulus, a biological stimulus, a thermal stimulus, a magnetic stimulus, an electric stimulus, a light stimulus, or any combination thereof.

(89) Analytes and/or reagents, such as oligonucleotide barcodes, for example, may be coupled/immobilized to the interior surface of a gel bead (e.g., the interior accessible via diffusion of an oligonucleotide barcode and/or materials used to generate an oligonucleotide barcode) and/or the outer surface of a gel bead or any other microcapsule described herein.

Coupling/immobilization may be via any form of chemical bonding (e.g., covalent bond, ionic bond) or physical phenomena (e.g., Van der Waals forces, dipole-dipole interactions, etc.). In some embodiments, coupling/immobilization of a reagent to a gel bead or any other microcapsule described herein may be reversible, such as, for example, via a labile moiety (e.g., via a chemical cross-linker, including chemical cross-linkers described herein). Upon application of a stimulus, the labile moiety may be cleaved and the immobilized reagent set free. In some embodiments, the labile moiety is a disulfide bond. For example, in the case where an oligonucleotide barcode is immobilized to a gel bead via a disulfide bond, exposure of the disulfide bond to a reducing agent can cleave the disulfide bond and free the oligonucleotide barcode from the bead. The labile moiety may be included as part of a gel bead or microcapsule, as part of a chemical linker that links a reagent or analyte to a gel bead or microcapsule, and/or as part of a reagent or analyte. In some embodiments, at least one barcode of the plurality of barcodes can be immobilized on the particle, partially immobilized on the particle, enclosed in the particle, partially enclosed in the particle, or any combination thereof.

(90) In some embodiments, a gel bead can comprise a wide range of different polymers including but not limited to: polymers, heat sensitive polymers, photosensitive polymers, magnetic polymers, pH sensitive polymers, salt-sensitive polymers, chemically sensitive polymers, polyelectrolytes, polysaccharides, peptides, proteins, and/or plastics. Polymers may include but are not limited to materials such as poly(N-isopropylacrylamide) (PNIPAAm), poly(styrene sulfonate) (PSS), poly(allyl amine) (PAAm), poly(acrylic acid) (PAA), poly(ethylene imine) (PEI), poly(diallyldimethyl-ammonium chloride) (PDADMAC), poly(pyrolle) (PPy), poly(vinylpyrrolidone) (PVPON), poly(vinyl pyridine) (PVP), poly(methacrylic acid) (PMAA), poly(methyl methacrylate) (PMMA), polystyrene (PS), poly(tetrahydrofuran) (PTHF), poly(phthalaldehyde) (PTHF), poly(hexyl viologen) (PHV), poly(L-lysine) (PLL), poly(L-arginine) (PARG), poly(lactic-co-glycolic acid) (PLGA).

(91) Numerous chemical stimuli can be used to trigger the disruption, dissolution, or degradation of the beads. Examples of these chemical changes may include, but are not limited to pH-mediated changes to the bead wall, disintegration of the bead wall via chemical cleavage of crosslink bonds, triggered depolymerization of the bead wall, and bead wall switching reactions. Bulk changes may also be used to trigger disruption of the beads.

(92) Bulk or physical changes to the microcapsule through various stimuli also offer many advantages in designing capsules to release reagents. Bulk or physical changes occur on a macroscopic scale, in which bead rupture is the result of mechano-physical forces induced by a stimulus. These processes may include, but are not limited to pressure induced rupture, bead wall melting, or changes in the porosity of the bead wall.

(93) Biological stimuli may also be used to trigger disruption, dissolution, or degradation of beads. Generally, biological triggers resemble chemical triggers, but many examples use biomolecules, or molecules commonly found in living systems such as enzymes, peptides, saccharides, fatty acids,

nucleic acids and the like. For example, beads may comprise polymers with peptide cross-links that are sensitive to cleavage by specific proteases. More specifically, one example may comprise a microcapsule comprising GFLGK peptide cross links. Upon addition of a biological trigger such as the protease Cathepsin B, the peptide cross links of the shell wall are cleaved and the contents of the beads are released. In other cases, the proteases may be heat-activated. In another example, beads comprise a shell wall comprising cellulose. Addition of the hydrolytic enzyme chitosan serves as biologic trigger for cleavage of cellulosic bonds, depolymerization of the shell wall, and release of its inner contents.

(94) The beads may also be induced to release their contents upon the application of a thermal stimulus. A change in temperature can cause a variety changes to the beads. A change in heat may cause melting of a bead such that the bead wall disintegrates. In other cases, the heat may increase the internal pressure of the inner components of the bead such that the bead ruptures or explodes. In still other cases, the heat may transform the bead into a shrunken dehydrated state. The heat may also act upon heat-sensitive polymers within the wall of a bead to cause disruption of the bead.

(95) Inclusion of magnetic nanoparticles to the bead wall of microcapsules may allow triggered rupture of the beads as well as guide the beads in an array. A device of this disclosure may comprise magnetic beads for either purpose. In one example, incorporation of Fe.sub.3O.sub.4 nanoparticles into polyelectrolyte containing beads triggers rupture in the presence of an oscillating magnetic field stimulus.

(96) A bead may also be disrupted, dissolved, or degraded as the result of electrical stimulation. Similar to magnetic particles described in the previous section, electrically sensitive beads can allow for both triggered rupture of the beads as well as other functions such as alignment in an electric field, electrical conductivity or redox reactions. In one example, beads containing electrically sensitive material are aligned in an electric field such that release of inner reagents can be controlled. In other examples, electrical fields may induce redox reactions within the bead wall itself that may increase porosity.

(97) A light stimulus may also be used to disrupt the beads. Numerous light triggers are possible and may include systems that use various molecules such as nanoparticles and chromophores capable of absorbing photons of specific ranges of wavelengths. For example, metal oxide coatings can be used as capsule triggers. UV irradiation of polyelectrolyte capsules coated with SiO.sub.2 may result in disintegration of the bead wall. In yet another example, photo switchable materials such as azobenzene groups may be incorporated in the bead wall. Upon the application of UV or visible light, chemicals such as these undergo a reversible cis-to-trans isomerization upon absorption of photons. In this aspect, incorporation of photon switches result in a bead wall that may disintegrate or become more porous upon the application of a light trigger.

(98) For example, in a non-limiting example of barcoding (e.g., stochastic barcoding) illustrated in FIG. 2, after introducing cells such as single cells onto a plurality of microwells of a microwell array at block 208, beads can be introduced onto the plurality of microwells of the microwell array at block 212. Each microwell can comprise one bead. The beads can comprise a plurality of barcodes. A barcode can comprise a 5' amine region attached to a bead. The barcode can comprise a universal label, a barcode sequence (e.g., a molecular label), a target-binding region, or any combination thereof.

(99) The barcodes disclosed herein can be associated with (e.g., attached to) a solid support (e.g., a bead). The barcodes associated with a solid support can each comprise a barcode sequence selected from a group comprising at least 100 or 1000 barcode sequences with unique sequences. In some embodiments, different barcodes associated with a solid support can comprise barcode with different sequences. In some embodiments, a percentage of barcodes associated with a solid support comprises the same cell label. For example, the percentage can be, or be about 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or a range between any two of these values. As another example, the percentage can be at least, or be at most 60%, 70%, 80%, 85%, 90%, 95%,

97%, 99%, or 100%. In some embodiments, barcodes associated with a solid support can have the same cell label. The barcodes associated with different solid supports can have different cell labels selected from a group comprising at least 100 or 1000 cell labels with unique sequences.

(100) The barcodes disclosed herein can be associated to (e.g., attached to) a solid support (e.g., a bead). In some embodiments, barcoding the plurality of targets in the sample can be performed with a solid support including a plurality of synthetic particles associated with the plurality of barcodes. In some embodiments, the solid support can include a plurality of synthetic particles associated with the plurality of barcodes. The spatial labels of the plurality of barcodes on different solid supports can differ by at least one nucleotide. The solid support can, for example, include the plurality of barcodes in two dimensions or three dimensions. The synthetic particles can be beads. The beads can be silica gel beads, controlled pore glass beads, magnetic beads, Dynabeads, Sephadex/Sepharose beads, cellulose beads, polystyrene beads, or any combination thereof. The solid support can include a polymer, a matrix, a hydrogel, a needle array device, an antibody, or any combination thereof. In some embodiments, the solid supports can be free floating. In some embodiments, the solid supports can be embedded in a semi-solid or solid array. The barcodes may not be associated with solid supports. The barcodes can be individual nucleotides. The barcodes can be associated with a substrate.

(101) As used herein, the terms “tethered,” “attached,” and “immobilized,” are used interchangeably, and can refer to covalent or non-covalent means for attaching barcodes to a solid support. Any of a variety of different solid supports can be used as solid supports for attaching pre-synthesized barcodes or for in situ solid-phase synthesis of barcode.

(102) In some embodiments, the solid support is a bead. The bead can comprise one or more types of solid, porous, or hollow sphere, ball, bearing, cylinder, or other similar configuration which a nucleic acid can be immobilized (e.g., covalently or non-covalently). The bead can be, for example, composed of plastic, ceramic, metal, polymeric material, or any combination thereof. A bead can be, or comprise, a discrete particle that is spherical (e.g., microspheres) or have a non-spherical or irregular shape, such as cubic, cuboid, pyramidal, cylindrical, conical, oblong, or disc-shaped, and the like. In some embodiments, a bead can be non-spherical in shape.

(103) Beads can comprise a variety of materials including, but not limited to, paramagnetic materials (e.g., magnesium, molybdenum, lithium, and tantalum), superparamagnetic materials (e.g., ferrite (Fe₃O₄; magnetite) nanoparticles), ferromagnetic materials (e.g., iron, nickel, cobalt, some alloys thereof, and some rare earth metal compounds), ceramic, plastic, glass, polystyrene, silica, methylstyrene, acrylic polymers, titanium, latex, Sepharose, agarose, hydrogel, polymer, cellulose, nylon, or any combination thereof.

(104) In some embodiments, the bead (e.g., the bead to which the labels are attached) is a hydrogel bead. In some embodiments, the bead comprises hydrogel.

(105) Some embodiments disclosed herein include one or more particles (for example, beads). Each of the particles can comprise a plurality of oligonucleotides (e.g., barcodes). Each of the plurality of oligonucleotides can comprise a barcode sequence (e.g., a molecular label sequence), a cell label, and a target-binding region (e.g., an oligo(dT) sequence, a gene-specific sequence, a random multimer, or a combination thereof). The cell label sequence of each of the plurality of oligonucleotides can be the same. The cell label sequences of oligonucleotides on different particles can be different such that the oligonucleotides on different particles can be identified. The number of different cell label sequences can be different in different implementations. In some embodiments, the number of cell label sequences can be, or be about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 10^{sup.6}, 10^{sup.7}, 10^{sup.8}, 10^{sup.9}, a number or a range between any two of these values, or more. In some embodiments, the number of cell label sequences can be at least, or be at most 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000,

60000, 70000, 80000, 90000, 100000, 10.sup.6, 10.sup.7, 10.sup.8, or 10.sup.9. In some embodiments, no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or more of the plurality of the particles include oligonucleotides with the same cell sequence. In some embodiment, the plurality of particles that include oligonucleotides with the same cell sequence can be at most 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more. In some embodiments, none of the plurality of the particles has the same cell label sequence.

(106) The plurality of oligonucleotides on each particle can comprise different barcode sequences (e.g., molecular labels). In some embodiments, the number of barcode sequences can be, or be about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9, or a number or a range between any two of these values. In some embodiments, the number of barcode sequences can be at least, or be at most 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 10.sup.6, 10.sup.7, 10.sup.8, or 10.sup.9. For example, at least 100 of the plurality of oligonucleotides comprise different barcode sequences. As another example, in a single particle, at least 100, 500, 1000, 5000, 10000, 15000, 20000, 50000, a number or a range between any two of these values, or more of the plurality of oligonucleotides comprise different barcode sequences. Some embodiments provide a plurality of the particles comprising barcodes. In some embodiments, the ratio of an occurrence (or a copy or a number) of a target to be labeled and the different barcode sequences can be at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, or more. In some embodiments, each of the plurality of oligonucleotides further comprises a sample label, a universal label, or both. The particle can be, for example, a nanoparticle or microparticle.

(107) The size of the beads can vary. For example, the diameter of the bead can range from 0.1 micrometer to 50 micrometer. In some embodiments, the diameter of the bead can be, or be about, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 micrometer, or a number or a range between any two of these values.

(108) The diameter of the bead can be related to the diameter of the wells of the substrate. In some embodiments, the diameter of the bead can be, or be about, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or a number or a range between any two of these values, longer or shorter than the diameter of the well. The diameter of the beads can be related to the diameter of a cell (e.g., a single cell entrapped by a well of the substrate). In some embodiments, the diameter of the bead can be at least, or be at most, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% longer or shorter than the diameter of the well. The diameter of the beads can be related to the diameter of a cell (e.g., a single cell entrapped by a well of the substrate). In some embodiments, the diameter of the bead can be, or be about, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, or a number or a range between any two of these values, longer or shorter than the diameter of the cell. In some embodiments, the diameter of the beads can be at least, or be at most, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, or 300% longer or shorter than the diameter of the cell.

(109) A bead can be attached to and/or embedded in a substrate. A bead can be attached to and/or embedded in a gel, hydrogel, polymer and/or matrix. The spatial position of a bead within a substrate (e.g., gel, matrix, scaffold, or polymer) can be identified using the spatial label present on the barcode on the bead which can serve as a location address.

(110) Examples of beads can include, but are not limited to, streptavidin beads, agarose beads, magnetic beads, Dynabeads®, MACS® microbeads, antibody conjugated beads (e.g., anti-immunoglobulin microbeads), protein A conjugated beads, protein G conjugated beads, protein A/G conjugated beads, protein L conjugated beads, oligo(dT) conjugated beads, silica beads, silica-

like beads, anti-biotin microbeads, anti-fluorochrome microbeads, and BcMag™ Carboxyl-Terminated Magnetic Beads.

(111) A bead can be associated with (e.g., impregnated with) quantum dots or fluorescent dyes to make it fluorescent in one fluorescence optical channel or multiple optical channels. A bead can be associated with iron oxide or chromium oxide to make it paramagnetic or ferromagnetic. Beads can be identifiable. For example, a bead can be imaged using a camera. A bead can have a detectable code associated with the bead. For example, a bead can comprise a barcode. A bead can change size, for example, due to swelling in an organic or inorganic solution. A bead can be hydrophobic. A bead can be hydrophilic. A bead can be biocompatible.

(112) A solid support (e.g., a bead) can be visualized. The solid support can comprise a visualizing tag (e.g., fluorescent dye). A solid support (e.g., a bead) can be etched with an identifier (e.g., a number). The identifier can be visualized through imaging the beads.

(113) A solid support can comprise an insoluble, semi-soluble, or soluble material. A solid support can be referred to as “functionalized” when it includes a linker, a scaffold, a building block, or other reactive moiety attached thereto, whereas a solid support may be “nonfunctionalized” when it lacks such a reactive moiety attached thereto. The solid support can be employed free in solution, such as in a microtiter well format; in a flow-through format, such as in a column; or in a dipstick.

(114) The solid support can comprise a membrane, paper, plastic, coated surface, flat surface, glass, slide, chip, or any combination thereof. A solid support can take the form of resins, gels, microspheres, or other geometric configurations. A solid support can comprise silica chips, microparticles, nanoparticles, plates, arrays, capillaries, flat supports such as glass fiber filters, glass surfaces, metal surfaces (steel, gold silver, aluminum, silicon and copper), glass supports, plastic supports, silicon supports, chips, filters, membranes, microwell plates, slides, plastic materials including multiwell plates or membranes (e.g., formed of polyethylene, polypropylene, polyamide, polyvinylidenedifluoride), and/or wafers, combs, pins or needles (e.g., arrays of pins suitable for combinatorial synthesis or analysis) or beads in an array of pits or nanoliter wells of flat surfaces such as wafers (e.g., silicon wafers), wafers with pits with or without filter bottoms.

(115) The solid support can comprise a polymer matrix (e.g., gel, hydrogel). The polymer matrix may be able to permeate intracellular space (e.g., around organelles). The polymer matrix may be able to be pumped throughout the circulatory system.

(116) Substrates and Microwell Array

(117) As used herein, a substrate can refer to a type of solid support. A substrate can refer to a solid support that can comprise barcodes or stochastic barcodes of the disclosure. A substrate can, for example, comprise a plurality of microwells. For example, a substrate can be a well array comprising two or more microwells. In some embodiments, a microwell can comprise a small reaction chamber of defined volume. In some embodiments, a microwell can entrap one or more cells. In some embodiments, a microwell can entrap only one cell. In some embodiments, a microwell can entrap one or more solid supports. In some embodiments, a microwell can entrap only one solid support. In some embodiments, a microwell entraps a single cell and a single solid support (e.g., a bead). A microwell can comprise barcode reagents of the disclosure.

(118) Methods of Barcoding

(119) The disclosure provides for methods for estimating the number of distinct targets at distinct locations in a physical sample (e.g., tissue, organ, tumor, cell). The methods can comprise placing barcodes (e.g., stochastic barcodes) in close proximity with the sample, lysing the sample, associating distinct targets with the barcodes, amplifying the targets and/or digitally counting the targets. The method can further comprise analyzing and/or visualizing the information obtained from the spatial labels on the barcodes. In some embodiments, a method comprises visualizing the plurality of targets in the sample. Mapping the plurality of targets onto the map of the sample can include generating a two dimensional map or a three dimensional map of the sample. The two

dimensional map and the three dimensional map can be generated prior to or after barcoding (e.g., stochastically barcoding) the plurality of targets in the sample. Visualizing the plurality of targets in the sample can include mapping the plurality of targets onto a map of the sample. Mapping the plurality of targets onto the map of the sample can include generating a two dimensional map or a three dimensional map of the sample. The two dimensional map and the three dimensional map can be generated prior to or after barcoding the plurality of targets in the sample. In some embodiments, the two dimensional map and the three dimensional map can be generated before or after lysing the sample. Lysing the sample before or after generating the two dimensional map or the three dimensional map can include heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.

(120) In some embodiments, barcoding the plurality of targets comprises hybridizing a plurality of barcodes with a plurality of targets to create barcoded targets (e.g., stochastically barcoded targets). Barcoding the plurality of targets can comprise generating an indexed library of the barcoded targets. Generating an indexed library of the barcoded targets can be performed with a solid support comprising the plurality of barcodes (e.g., stochastic barcodes).

(121) Contacting a Sample and a Barcode

(122) The disclosure provides for methods for contacting a sample (e.g., cells) to a substrate of the disclosure. A sample comprising, for example, a cell, organ, or tissue thin section, can be contacted to barcodes (e.g., stochastic barcodes). The cells can be contacted, for example, by gravity flow wherein the cells can settle and create a monolayer. The sample can be a tissue thin section. The thin section can be placed on the substrate. The sample can be one-dimensional (e.g., forms a planar surface). The sample (e.g., cells) can be spread across the substrate, for example, by growing/culturing the cells on the substrate.

(123) When barcodes are in close proximity to targets, the targets can hybridize to the barcode. The barcodes can be contacted at a non-depletable ratio such that each distinct target can associate with a distinct barcode of the disclosure. To ensure efficient association between the target and the barcode, the targets can be cross-linked to barcode.

(124) Cell Lysis

(125) Following the distribution of cells and barcodes, the cells can be lysed to liberate the target molecules. Cell lysis can be accomplished by any of a variety of means, for example, by chemical or biochemical means, by osmotic shock, or by means of thermal lysis, mechanical lysis, or optical lysis. Cells can be lysed by addition of a cell lysis buffer comprising a detergent (e.g., SDS, Li dodecyl sulfate, Triton X-100, Tween-20, or NP-40), an organic solvent (e.g., methanol or acetone), or digestive enzymes (e.g., proteinase K, pepsin, or trypsin), or any combination thereof. To increase the association of a target and a barcode, the rate of the diffusion of the target molecules can be altered by for example, reducing the temperature and/or increasing the viscosity of the lysate.

(126) In some embodiments, the sample can be lysed using a filter paper. The filter paper can be soaked with a lysis buffer on top of the filter paper. The filter paper can be applied to the sample with pressure which can facilitate lysis of the sample and hybridization of the targets of the sample to the substrate.

(127) In some embodiments, lysis can be performed by mechanical lysis, heat lysis, optical lysis, and/or chemical lysis. Chemical lysis can include the use of digestive enzymes such as proteinase K, pepsin, and trypsin. Lysis can be performed by the addition of a lysis buffer to the substrate. A lysis buffer can comprise Tris HCl. A lysis buffer can comprise at least about 0.01, 0.05, 0.1, 0.5, or 1 M or more Tris HCl. A lysis buffer can comprise at most about 0.01, 0.05, 0.1, 0.5, or 1 M or more Tris HCl. A lysis buffer can comprise about 0.1 M Tris HCl. The pH of the lysis buffer can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. The pH of the lysis buffer can be at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. In some embodiments, the pH of the lysis buffer is about 7.5. The lysis buffer can comprise a salt (e.g., LiCl). The concentration of salt in the lysis buffer can be

at least about 0.1, 0.5, or 1 M or more. The concentration of salt in the lysis buffer can be at most about 0.1, 0.5, or 1 M or more. In some embodiments, the concentration of salt in the lysis buffer is about 0.5M. The lysis buffer can comprise a detergent (e.g., SDS, Li dodecyl sulfate, triton X, tween, NP-40). The concentration of the detergent in the lysis buffer can be at least about 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, or 7%, or more. The concentration of the detergent in the lysis buffer can be at most about 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, or 7%, or more. In some embodiments, the concentration of the detergent in the lysis buffer is about 1% Li dodecyl sulfate. The time used in the method for lysis can be dependent on the amount of detergent used. In some embodiments, the more detergent used, the less time needed for lysis. The lysis buffer can comprise a chelating agent (e.g., EDTA and EGTA). The concentration of a chelating agent in the lysis buffer can be at least about 1, 5, 10, 15, 20, 25, or 30 mM or more. The concentration of a chelating agent in the lysis buffer can be at most about 1, 5, 10, 15, 20, 25, or 30 mM or more. In some embodiments, the concentration of chelating agent in the lysis buffer is about 10 mM. The lysis buffer can comprise a reducing reagent (e.g., beta-mercaptoethanol, DTT). The concentration of the reducing reagent in the lysis buffer can be at least about 1, 5, 10, 15, or 20 mM or more. The concentration of the reducing reagent in the lysis buffer can be at most about 1, 5, 10, 15, or 20 mM or more. In some embodiments, the concentration of reducing reagent in the lysis buffer is about 5 mM. In some embodiments, a lysis buffer can comprise about 0.1M TrisHCl, about pH 7.5, about 0.5M LiCl, about 1% lithium dodecyl sulfate, about 10 mM EDTA, and about 5 mM DTT.

(128) Lysis can be performed at a temperature of about 4, 10, 15, 20, 25, or 30° C. Lysis can be performed for about 1, 5, 10, 15, or 20 or more minutes. A lysed cell can comprise at least about 100000, 200000, 300000, 400000, 500000, 600000, or 700000 or more target nucleic acid molecules. A lysed cell can comprise at most about 100000, 200000, 300000, 400000, 500000, 600000, or 700000 or more target nucleic acid molecules.

(129) Attachment of Barcodes to Target Nucleic Acid Molecules

(130) Following lysis of the cells and release of nucleic acid molecules therefrom, the nucleic acid molecules can randomly associate with the barcodes of the co-localized solid support. Association can comprise hybridization of a barcode's target recognition region to a complementary portion of the target nucleic acid molecule (e.g., oligo(dT) of the barcode can interact with a poly(A) tail of a target). The assay conditions used for hybridization (e.g., buffer pH, ionic strength, temperature, etc.) can be chosen to promote formation of specific, stable hybrids. In some embodiments, the nucleic acid molecules released from the lysed cells can associate with the plurality of probes on the substrate (e.g., hybridize with the probes on the substrate). When the probes comprise oligo(dT), mRNA molecules can hybridize to the probes and be reverse transcribed. The oligo(dT) portion of the oligonucleotide can act as a primer for first strand synthesis of the cDNA molecule. For example, in a non-limiting example of barcoding illustrated in FIG. 2, at block **216**, mRNA molecules can hybridize to barcodes on beads. For example, single-stranded nucleotide fragments can hybridize to the target-binding regions of barcodes.

(131) Attachment can further comprise ligation of a barcode's target recognition region and a portion of the target nucleic acid molecule. For example, the target binding region can comprise a nucleic acid sequence that can be capable of specific hybridization to a restriction site overhang (e.g., an EcoRI sticky-end overhang). The assay procedure can further comprise treating the target nucleic acids with a restriction enzyme (e.g., EcoRI) to create a restriction site overhang. The barcode can then be ligated to any nucleic acid molecule comprising a sequence complementary to the restriction site overhang. A ligase (e.g., T4 DNA ligase) can be used to join the two fragments.

(132) For example, in a non-limiting example of barcoding illustrated in FIG. 2, at block **220**, the labeled targets from a plurality of cells (or a plurality of samples) (e.g., target-barcode molecules) can be subsequently pooled, for example, into a tube. The labeled targets can be pooled by, for example, retrieving the barcodes and/or the beads to which the target-barcode molecules are

attached.

(133) The retrieval of solid support-based collections of attached target-barcode molecules can be implemented by use of magnetic beads and an externally-applied magnetic field. Once the target-barcode molecules have been pooled, all further processing can proceed in a single reaction vessel. Further processing can include, for example, reverse transcription reactions, amplification reactions, cleavage reactions, dissociation reactions, and/or nucleic acid extension reactions. Further processing reactions can be performed within the microwells, that is, without first pooling the labeled target nucleic acid molecules from a plurality of cells.

(134) Reverse Transcription or Nucleic Acid Extension

(135) The disclosure provides for a method to create a target-barcode conjugate using reverse transcription (e.g., at block **224** of FIG. **2**) or nucleic acid extension. The target-barcode conjugate can comprise the barcode and a complementary sequence of all or a portion of the target nucleic acid (i.e., a barcoded cDNA molecule, such as a stochastically barcoded cDNA molecule). Reverse transcription of the associated RNA molecule can occur by the addition of a reverse transcription primer along with the reverse transcriptase. The reverse transcription primer can be an oligo(dT) primer, a random hexanucleotide primer, or a target-specific oligonucleotide primer. Oligo(dT) primers can be, or can be about, 12-18 nucleotides in length and bind to the endogenous poly(A) tail at the 3' end of mammalian mRNA. Random hexanucleotide primers can bind to mRNA at a variety of complementary sites. Target-specific oligonucleotide primers typically selectively prime the mRNA of interest.

(136) In some embodiments, reverse transcription of an mRNA molecule to a labeled-RNA molecule can occur by the addition of a reverse transcription primer. In some embodiments, the reverse transcription primer is an oligo(dT) primer, random hexanucleotide primer, or a target-specific oligonucleotide primer. Generally, oligo(dT) primers are 12-18 nucleotides in length and bind to the endogenous poly(A) tail at the 3' end of mammalian mRNA. Random hexanucleotide primers can bind to mRNA at a variety of complementary sites. Target-specific oligonucleotide primers typically selectively prime the mRNA of interest.

(137) In some embodiments, a target is a cDNA molecule. For example, an mRNA molecule can be reverse transcribed using a reverse transcriptase, such as Moloney murine leukemia virus (MMLV) reverse transcriptase, to generate a cDNA molecule with a poly(dC) tail. A barcode can include a target binding region with a poly(dG) tail. Upon base pairing between the poly(dG) tail of the barcode and the poly(dC) tail of the cDNA molecule, the reverse transcriptase switches template strands, from cellular RNA molecule to the barcode, and continues replication to the 5' end of the barcode. By doing so, the resulting cDNA molecule contains the sequence of the barcode (such as the molecular label) on the 3' end of the cDNA molecule.

(138) Reverse transcription can occur repeatedly to produce multiple labeled-cDNA molecules. The methods disclosed herein can comprise conducting at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 reverse transcription reactions. The method can comprise conducting at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 reverse transcription reactions.

(139) Amplification

(140) One or more nucleic acid amplification reactions (e.g., at block **228** of FIG. **2**) can be performed to create multiple copies of the labeled target nucleic acid molecules. Amplification can be performed in a multiplexed manner, wherein multiple target nucleic acid sequences are amplified simultaneously. The amplification reaction can be used to add sequencing adaptors to the nucleic acid molecules. The amplification reactions can comprise amplifying at least a portion of a sample label, if present. The amplification reactions can comprise amplifying at least a portion of the cellular label and/or barcode sequence (e.g., a molecular label). The amplification reactions can comprise amplifying at least a portion of a sample tag, a cell label, a spatial label, a barcode sequence (e.g., a molecular label), a target nucleic acid, or a combination thereof. The amplification

reactions can comprise amplifying 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 100%, or a range or a number between any two of these values, of the plurality of nucleic acids. The method can further comprise conducting one or more cDNA synthesis reactions to produce one or more cDNA copies of target-barcode molecules comprising a sample label, a cell label, a spatial label, and/or a barcode sequence (e.g., a molecular label).

(141) In some embodiments, amplification can be performed using a polymerase chain reaction (PCR). As used herein, PCR can refer to a reaction for the in vitro amplification of specific DNA sequences by the simultaneous primer extension of complementary strands of DNA. As used herein, PCR can encompass derivative forms of the reaction, including but not limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, digital PCR, and assembly PCR.

(142) Amplification of the labeled nucleic acids can comprise non-PCR based methods. Examples of non-PCR based methods include, but are not limited to, multiple displacement amplification (MDA), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), real-time SDA, rolling circle amplification, or circle-to-circle amplification. Other non-PCR-based amplification methods include multiple cycles of DNA-dependent RNA polymerase-driven RNA transcription amplification or RNA-directed DNA synthesis and transcription to amplify DNA or RNA targets, a ligase chain reaction (LCR), and a Q β replicase (Q β) method, use of palindromic probes, strand displacement amplification, oligonucleotide-driven amplification using a restriction endonuclease, an amplification method in which a primer is hybridized to a nucleic acid sequence and the resulting duplex is cleaved prior to the extension reaction and amplification, strand displacement amplification using a nucleic acid polymerase lacking 5' exonuclease activity, rolling circle amplification, and ramification extension amplification (RAM). In some embodiments, the amplification does not produce circularized transcripts.

(143) In some embodiments, the methods disclosed herein further comprise conducting a polymerase chain reaction on the labeled nucleic acid (e.g., labeled-RNA, labeled-DNA, labeled-cDNA) to produce a labeled amplicon (e.g., a stochastically labeled amplicon). The labeled amplicon can be double-stranded molecule. The double-stranded molecule can comprise a double-stranded RNA molecule, a double-stranded DNA molecule, or a RNA molecule hybridized to a DNA molecule. One or both of the strands of the double-stranded molecule can comprise a sample label, a spatial label, a cell label, and/or a barcode sequence (e.g., a molecular label). The labeled amplicon can be a single-stranded molecule. The single-stranded molecule can comprise DNA, RNA, or a combination thereof. The nucleic acids of the disclosure can comprise synthetic or altered nucleic acids.

(144) Amplification can comprise use of one or more non-natural nucleotides. Non-natural nucleotides can comprise photolabile or triggerable nucleotides. Examples of non-natural nucleotides can include, but are not limited to, peptide nucleic acid (PNA), morpholino and locked nucleic acid (LNA), as well as glycol nucleic acid (GNA) and threose nucleic acid (TNA). Non-natural nucleotides can be added to one or more cycles of an amplification reaction. The addition of the non-natural nucleotides can be used to identify products as specific cycles or time points in the amplification reaction.

(145) Conducting the one or more amplification reactions can comprise the use of one or more primers. The one or more primers can comprise, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more nucleotides. The one or more primers can comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more nucleotides. The one or more primers can comprise less than 12-15 nucleotides. The one or more primers can anneal to at least a portion of the plurality of labeled targets (e.g., stochastically labeled targets). The one or more primers can anneal to the 3' end or 5' end of the plurality of labeled targets. The one or more primers can anneal to an internal region of the plurality of labeled targets. The internal region can be at least about 50, 100, 150, 200, 220,

230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides from the 3' ends the plurality of labeled targets. The one or more primers can comprise a fixed panel of primers. The one or more primers can comprise at least one or more custom primers. The one or more primers can comprise at least one or more control primers. The one or more primers can comprise at least one or more gene-specific primers.

(146) The one or more primers can comprise a universal primer. The universal primer can anneal to a universal primer binding site. The one or more custom primers can anneal to a first sample label, a second sample label, a spatial label, a cell label, a barcode sequence (e.g., a molecular label), a target, or any combination thereof. The one or more primers can comprise a universal primer and a custom primer. The custom primer can be designed to amplify one or more targets. The targets can comprise a subset of the total nucleic acids in one or more samples. The targets can comprise a subset of the total labeled targets in one or more samples. The one or more primers can comprise at least 96 or more custom primers. The one or more primers can comprise at least 960 or more custom primers. The one or more primers can comprise at least 9600 or more custom primers. The one or more custom primers can anneal to two or more different labeled nucleic acids. The two or more different labeled nucleic acids can correspond to one or more genes.

(147) Any amplification scheme can be used in the methods of the present disclosure. For example, in one scheme, the first round PCR can amplify molecules attached to the bead using a gene specific primer and a primer against the universal Illumina sequencing primer 1 sequence. The second round of PCR can amplify the first PCR products using a nested gene specific primer flanked by Illumina sequencing primer 2 sequence, and a primer against the universal Illumina sequencing primer 1 sequence. The third round of PCR adds P5 and P7 and sample index to turn PCR products into an Illumina sequencing library. Sequencing using 150 bp×2 sequencing can reveal the cell label and barcode sequence (e.g., molecular label) on read 1, the gene on read 2, and the sample index on index 1 read.

(148) In some embodiments, nucleic acids can be removed from the substrate using chemical cleavage. For example, a chemical group or a modified base present in a nucleic acid can be used to facilitate its removal from a solid support. For example, an enzyme can be used to remove a nucleic acid from a substrate. For example, a nucleic acid can be removed from a substrate through a restriction endonuclease digestion. For example, treatment of a nucleic acid containing a dUTP or ddUTP with uracil-d-glycosylase (UDG) can be used to remove a nucleic acid from a substrate. For example, a nucleic acid can be removed from a substrate using an enzyme that performs nucleotide excision, such as a base excision repair enzyme, such as an apurinic/apyrimidinic (AP) endonuclease. In some embodiments, a nucleic acid can be removed from a substrate using a photocleavable group and light. In some embodiments, a cleavable linker can be used to remove a nucleic acid from the substrate. For example, the cleavable linker can comprise at least one of biotin/avidin, biotin/streptavidin, biotin/neutravidin, Ig-protein A, a photolabile linker, acid or base labile linker group, or an aptamer.

(149) When the probes are gene-specific, the molecules can hybridize to the probes and be reverse transcribed and/or amplified. In some embodiments, after the nucleic acid has been synthesized (e.g., reverse transcribed), it can be amplified. Amplification can be performed in a multiplex manner, wherein multiple target nucleic acid sequences are amplified simultaneously. Amplification can add sequencing adaptors to the nucleic acid.

(150) In some embodiments, amplification can be performed on the substrate, for example, with bridge amplification. cDNAs can be homopolymer tailed in order to generate a compatible end for bridge amplification using oligo(dT) probes on the substrate. In bridge amplification, the primer that is complementary to the 3' end of the template nucleic acid can be the first primer of each pair that is covalently attached to the solid particle. When a sample containing the template nucleic acid is contacted with the particle and a single thermal cycle is performed, the template molecule can be

annealed to the first primer and the first primer is elongated in the forward direction by addition of nucleotides to form a duplex molecule consisting of the template molecule and a newly formed DNA strand that is complementary to the template. In the heating step of the next cycle, the duplex molecule can be denatured, releasing the template molecule from the particle and leaving the complementary DNA strand attached to the particle through the first primer. In the annealing stage of the annealing and elongation step that follows, the complementary strand can hybridize to the second primer, which is complementary to a segment of the complementary strand at a location removed from the first primer. This hybridization can cause the complementary strand to form a bridge between the first and second primers secured to the first primer by a covalent bond and to the second primer by hybridization. In the elongation stage, the second primer can be elongated in the reverse direction by the addition of nucleotides in the same reaction mixture, thereby converting the bridge to a double-stranded bridge. The next cycle then begins, and the double-stranded bridge can be denatured to yield two single-stranded nucleic acid molecules, each having one end attached to the particle surface via the first and second primers, respectively, with the other end of each unattached. In the annealing and elongation step of this second cycle, each strand can hybridize to a further complementary primer, previously unused, on the same particle, to form new single-strand bridges. The two previously unused primers that are now hybridized elongate to convert the two new bridges to double-strand bridges.

(151) The amplification reactions can comprise amplifying at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 100% of the plurality of nucleic acids.

(152) Amplification of the labeled nucleic acids can comprise PCR-based methods or non-PCR based methods. Amplification of the labeled nucleic acids can comprise exponential amplification of the labeled nucleic acids. Amplification of the labeled nucleic acids can comprise linear amplification of the labeled nucleic acids. Amplification can be performed by polymerase chain reaction (PCR). PCR can refer to a reaction for the in vitro amplification of specific DNA sequences by the simultaneous primer extension of complementary strands of DNA. PCR can encompass derivative forms of the reaction, including but not limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, digital PCR, suppression PCR, semi-suppressive PCR and assembly PCR.

(153) In some embodiments, amplification of the labeled nucleic acids comprises non-PCR based methods. Examples of non-PCR based methods include, but are not limited to, multiple displacement amplification (MDA), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), real-time SDA, rolling circle amplification, or circle-to-circle amplification. Other non-PCR-based amplification methods include multiple cycles of DNA-dependent RNA polymerase-driven RNA transcription amplification or RNA-directed DNA synthesis and transcription to amplify DNA or RNA targets, a ligase chain reaction (LCR), a Q β replicase (Q β), use of palindromic probes, strand displacement amplification, oligonucleotide-driven amplification using a restriction endonuclease, an amplification method in which a primer is hybridized to a nucleic acid sequence and the resulting duplex is cleaved prior to the extension reaction and amplification, strand displacement amplification using a nucleic acid polymerase lacking 5' exonuclease activity, rolling circle amplification, and/or ramification extension amplification (RAM).

(154) In some embodiments, the methods disclosed herein further comprise conducting a nested polymerase chain reaction on the amplified amplicon (e.g., target). The amplicon can be double-stranded molecule. The double-stranded molecule can comprise a double-stranded RNA molecule, a double-stranded DNA molecule, or a RNA molecule hybridized to a DNA molecule. One or both of the strands of the double-stranded molecule can comprise a sample tag or molecular identifier label. Alternatively, the amplicon can be a single-stranded molecule. The single-stranded molecule can comprise DNA, RNA, or a combination thereof. The nucleic acids of the present invention can

comprise synthetic or altered nucleic acids.

(155) In some embodiments, the method comprises repeatedly amplifying the labeled nucleic acid to produce multiple amplicons. The methods disclosed herein can comprise conducting at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amplification reactions. Alternatively, the method comprises conducting at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amplification reactions.

(156) Amplification can further comprise adding one or more control nucleic acids to one or more samples comprising a plurality of nucleic acids. Amplification can further comprise adding one or more control nucleic acids to a plurality of nucleic acids. The control nucleic acids can comprise a control label.

(157) Amplification can comprise use of one or more non-natural nucleotides. Non-natural nucleotides can comprise photolabile and/or triggerable nucleotides. Examples of non-natural nucleotides include, but are not limited to, peptide nucleic acid (PNA), morpholino and locked nucleic acid (LNA), as well as glycol nucleic acid (GNA) and threose nucleic acid (TNA). Non-natural nucleotides can be added to one or more cycles of an amplification reaction. The addition of the non-natural nucleotides can be used to identify products as specific cycles or time points in the amplification reaction.

(158) Conducting the one or more amplification reactions can comprise the use of one or more primers. The one or more primers can comprise one or more oligonucleotides. The one or more oligonucleotides can comprise at least about 7-9 nucleotides. The one or more oligonucleotides can comprise less than 12-15 nucleotides. The one or more primers can anneal to at least a portion of the plurality of labeled nucleic acids. The one or more primers can anneal to the 3' end and/or 5' end of the plurality of labeled nucleic acids. The one or more primers can anneal to an internal region of the plurality of labeled nucleic acids. The internal region can be at least about 50, 100, 150, 200, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides from the 3' ends the plurality of labeled nucleic acids. The one or more primers can comprise a fixed panel of primers. The one or more primers can comprise at least one or more custom primers. The one or more primers can comprise at least one or more control primers. The one or more primers can comprise at least one or more housekeeping gene primers. The one or more primers can comprise a universal primer. The universal primer can anneal to a universal primer binding site. The one or more custom primers can anneal to the first sample tag, the second sample tag, the molecular identifier label, the nucleic acid or a product thereof. The one or more primers can comprise a universal primer and a custom primer. The custom primer can be designed to amplify one or more target nucleic acids. The target nucleic acids can comprise a subset of the total nucleic acids in one or more samples. In some embodiments, the primers are the probes attached to the array of the disclosure.

(159) In some embodiments, barcoding (e.g., stochastically barcoding) the plurality of targets in the sample further comprises generating an indexed library of the barcoded targets (e.g., stochastically barcoded targets) or barcoded fragments of the targets. The barcode sequences of different barcodes (e.g., the molecular labels of different stochastic barcodes) can be different from one another. Generating an indexed library of the barcoded targets includes generating a plurality of indexed polynucleotides from the plurality of targets in the sample. For example, for an indexed library of the barcoded targets comprising a first indexed target and a second indexed target, the label region of the first indexed polynucleotide can differ from the label region of the second indexed polynucleotide by, by about, by at least, or by at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or a number or a range between any two of these values, nucleotides. In some embodiments, generating an indexed library of the barcoded targets includes contacting a plurality of targets, for example mRNA molecules, with a plurality of oligonucleotides including a poly(T) region and a label region; and conducting a first strand synthesis using a reverse transcriptase to produce single-strand

labeled cDNA molecules each comprising a cDNA region and a label region, wherein the plurality of targets includes at least two mRNA molecules of different sequences and the plurality of oligonucleotides includes at least two oligonucleotides of different sequences. Generating an indexed library of the barcoded targets can further comprise amplifying the single-strand labeled cDNA molecules to produce double-strand labeled cDNA molecules; and conducting nested PCR on the double-strand labeled cDNA molecules to produce labeled amplicons. In some embodiments, the method can include generating an adaptor-labeled amplicon.

(160) Barcoding (e.g., stochastic barcoding) can include using nucleic acid barcodes or tags to label individual nucleic acid (e.g., DNA or RNA) molecules. In some embodiments, it involves adding DNA barcodes or tags to cDNA molecules as they are generated from mRNA. Nested PCR can be performed to minimize PCR amplification bias. Adaptors can be added for sequencing using, for example, next generation sequencing (NGS). The sequencing results can be used to determine cell labels, molecular labels, and sequences of nucleotide fragments of the one or more copies of the targets, for example at block **232** of FIG. **2**.

(161) FIG. **3** is a schematic illustration showing a non-limiting exemplary process of generating an indexed library of the barcoded targets (e.g., stochastically barcoded targets), such as barcoded mRNAs or fragments thereof. As shown in step **1**, the reverse transcription process can encode each mRNA molecule with a unique molecular label sequence, a cell label sequence, and a universal PCR site. In particular, RNA molecules **302** can be reverse transcribed to produce labeled cDNA molecules **304**, including a cDNA region **306**, by hybridization (e.g., stochastic hybridization) of a set of barcodes (e.g., stochastic barcodes) **310** to the poly(A) tail region **308** of the RNA molecules **302**. Each of the barcodes **310** can comprise a target-binding region, for example a poly(dT) region **312**, a label region **314** (e.g., a barcode sequence or a molecule), and a universal PCR region **316**.

(162) In some embodiments, the cell label sequence can include 3 to 20 nucleotides. In some embodiments, the molecular label sequence can include 3 to 20 nucleotides. In some embodiments, each of the plurality of stochastic barcodes further comprises one or more of a universal label and a cell label, wherein universal labels are the same for the plurality of stochastic barcodes on the solid support and cell labels are the same for the plurality of stochastic barcodes on the solid support. In some embodiments, the universal label can include 3 to 20 nucleotides. In some embodiments, the cell label comprises 3 to 20 nucleotides.

(163) In some embodiments, the label region **314** can include a barcode sequence or a molecular label **318** and a cell label **320**. In some embodiments, the label region **314** can include one or more of a universal label, a dimension label, and a cell label. The barcode sequence or molecular label **318** can be, can be about, can be at least, or can be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or a range between any of these values, of nucleotides in length. The cell label **320** can be, can be about, can be at least, or can be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or a range between any of these values, of nucleotides in length. The universal label can be, can be about, can be at least, or can be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or a range between any of these values, of nucleotides in length. Universal labels can be the same for the plurality of stochastic barcodes on the solid support and cell labels are the same for the plurality of stochastic barcodes on the solid support. The dimension label can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or a range between any of these values, of nucleotides in length.

(164) In some embodiments, the label region **314** can comprise, comprise about, comprise at least, or comprise at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or a range between any of these values, different labels, such as a barcode sequence or a molecular label **318** and a cell label **320**. Each label can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90,

100, or a number or a range between any of these values, of nucleotides in length. A set of barcodes or stochastic barcodes **310** can contain, contain about, contain at least, or can be at most, 10, 20, 40, 50, 70, 80, 90, 10.sup.2, 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9, 10.sup.10, 10.sup.11, 10.sup.12, 10.sup.13, 10.sup.14, 10.sup.15, 10.sup.20, or a number or a range between any of these values, barcodes or stochastic barcodes **310**. And the set of barcodes or stochastic barcodes **310** can, for example, each contain a unique label region **314**. The labeled cDNA molecules **304** can be purified to remove excess barcodes or stochastic barcodes **310**. Purification can comprise Ampure bead purification.

(165) As shown in step **2**, products from the reverse transcription process in step **1** can be pooled into 1 tube and PCR amplified with a 1.sup.st PCR primer pool and a 1.sup.st universal PCR primer. Pooling is possible because of the unique label region **314**. In particular, the labeled cDNA molecules **304** can be amplified to produce nested PCR labeled amplicons **322**. Amplification can comprise multiplex PCR amplification. Amplification can comprise a multiplex PCR amplification with **96** multiplex primers in a single reaction volume. In some embodiments, multiplex PCR amplification can utilize, utilize about, utilize at least, or utilize at most, 10, 20, 40, 50, 70, 80, 90, 10.sup.2, 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9, 10.sup.10, 10.sup.11, 10.sup.12, 10.sup.13, 10.sup.14, 10.sup.15, 10.sup.20, or a number or a range between any of these values, multiplex primers in a single reaction volume. Amplification can comprise using a 1.sup.st PCR primer pool **324** comprising custom primers **326A-C** targeting specific genes and a universal primer **328**. The custom primers **326** can hybridize to a region within the cDNA portion **306'** of the labeled cDNA molecule **304**. The universal primer **328** can hybridize to the universal PCR region **316** of the labeled cDNA molecule **304**.

(166) As shown in step **3** of FIG. **3**, products from PCR amplification in step **2** can be amplified with a nested PCR primers pool and a 2.sup.nd universal PCR primer. Nested PCR can minimize PCR amplification bias. In particular, the nested PCR labeled amplicons **322** can be further amplified by nested PCR. The nested PCR can comprise multiplex PCR with nested PCR primers pool **330** of nested PCR primers **332a-c** and a 2.sup.nd universal PCR primer **328'** in a single reaction volume. The nested PCR primer pool **328** can contain, contain about, contain at least, or contain at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or a range between any of these values, different nested PCR primers **330**. The nested PCR primers **332** can contain an adaptor **334** and hybridize to a region within the cDNA portion **306''** of the labeled amplicon **322**. The universal primer **328'** can contain an adaptor **336** and hybridize to the universal PCR region **316** of the labeled amplicon **322**. Thus, step **3** produces adaptor-labeled amplicon **338**. In some embodiments, nested PCR primers **332** and the 2.sup.nd universal PCR primer **328'** may not contain the adaptors **334** and **336**. The adaptors **334** and **336** can instead be ligated to the products of nested PCR to produce adaptor-labeled amplicon **338**.

(167) As shown in step **4**, PCR products from step **3** can be PCR amplified for sequencing using library amplification primers. In particular, the adaptors **334** and **336** can be used to conduct one or more additional assays on the adaptor-labeled amplicon **338**. The adaptors **334** and **336** can be hybridized to primers **340** and **342**. The one or more primers **340** and **342** can be PCR amplification primers. The one or more primers **340** and **342** can be sequencing primers. The one or more adaptors **334** and **336** can be used for further amplification of the adaptor-labeled amplicons **338**. The one or more adaptors **334** and **336** can be used for sequencing the adaptor-labeled amplicon **338**. The primer **342** can contain a plate index **344** so that amplicons generated using the same set of barcodes or stochastic barcodes **310** can be sequenced in one sequencing reaction using next generation sequencing (NGS).

(168) Methods and Compositions for Single Cell Secretomics

(169) There are provided, in some embodiments, systems, methods, compositions, and kits for single cell secretomics. The methods and compositions disclosed herein can determine the number

of copies of one or more secreted factors secreted by a single cell (e.g., secretomics, secreted factor profiling). There are provided, in some embodiments, compositions and methods for single cell secretome analysis. Some embodiments described herein employ antibodies capable of binding secreted factors, and said antibodies can be associated with oligonucleotides. In some embodiments, the methods and compositions provided herein are compatible with single cell analysis systems, workflows, and platforms (e.g., BD Rhapsody). There is a need for compositions and methods for analyzing the secretome profile of individual cells. Currently available methods of secretome profiling (e.g., fluorescence- or microarray chip-based) are high-cost and low-throughput, and are less quantitative than the secretome profiling methods and compositions provided herein. In some embodiments, secreted proteins of single cells are captured by synthetic beads (a cell mimic) with multiple antibodies (specific for said secreted proteins) conjugated thereto. In some embodiments, said beads can then be probed with secreted factor binding-reagents as described herein. Said secreted factor binding-reagents can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. Barcoding and sequence analysis of said secreted factor-binding reagent specific oligonucleotides as described herein can enable high-throughput single cell secretome analysis.

(170) There are provided, in some embodiments solid supports (e.g., beads, first solid supports, second solid supports) that are cell-sized. Said solid supports can comprise a functional surface for antibody conjugation (e.g., conjugation of antibodies versus secreted proteins). The method can comprise incubation of single cells with said antibody-coated solid support. The incubation can take place in partitions (e.g., wells). Partition size can be optimized to capture most of secreted proteins. The time, media, and/or temperature of incubation can be varied depending on the needs of the user. Cells can, depending on the embodiment, die during the incubation; however, in some such embodiments, the secretome information is still valuable. Thus, the compositions and methods provided herein can still acquire useful secretome information even in cases of cell death. The solid supports can be collected from said partitions and stained with the secreted factor-binding reagents provided herein. The staining can be multiplexed. In some embodiments provided herein, flow Abs can be also added for sorting to enrich certain secretomic types. In some embodiments, solid supports are stained with antibodies comprising a detectable moiety that enable the sorting of solid supports by flow cytometry for one or more desired properties. The method can comprise washing of unbound the secreted factor-binding reagents. The solid supports can be loaded into a plurality of partitions (e.g., wells, droplets, partitions of a single cell analysis platform such as BD Rhapsody). A single partition of the plurality of partitions can comprise a single solid support. A single partition of the plurality of partitions can comprise a plurality of oligonucleotide barcodes. A single partition of the plurality of partitions can comprise a barcoding particle (e.g., a single third solid support as described herein). Barcoding of barcoded secreted factor-binding reagent specific oligonucleotides with said oligonucleotide barcodes can be performed as described herein. Library generation and obtaining the sequence information can yield secretome data.

(171) There are provided, in some embodiments, compositions and methods for simultaneous high-throughput single cell secretome and transcriptome analysis. In some such embodiments, the solid support (e.g. second solid support) comprises a plurality of capture probes and a plurality of anchor probes. Each of the plurality of anchor probes can be capable of specifically binding to a surface cellular target to form single cells associated with a second solid support. Barcoding and sequence analysis of said secreted factor-binding reagent specific oligonucleotides as well as the nucleic acid targets of the associated single cells as described herein can enable high-throughput single cell secretome and transcriptome analysis. In some embodiments, single cell secretome analysis and single cell protein profiling can be performed using the compositions and methods provided herein. In some embodiments, compositions and methods for simultaneous single cell secretome analysis, transcriptome analysis, and protein profiling are described. Embodiments of using AbOs to

determine protein expression profiles in single cells and tracking sample origins have been described in U.S. patent application Ser. No. 15/715,028, published as U.S. Patent Application Publication No. 2018/0088112, and U.S. patent application Ser. No. 15/937,713; the content of each is incorporated by reference herein in its entirety.

(172) In some embodiments, the solid support (e.g., bead, first solid support, second solid support) comprising a plurality of capture probes (e.g., multiple different antibodies for secreted protein) is a cell mimic. A single cell and one of said solid supports can be located in a partition (e.g., well) of a plurality of partitions (e.g., a culture plate) with media so secreted proteins will be captured by capture probes on the solid support from the given cell. Then the solid support can be stained with secreted factor binding reagents that can detect the captured proteins and those solid supports can be loaded onto a plurality of partitions (e.g., wells, droplets, partitions of a single cell analysis platform such as BD Rhapsody) for library generation. Said secreted factor binding-reagents can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The secreted factor-binding reagent specific oligonucleotide library can be sequenced and generate the secretome information of single cells. Currently available methods for detecting secreted proteins have a limitation on the number of proteins that can be detected due to the number of fluorescence markers that can be used in the microscope or flow cytometry analysis. The compositions and methods provided herein remove this limitation and can enable detection of secreted proteins with as many pairs of capture probe/secreted factor-binding reagent needed by the user. Moreover, as described therein, the disclosed methods can comprise the capture of both secreted protein and single cells for the analysis of the transcriptome and secretome of a single cell. Systems, methods, compositions, and kits for measuring secreted factors from cells employing (i) bispecific probes comprising anchor probe(s) capable of specifically binding to a surface cellular target of a cell and capture probe(s) capable of specifically binding to a secreted factor secreted by a cell that is associated with the capture probe, and/or (ii) secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, are described in the U.S. Patent Application No. 62/962,927, filed Jan. 17, 2020, entitled "METHODS AND COMPOSITIONS FOR SINGLE CELL SECRETOMICS", the content of which is incorporated herein by reference in its entirety.

(173) Currently available methods of single cell secretome profiling, such as those using fluorescence detection on microarray chips, suffer from the deficiencies of being less quantitative due to the fluorescence intensity differences and low potential to capture transcriptome of given cell. The limitations of fluorescence intensity difference-based methods and low number of secreted proteins that can be detected from a given cell are solved with the methods and compositions provided herein, in some embodiments, by utilizing the sequence analysis of secreted factor-binding reagent specific oligonucleotides, which are not limited by fluorescent markers and are more quantitative due to the ability to count the number of molecules (instead of fluorescent intensity).

(174) Cytokines and other proteins released by the cell are of keen interest to immunologists and other cell biologists. Traditional methods for detecting and measuring secreted proteins are typically measured in bulk (rather than at the single cell level). For example, currently available methods include bead-based assays and ELISA for studying secreted factors in bulk. Therefore, single cell quantification and cellular phenotype analysis are missing in the data. As with the comparison of flow cytometry to traditional western blots, there is tremendous value in studying the individual cells from a heterogeneous mixture of cells. The methods and compositions provided herein enable detection and relative quantification of secreted proteins of individual cells in a heterogeneous mixture. Oligonucleotide barcoded detection probes (e.g., secreted factor-binding reagent specific oligonucleotides) can be optimized for single cell genomics analysis. The secreted factor analysis methods provided herein can be compatible with other analyses techniques for single cell multiomics platforms. Disclosed herein include methods and compositions enabling

rapid adoption of single-cell secretomic assays across a flexible portfolio of targets without the need for specialized instrumentation. In some embodiments, the methods disclosed herein can provide the ability to assay secreted proteins without compromising cell-viability, and thus can enable the sorting of live cells based on their protein secretion profile. Additionally, the methods provided herein enable a broader suite of single cell omic data downstream of cell preparation. (175) The use of an oligo-barcoded detection probe (e.g., an secreted factor binding reagent) as provided herein enables, for the first time, the ability to assess secreted factors from individual cells simultaneously with surface proteins (e.g., cellular component targets) and intracellular transcript (mRNA). The methods and compositions provided herein enable, for the first time, single cell secretion analysis on single cell genomic platforms.

(176) In some embodiments of the methods and compositions provided herein, a DNA cellular component binding reagent specific oligonucleotide (e.g., an antibody oligonucleotide) is hybridized to an oligonucleotide barcode and extended to enable a separate, but parallel workflow for protein quantitation and mRNA quantitation from the same beads, as described in U.S. application Ser. No. 17/147,272, the content of which is incorporated herein by reference in its entirety. Some embodiments of the methods and compositions provided herein employ the separate, but parallel workflow concept described in U.S. application Ser. No. 17/147,272; for example, in some embodiments, a secreted factor-binding reagent specific oligonucleotide (e.g., an antibody oligonucleotide) is hybridized to an oligonucleotide barcode and extended to enable a separate, but parallel workflow for secreted factor quantitation and mRNA quantitation from the same beads. (177) In some embodiments of the methods and compositions provided herein, the oligonucleotide barcode comprises a cleavage region (comprising, for example, one or more cleavage sites such as a non-canonical nucleotide (e.g., deoxyuridine) or a restriction enzyme recognition sequence) as described in U.S. application Ser. No. 17/147,283, the content of which is incorporated herein by reference in its entirety.

(178) FIG. 6 shows a non-limiting exemplary design of a secreted factor binding reagent specific oligonucleotide (antibody oligonucleotide illustrated here) that is associated with a secreted factor-binding reagent (antibody illustrated here). The secreted factor-binding reagent specific oligonucleotide **604** can be associated with secreted factor-binding reagent **602** through linker **616**. The secreted factor-binding reagent specific oligonucleotide **604** can be detached from the secreted factor-binding reagent **602** using chemical, optical or other means. The secreted factor-binding reagent specific oligonucleotide **604** can be an mRNA mimic. The secreted factor-binding reagent specific oligonucleotide **604** can include a second universal sequence **606** (e.g., a primer adapter), a second molecular label **608** (e.g., a unique molecular label sequence), an antibody barcode **610** (e.g., a unique factor identifier sequence), an alignment sequence **612**, and a poly(A) tail **614**.

(179) FIGS. 4A-4C show a schematic illustration of a non-limiting exemplary workflow for measurement of the number of copies of one or more secreted factors secreted by a single cell. The workflow can comprise analysis of cells **404** (e.g., T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof) with first plurality of first solid supports **410** (e.g., beads). The workflow can comprise contacting cells **404** with first solid supports **410**. The workflow can comprise partitioning **400a** the cells **404** and the first solid supports **410** to a plurality of first partitions **402**. A first partition **402** (e.g., a well, a droplet) of the plurality of first partitions can comprise a single cell **404** and a single first solid support **410**. A cell **404** can comprise secretory vesicles **406** comprising unreleased secretory factors **408**. A cell **404** can be capable of secreting a plurality of secreted factors **408**. A first solid support **410** can comprise capture probes **412** capable of specifically binding to at least one of the plurality of secreted factors **408** secreted by a single cell **404**. The workflow can comprise an incubation **400b** comprising secretion of secreted factors and binding thereof to capture probes. The workflow can comprise pooling **400c** of the single first solid supports **410** from each first partition **402** (to generate a second plurality of first solid supports). The workflow can comprise contacting **400d** the first solid

support **410** with a plurality of secreted factor-binding reagents **414** each capable of specifically binding to a secreted factor bound by a capture probe. Each of the plurality of secreted factor-binding reagents can comprise a secreted factor-binding reagent specific oligonucleotide **416** comprising a unique factor identifier sequence for the secreted factor-binding reagent. The workflow can comprise an incubation **400e** comprising binding of the secreted factor-binding reagents **414** to secreted factor **408** bound by a capture probe **412**. The workflow can comprise one or more washes **400f** comprising removal of secreted factor-binding reagents **414** that are not bound to secreted factor **408** bound by a capture probe **412** (to generate a third plurality of first solid supports). The workflow can comprise partitioning **400g** the first solid supports **410** to a plurality of second partitions **418**. A second partition **418** (e.g., a well, a droplet) of the plurality of second partitions can comprise a single first solid support **410** and a single third solid support **420**. Third solid support **420** can comprise a plurality of oligonucleotide barcodes **422**. Oligonucleotide barcodes **422** can comprise a first molecular label and/or cellular label. The workflow can comprise contacting oligonucleotide barcodes **422** with the secreted factor-binding reagent specific oligonucleotides **416** for hybridization. The workflow can comprise barcoding, library preparation, and/or sequencing **400h** as described herein. For example, the workflow can comprise extending oligonucleotide barcodes **422** hybridized to the secreted factor-binding reagent specific oligonucleotides **416** to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise obtaining sequence information of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of a secreted factor **408** secreted by each of the one or more single cells **404**. The workflow can comprise performing the steps with a plurality of cells (e.g., in bulk).

(180) FIGS. 5A-5C show a schematic illustration of a non-limiting exemplary workflow for measuring the number of copies of a secreted factor secreted by a single cell and the number of copies of a nucleic acid target in a single cell. The workflow can comprise analysis of cells **504** (e.g., T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof) with first plurality of second solid supports **510** (e.g., beads). The workflow can comprise contacting cells **504** with second solid supports **510**. The workflow can comprise partitioning **500a** the cells **504** and the second solid supports **510** to a plurality of first partitions **502**. A first partition **502** (e.g., a well, a droplet) of the plurality of first partitions can comprise a single cell **504** and a single second solid support **510**. A cell **504** can comprise secretory vesicles **506** comprising unreleased secretory factors **508**. A cell **504** can be capable of secreting a plurality of secreted factors **508**. A second solid support **510** can comprise capture probes **512** capable of specifically binding to at least one of the plurality of secreted factors **508** secreted by a single cell **504**. Cells **504** can comprise a surface cellular target **524** and copies of a nucleic acid target **526**. The second solid support **510** can comprise anchor probes **528** capable of specifically binding to the surface cellular target **524**. The single cell **504** can be capable of becoming associated with a second solid support **510** via the anchor probe **528** binding to the surface cellular target **524**. The workflow can comprise an incubation **500b** comprising secretion of secreted factors and binding thereof to capture probes and the single cell **504** becoming associated with a second solid support **510** via the anchor probe **528** binding to the surface cellular target **524**. The workflow can comprise pooling **500c** of single cells associated with a second solid support from each first partition **502** (to generate a first plurality of single cells associated with a second solid support). The workflow can comprise contacting **500d** the single cells associated with a second solid support with a plurality of secreted factor-binding reagents **514** each capable of specifically binding to a secreted factor bound by a capture probe. Each of the plurality of secreted factor-binding reagents can comprise a secreted factor-binding reagent specific oligonucleotide **516** comprising a unique factor identifier sequence for the secreted factor-binding reagent. The workflow can comprise an

incubation **500e** comprising binding of the secreted factor-binding reagents **514** to secreted factor **508** bound by a capture probe **512**. The workflow can comprise one or more washes **500f** comprising removal of secreted factor-binding reagents **514** that are not bound to secreted factor **508** bound by a capture probe **512** (to generate a second plurality of single cells associated with a second solid support). The workflow can comprise partitioning **500g** single cells associated with a second solid support to a plurality of second partitions **518**. A second partition **518** (e.g., a well, a droplet) of the plurality of second partitions can comprise a single cells associated with a second solid support and a single third solid support **520**. Third solid support **520** can comprise a plurality of oligonucleotide barcodes **522**. Oligonucleotide barcodes **522** can comprise a first molecular label and/or cellular label. The workflow can comprise contacting oligonucleotide barcodes **522** with the secreted factor-binding reagent specific oligonucleotides **516** for hybridization. The workflow can comprise cell lysis barcoding, library preparation, and/or sequencing **500h** as described herein. For example, the workflow can comprise extending oligonucleotide barcodes **522** hybridized to the secreted factor-binding reagent specific oligonucleotides **516** to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The workflow can comprise lysing the single cell **504** to release copies of the nucleic acid target **526** contained therein. The workflow can comprise contacting oligonucleotide barcodes **522** with the copies of the nucleic acid target **526** for hybridization. The workflow can comprise extending the plurality of oligonucleotide barcodes **522** hybridized to the copies of a nucleic acid target **526** to generate a plurality of barcoded nucleic acid molecules each comprising a sequence complementary to at least a portion of the nucleic acid target and the first molecular label. The method can comprise obtaining sequence information of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of a secreted factor **508** secreted by each of the one or more single cells **504**. The workflow can comprise obtaining sequence information of the plurality of barcoded nucleic acid molecules, or products thereof, to determine the copy number of the nucleic acid target **526** in each of the one or more single cells **504**. The workflow can comprise performing the steps with a plurality of cells (e.g., in bulk).

(181) Some embodiments disclosed herein provide a plurality of compositions each comprising a secreted factor binding reagent (such as a protein binding reagent). The secreted factor binding reagent can be conjugated with an oligonucleotide, wherein the oligonucleotide comprises a unique factor identifier for the secreted factor binding reagent that it is conjugated with. The unique factor identifiers can be, for example, a nucleotide sequence having any suitable length, for example, from about 4 nucleotides to about 200 nucleotides. In some embodiments, the unique factor identifier is a nucleotide sequence of 25 nucleotides to about 45 nucleotides in length. In some embodiments, the unique factor identifier can have a length that is, is about, is less than, is greater than, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 200 nucleotides, or a range that is between any two of the above values.

(182) In some embodiments, the unique factor identifiers are selected from a diverse set of unique factor identifiers. The diverse set of unique factor identifiers can comprise, or comprise about, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, or a number or a range between any two of these values, different unique factor identifiers. The diverse set of unique factor identifiers can comprise at least, or comprise at most, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, or 5000, different unique factor identifiers. In some embodiments, the set of unique factor identifiers is designed to have minimal sequence homology to the DNA or RNA sequences of the sample to be analyzed. In some embodiments, the sequences of the set of unique factor identifiers are different from each other, or the complement thereof, by, or by about, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, or a number or a range between any two of these values. In some embodiments, the sequences of the set of unique

factor identifiers are different from each other, or the complement thereof, by at least, or by at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the sequences of the set of unique factor identifiers are different from each other, or the complement thereof, by at least 3%, at least 5%, at least 8%, at least 10%, at least 15%, at least 20%, or more.

(183) Any suitable secreted factor binding reagents, anchor probes, and capture probes are contemplated in this disclosure, such as protein binding reagents, antibodies or fragments thereof, aptamers, small molecules, ligands, peptides, oligonucleotides, etc., or any combination thereof. The secreted factor binding reagents, anchor probes, and/or capture probes can be polyclonal antibodies, monoclonal antibodies, recombinant antibodies, single chain antibody (sc-Ab), or fragments thereof, such as Fab, Fv, etc. In some embodiments, the plurality of secreted factor binding reagents can comprise, or comprise about, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, or a number or a range between any two of these values, different secreted factor binding reagents. In some embodiments, the plurality of secreted factor binding reagents can comprise at least, or comprise at most, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, or 5000, different secreted factor binding reagents. In some embodiments, the plurality of anchor probes can comprise, or comprise about, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, or a number or a range between any two of these values, different anchor probes. In some embodiments, the plurality of anchor probes can comprise at least, or comprise at most, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, or 5000, different anchor probes. In some embodiments, the plurality of capture probes can comprise, or comprise about, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000, or a number or a range between any two of these values, different capture probes. In some embodiments, the plurality of capture probes can comprise at least, or comprise at most, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, or 5000, different capture probes.

(184) The oligonucleotide can be conjugated with the secreted factor binding reagent through various mechanisms. In some embodiments, the oligonucleotide can be conjugated with the secreted factor binding reagent covalently. In some embodiment, the oligonucleotide can be conjugated with the secreted factor binding reagent non-covalently. In some embodiments, the oligonucleotide is conjugated with the secreted factor binding reagent through a linker. The linker can be, for example, cleavable or detachable from the secreted factor binding reagent and/or the oligonucleotide. In some embodiments, the linker can comprise a chemical group that reversibly attaches the oligonucleotide to the secreted factor binding reagents. The chemical group can be conjugated to the linker, for example, through an amine group. In some embodiments, the linker can comprise a chemical group that forms a stable bond with another chemical group conjugated to the secreted factor binding reagent. For example, the chemical group can be a UV photocleavable group, a disulfide bond, a streptavidin, a biotin, an amine, etc. In some embodiments, the chemical group can be conjugated to the secreted factor binding reagent through a primary amine on an amino acid, such as lysine, or the N-terminus. Commercially available conjugation kits, such as the Protein-Oligo Conjugation Kit (Solulink, Inc., San Diego, California), the Thunder-Link® oligo conjugation system (Innova Biosciences, Cambridge, United Kingdom), etc., can be used to conjugate the oligonucleotide to the secreted factor binding reagent.

(185) The oligonucleotide can be conjugated to any suitable site of the secreted factor binding reagent (e.g., a protein binding reagent), as long as it does not interfere with the specific binding between the secreted factor binding reagent and its secreted factor. In some embodiments, the secreted factor binding reagent is a protein, such as an antibody. In some embodiments, the secreted factor binding reagent is not an antibody. In some embodiments, the oligonucleotide can be conjugated to the antibody anywhere other than the antigen-binding site, for example, the Fc region, the C.sub.H1 domain, the C.sub.H2 domain, the C.sub.H3 domain, the C.sub.L domain, etc. Methods of conjugating oligonucleotides to binding reagents (e.g., antibodies) have been

previously disclosed, for example, in U.S. Pat. No. 6,531,283, the content of which is hereby expressly incorporated by reference in its entirety. Stoichiometry of oligonucleotide to secreted factor binding reagent can be varied. To increase the sensitivity of detecting the secreted factor binding reagent specific oligonucleotide in sequencing, it may be advantageous to increase the ratio of oligonucleotide to secreted factor binding reagent during conjugation. In some embodiments, each secreted factor binding reagent can be conjugated with a single oligonucleotide molecule. In some embodiments, each secreted factor binding reagent can be conjugated with more than one oligonucleotide molecule, for example, at least, or at most, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, or a number or a range between any two of these values, oligonucleotide molecules wherein each of the oligonucleotide molecule comprises the same, or different, unique factor identifiers. In some embodiments, each secreted factor binding reagent can be conjugated with more than one oligonucleotide molecule, for example, at least, or at most, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, oligonucleotide molecules, wherein each of the oligonucleotide molecule comprises the same, or different, unique factor identifiers.

(186) In some embodiments, the plurality of secreted factor binding reagents are capable of specifically binding to a plurality of secreted factors in a sample, such as a single cell, a plurality of cells, a tissue sample, a tumor sample, a blood sample, or the like. In some embodiments, the plurality of secreted factors can comprise, or comprise about, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000, or a number or a range between any two of these values, different secreted factors. In some embodiments, the plurality of secreted factors can comprise at least, or comprise at most, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000, different secreted factors.

(187) In some embodiments, the secreted factor binding reagent specific oligonucleotide can comprise a nucleotide sequence of, or a nucleotide sequence of about, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 128, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, or a number or a range between any two of these values, nucleotides in length. In some embodiments, the secreted factor binding reagent specific oligonucleotide comprises a nucleotide sequence of at least, or of at most, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 128, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000, nucleotides in length.

(188) Oligonucleotide-Conjugated Antibodies

(189) Some embodiments disclosed herein provide a plurality of compositions each comprising a cellular component binding reagent (such as a protein binding reagent) that is conjugated with an oligonucleotide, wherein the oligonucleotide comprises a unique identifier for the cellular component binding reagent that it is conjugated with. Cellular component binding reagents (such as barcoded antibodies) and their uses (such as sample indexing of cells) have been described in U.S. Patent Application Publication No. US2018/0088112 and U.S. Patent Application Publication No. US2018/0346970; the content of each of these is incorporated herein by reference in its entirety. There are provided, in some embodiments provided herein, secreted factor-binding reagents capable of specifically binding to a secreted factor. Secreted factor-binding reagents can comprise a secreted factor-binding reagent specific oligonucleotide. There are provided, in some embodiments, methods for simultaneous quantitative analysis of a plurality of cellular component targets (e.g., protein targets) and copies of a secreted factor secreted by a single cell. The methods and systems

described herein can be used with methods and systems using antibodies associated with (e.g., attached to or conjugated with) oligonucleotides (also referred to herein as AbOs or AbOligos). Embodiments of using AbOs to determine protein expression profiles in single cells and tracking sample origins have been described in U.S. patent application Ser. No. 15/715,028, published as U.S. Patent Application Publication No. 2018/0088112, and U.S. patent application Ser. No. 15/937,713; the content of each is incorporated by reference herein in its entirety.

(190) Unique Molecular Label Sequence

(191) In some embodiments, the methods and compositions provided herein comprise an oligonucleotide associated with a cellular component-binding reagent (e.g., antibody oligonucleotide (“AbOligo” or “AbO”), binding reagent oligonucleotide, cellular component-binding reagent specific oligonucleotides, sample indexing oligonucleotides) as described in U.S. application Ser. No. 16/747,737, filed on Jan. 21, 2020, the content of which is incorporated herein by reference in its entirety. In some embodiments, the oligonucleotide associated with a cellular component-binding reagent (e.g., antibody oligonucleotide (“AbOligo” or “AbO”), binding reagent oligonucleotide, a secreted factor-binding reagent specific oligonucleotide, cellular component-binding reagent specific oligonucleotides, sample indexing oligonucleotides) comprises a unique molecular label sequence (also referred to as a molecular index (MI), “molecular barcode,” or Unique Molecular Identifier (UMI)). In some embodiments, binding reagent oligonucleotide species comprising molecule barcodes as described herein reduce bias by increasing sensitivity, decreasing relative standard error, or increasing sensitivity and/or reducing standard error. The molecule barcode can comprise a unique sequence, so that when multiple sample nucleic acids (which can be the same and/or different from each other) are associated one-to-one with molecule barcodes, different sample nucleic acids can be differentiated from each other by the molecule barcodes. As such, even if a sample comprises two nucleic acids having the same sequence, each of these two nucleic acids can be labeled with a different molecule barcode, so that nucleic acids in the population can be quantified, even after amplification. The molecule barcode can comprise a nucleic acid sequence of at least 5 nucleotides, for example at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, including ranges between any two of the listed values, for example 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-50, 6-45, 6-40, 6-35, 6-30, 6-25, 6-20, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-50, 7-45, 7-40, 7-35, 7-30, 7-25, 7-20, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-50, 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-50, 9-45, 9-40, 9-35, 9-30, 9-25, 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 9-10, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12, or 10-11 nucleotides. In some embodiments, the nucleic acid sequence of the molecule barcode comprises a unique sequence, for example, so that each unique oligonucleotide species in a composition comprises a different molecule barcode. In some embodiments, two or more unique oligonucleotide species can comprise the same molecule barcode, but still differ from each other. For example, if the unique oligonucleotide species include sample barcodes, each unique oligonucleotide species with a particular sample barcode can comprise a different molecule barcode. In some embodiments, a composition comprising unique oligonucleotide species comprises a molecule barcode diversity of at least 1000 different molecule barcodes, and thus at least 1000 unique oligonucleotide species. In some embodiments, a composition comprising unique oligonucleotide species comprises a molecule barcode diversity of at least 6,500 different molecule barcodes, and thus at least 6,500 unique oligonucleotide species. In some embodiments, a composition comprising unique oligonucleotide species comprises a molecule barcode diversity of at least 65,000 different molecule barcodes, and thus at least 65,000 unique oligonucleotide species.

(192) In some embodiments, the unique molecular label sequence is positioned 5' of the unique identifier sequence without any intervening sequences between the unique molecular label

sequence and the unique identifier sequence. In some embodiments, the unique molecular label sequence is positioned 5' of a spacer, which is positioned 5' of the unique identifier sequence, so that a spacer is between the unique molecular label sequence and the unique identifier sequence. In some embodiments, the unique identifier sequence is positioned 5' of the unique molecular label sequence without any intervening sequences between the unique identifier sequence and the unique molecular label sequence. In some embodiments, the unique identifier sequence is positioned 5' of a spacer, which is positioned 5' of the unique molecular label sequence, so that a spacer is between the unique identifier sequence and the unique molecular label sequence.

(193) The unique molecular label sequence can comprise a nucleic acid sequence of at least 3 nucleotides, for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides, including ranges between any two of the listed values, for example 3-50, 3-45, 3-40, 3-35, 3-30, 3-25, 3-20, 3-15, 3-14, 3-13, 3-12, 3-11, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-50, 4-45, 4-40, 4-35, 4-30, 4-25, 4-20, 4-15, 4-14, 4-13, 4-12, 4-11, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-50, 6-45, 6-40, 6-35, 6-30, 6-25, 6-20, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-50, 7-45, 7-40, 7-35, 7-30, 7-25, 7-20, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-50, 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-50, 9-45, 9-40, 9-35, 9-30, 9-25, 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 9-10, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12, or 10-11 nucleotides. In some embodiments, the unique molecular label sequence is 2-20 nucleotides in length.

(194) In some embodiments, the unique molecular label sequence of the binding reagent oligonucleotide comprises the sequence of at least three repeats of the doublets "VN" and/or "NV" (in which each "V" is any of A, C, or G, and in which "N" is any of A, G, C, or T), for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. Examples of multiple repeats of the doublet "VN" include VN, VNVN, VNVNVN, and VNVNVNVN. It is noted that while the formulas "VN" and "NV" describe constraints on the base content, not every V or every N has to be the same or different. For example, if the molecule barcodes of unique oligonucleotide species in a composition comprised VNVNVN, one molecule barcode can comprise the sequence ACGGCA, while another molecule barcode can comprise the sequence ATACAT, while another molecule barcode could comprise the sequence ATACAC. It is noted that any number of repeats of the doublet "VN" would have a T content of no more than 50%. In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets "VN" and/or "NV," for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets "VN" and/or "NV," for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99.9% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets "VN" and/or "NV," for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets "VN" and/or "NV," for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species

comprise molecule barcodes comprising at least three repeats of the doublets “VN” and/or “NV,” for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99.9% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets “VN” and/or “NV,” for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 65,000 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets “VN” and/or “NV,” for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 65,000 unique oligonucleotide species comprise molecule barcodes comprising at least three repeats of the doublets “VN” and/or “NV,” for example at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, the composition consists of or consists essentially of at least 1000, 6500, or 65,000 unique oligonucleotide species that each have a molecule barcode comprising the sequence VNVNVN. In some embodiments, the composition consists of or consists essentially of at least 1000, 6500, or 65,000 unique oligonucleotide species that each has a molecule barcode comprising the sequence VNVNVNVN. In some embodiments, at least 95%, 99%, or 99.9% of the barcode regions of the composition as described herein comprise at least three repeats of the doublets “VN” and/or “NV,” as described herein. In some embodiments, unique molecular label sequences comprising repeated “doublets “VN” and/or “NV” can yield low bias, while providing a compromise between reducing bias and maintaining a relatively large quantity of available nucleotide sequences, so that relatively high diversity can be obtained in a relatively short sequence, while still minimizing bias. In some embodiments, unique molecular label sequences comprising repeated “doublets “VN” and/or “NV” can reduce bias by increasing sensitivity, decreasing relative standard error, or increasing sensitivity and reducing standard error. In some embodiments, unique molecular label sequences comprising repeated “doublets “VN” and/or “NV” improve informatics analysis by serving as a geomarker. In some embodiments, the repeated doublets “VN” and/or “NV” described herein reduce the incidence of homopolymers within the unique molecular label sequences. In some embodiments, the repeated doublets “VN” and/or “NV” described herein break up homopolymers.

(195) In some embodiments, the sample indexing oligonucleotide comprises a first molecular label sequence. In some embodiments, the first molecular label sequences of at least two sample indexing oligonucleotides are different, and the sample indexing sequences of the at least two sample indexing oligonucleotides are identical. In some embodiments, the first molecular label sequences of at least two sample indexing oligonucleotides are different, and the sample indexing sequences of the at least two sample indexing oligonucleotides are different. In some embodiments, the cellular component-binding reagent specific oligonucleotide comprises a second molecular label sequence. In some embodiments, the second molecular label sequences of at least two cellular component-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two cellular component-binding reagent specific oligonucleotides are identical. In some embodiments, the second molecular label sequences of at least two cellular component-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two cellular component-binding reagent specific oligonucleotides are different. In some embodiments, the number of unique second molecular label sequences

associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the number of copies of the at least one cellular component target in the one or more of the plurality of cells. In some embodiment, a combination (e.g., minimum, average, and maximum) of (1) the number of unique first molecular label sequences associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data and (2) the number of unique second molecular label sequences associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the number of copies of the at least one cellular component target in the one or more of the plurality of cells.

(196) Alignment Sequence

(197) In some embodiments, the binding reagent oligonucleotide comprises an alignment sequence (e.g., the alignment sequence 825bb) adjacent to the poly(dA) region. The alignment sequence can be 1 or more nucleotides in length. The alignment sequence can be 2 nucleotides in length. The alignment sequence can comprise a guanine, a cytosine, a thymine, a uracil, or a combination thereof. The alignment sequence can comprise a poly(dT) region, a poly(dG) region, a poly(dC) region, a poly(dU) region, or a combination thereof. In some embodiments, the alignment sequence is 5' to the poly(dA) region. Advantageously, in some embodiments, the presence of the alignment sequence enables the poly(A) tail of each of the binding reagent oligonucleotides to have the same length, leading to greater uniformity of performance. In some embodiments, the percentage of binding reagent oligonucleotides with an identical poly(dA) region length within a plurality of binding reagent oligonucleotides, each of which comprise an alignment sequence, can be, or be about, 80%, 90%, 91%, 93%, 95%, 97%, 99.9%, 99.9%, 99.99%, or 100%, or a number or a range between any two of these values. In some embodiments, the percentage of binding reagent oligonucleotides with an identical poly(dA) region length within the plurality of binding reagent oligonucleotides, each of which comprise an alignment sequence, can be at least, or be at most, 80%, 90%, 91%, 93%, 95%, 97%, 99.9%, 99.9%, 99.99%, or 100%.

(198) The length of the alignment sequence can be different in different implementations. In some embodiments, the length of the alignment sequence can be, or can be about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or a number or a range between any two of these values. In some embodiments, the length of the alignment sequence can be at least, or can be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100. The number of guanine(s), cytosine(s), thymine(s), or uracil(s) in the alignment sequence can be different in different implementations. The number of guanine(s), cytosine(s), thymine(s), or uracil(s) can be, or can be about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or a number or a range between any two of these values. The number of guanine(s), cytosine(s), thymine(s), or uracil(s) can be at least, or can be at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,

97, 98, 99, or 100. In some embodiments, the sample indexing oligonucleotide comprises an alignment sequence. In some embodiments, the cellular component-binding reagent specific oligonucleotide and/or secreted factor-binding reagent specific oligonucleotide comprises an alignment sequence.

(199) Linker

(200) The binding reagent oligonucleotide (e.g., secreted factor-binding reagent specific oligonucleotide) can be conjugated with the cellular component binding reagent through various mechanisms. In some embodiments, the binding reagent oligonucleotide can be conjugated with the cellular component binding reagent covalently. In some embodiments, the binding reagent oligonucleotide can be conjugated with the cellular component binding reagent non-covalently. In some embodiments, the binding reagent oligonucleotide is conjugated with the cellular component binding reagent through a linker. In some embodiments, the binding reagent oligonucleotide can comprise the linker. The linker can comprise a chemical group. The chemical group can be reversibly, or irreversibly, attached to the molecule of the cellular component binding reagent. The chemical group can be selected from the group consisting of a UV photocleavable group, a disulfide bond, a streptavidin, a biotin, an amine, and any combination thereof. The linker can comprise a carbon chain. The carbon chain can comprise, for example, 5-50 carbon atoms. The carbon chain can have different numbers of carbon atoms in different embodiments. In some embodiments, the number of carbon atoms in the carbon chain can be, or can be about, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or a number or a range between any two of these values. In some embodiments, the number of carbon atoms in the carbon chain can be at least, or can be at most, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, the carbon chain comprises 2-30 carbons. In some embodiments, the carbon chain comprises 12 carbons. In some embodiments, amino modifiers employed for binding reagent oligonucleotide can be conjugated to the cellular component binding reagent. In some embodiments, the linker comprises 5' amino modifier C6 (5AmMC6). In some embodiments, the linker comprises 5' amino modifier C12 (5AmMC12). In some embodiments, the linker comprises a derivative of 5AmMC12. In some embodiments, a longer linker achieves a higher efficiency of conjugation. In some embodiments, a longer linker achieves a higher efficiency of modification prior to conjugation. In some embodiments, increasing the distance between the functional amine and the DNA sequence yields a higher efficiency of conjugation. In some embodiments, increasing the distance between the functional amine and the DNA sequence yields a higher efficiency of modification prior to conjugation. In some embodiments, the use of 5AmMC12 as a linker yields a higher efficiency of modification (prior to conjugation) than the use of 5AmMC6 as a linker. In some embodiments the use of 5AmMC12 as a linker yields a higher efficiency of conjugation than the use of 5AmMC6 as a linker. In some embodiments, the sample indexing oligonucleotide is associated with the cellular component-binding reagent through a linker. In some embodiments, the cellular component-binding reagent specific oligonucleotide and/or secreted factor-binding reagent specific oligonucleotide is associated with the cellular component-binding reagent through a linker.

(201) Antibody-Specific Barcode Sequence

(202) Disclosed herein, in several embodiments, are improvements to the design of the unique identifier sequence (e.g., antibody-specific barcode sequence) of a binding reagent oligonucleotide (e.g., secreted factor-binding reagent specific oligonucleotide). In some embodiments the unique identifier sequence (e.g, sample indexing sequence, unique factor identifier sequence, a unique identifier sequence of a cellular component-binding reagent specific oligonucleotide) is designed to have a Hamming distance greater than 3. In some embodiments, the Hamming distance of the unique identifier sequence can be, or be about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or a number or a range between any two of these values. In some embodiments, the unique identifier sequences has a GC

content in the range of 40% to 60% and does not have a predicted secondary structure (e.g., hairpin). In some embodiments, the unique identifier sequence does not comprise any sequences predicted in silico to bind to the mouse and/or human transcripts. In some embodiments, the unique identifier sequence does not comprise any sequences predicted in silico to bind to Rhapsody™ and/or SCMK system primers. In some embodiments, the unique identifier sequence does not comprise homopolymers.

(203) Primer Adapter

(204) In some embodiments, the binding reagent oligonucleotide (e.g., secreted factor-binding reagent specific oligonucleotide) comprises a primer adapter. In some embodiments, the primer adapter comprises the sequence of a first universal primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof. In some embodiments, the first universal primer comprises an amplification primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof. In some embodiments, the first universal primer comprises a sequencing primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof. In some embodiments, the sequencing primer comprises an Illumina sequencing primer. In some embodiments, the sequencing primer comprises a portion of an Illumina sequencing primer. In some embodiments, the sequencing primer comprises a P7 sequencing primer or a portion of P7 sequencing primer. In some embodiments, the primer adapter comprises an adapter for Illumina P7 or a partial adapter for Illumina P7. In some embodiments, the amplification primer is an Illumina P7 sequence or a subsequence thereof. In some embodiments, the sequencing primer is an Illumina R2 sequence or a subsequence thereof. In some embodiments, the first universal primer is 5-50 nucleotides in length. In some embodiments, The primer adapter can comprise a nucleic acid sequence of at least 5 nucleotides, for example at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, including ranges between any two of the listed values, for example 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-50, 6-45, 6-40, 6-35, 6-30, 6-25, 6-20, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-50, 7-45, 7-40, 7-35, 7-30, 7-25, 7-20, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-50, 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-50, 9-45, 9-40, 9-35, 9-30, 9-25, 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 9-10, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12, or 10-11 nucleotides. The primer adapter can comprise a nucleic acid sequence of at least 5 nucleotides of the sequence of a first universal primer, an amplification primer, a sequencing primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof, for example at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, including ranges between any two of the listed values, for example 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-50, 6-45, 6-40, 6-35, 6-30, 6-25, 6-20, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-50, 7-45, 7-40, 7-35, 7-30, 7-25, 7-20, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-50, 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-50, 9-45, 9-40, 9-35, 9-30, 9-25, 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 9-10, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12, or 10-11 nucleotides of the sequence of a first universal primer, an amplification primer, a sequencing primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof.

(205) A conventional amplification workflow for sequencing library preparation can employ three rounds of PCR, such as, for example: a first round (“PCR 1”) employing a target-specific primer and a primer against the universal Illumina sequencing primer 1 sequence; a second round (“PCR 2”) using a nested target-specific primer flanked by Illumina sequencing primer 2 sequence, and a primer against the universal Illumina sequencing primer 1 sequence; and a third round (“PCR 3”) adding Illumina P5 and P7 and sample index. Advantageously, in some embodiments, the primer adapter disclosed herein enables a shorter and simpler workflow in library preparation as compared

to if the starting template (e.g., a sample indexing oligonucleotide attached to a bead) does not have a primer adapter. In some embodiments, the primer adapter reduces pre-sequencing PCR amplification of a template by one round (as compared to if the template does not comprise a primer adapter). In some embodiments, the primer adapter reduces pre-sequencing PCR amplification of the template to one round (as compared to if the template does not comprise a primer adapter). In some embodiments, a template comprising the primer adapter does not require a PCR amplification step for attachment of Illumina sequencing adapters that would require pre-sequencing if the template did not comprise a primer adapter. In some embodiments, the primer adapter sequence (or a subsequence thereof) is not part of the sequencing readout of a sequencing template comprising a primer adapter sequence and therefore does not affect read quality of a template comprising a primer adapter. In some embodiments, a template comprising the primer adapter has decreased sequencing diversity as compared to if the template does not comprise a primer adapter.

(206) In some embodiments, the sample indexing oligonucleotide comprises a primer adapter. In some embodiments, replicating a sample indexing oligonucleotide, a barcoded sample indexing oligonucleotide, or a product thereof, comprises using a first universal primer, a first primer comprising the sequence of the first universal primer, or a combination thereof, to generate a plurality of replicated sample indexing oligonucleotides. In some embodiments, replicating a sample indexing oligonucleotide, a barcoded sample indexing oligonucleotide, or a product thereof, comprises using a first universal primer, a first primer comprising the sequence of the first universal primer, a second universal primer, a second primer comprising the sequence of the second universal primer, or a combination thereof, to generate the plurality of replicated sample indexing oligonucleotides. In some embodiments, the cellular component-binding reagent specific oligonucleotide and/or secreted factor-binding reagent specific oligonucleotide comprises a primer adapter, the sequence of a first universal primer, a complementary sequence thereof, a partial sequence thereof, or a combination thereof.

(207) Binding Reagent Oligonucleotide Barcoding

(208) FIG. 8 shows a schematic illustration of a non-limiting exemplary workflow of barcoding of a binding reagent oligonucleotide **825** (antibody oligonucleotide illustrated here, e.g., secreted factor-binding reagent specific oligonucleotide) that is associated with a binding reagent **805** (antibody illustrated here, such as, for example, a secreted factor-binding reagent). The binding reagent oligonucleotide **825** can be associated with binding reagent **805** through linker **8251**. The binding reagent oligonucleotide **825** can be detached from the binding reagent using chemical, optical or other means. The binding reagent oligonucleotide **825** can be an mRNA mimic. The binding reagent oligonucleotide **825** can include a primer adapter **825pa**, an antibody molecular label **825am** (e.g., a unique molecular label sequence), an antibody barcode **825ab** (e.g., a unique identifier sequence), an alignment sequence **825bb**, and a poly(A) tail **825a**. In some embodiments, the primer adapter **825pa** comprises the sequence of a first universal primer, a complimentary sequence thereof, a partial sequence thereof, or a combination thereof. In some embodiments, the primer adapter **825pa** can be the same for all or some of binding reagent oligonucleotides **825**. In some embodiments, the antibody barcode **825ab** can be the same for all or some of binding reagent oligonucleotides **825**. In some embodiments, the antibody barcode **825ab** of different binding reagent oligonucleotides **825** are different. In some embodiments, the antibody molecular label **825am** of different binding reagent oligonucleotides **825** are different.

(209) The binding reagent oligonucleotides **825** can be barcoded using a plurality of barcodes **815** (e.g., barcodes **815** associated with a particle, such as a bead **810**) to create a plurality of barcoded binding reagent oligonucleotides **840**. In some embodiments, a barcode **815** can include a poly(dT) region **815t** for binding to a binding reagent oligonucleotide **825**, optionally a molecular label **815m** (e.g., for determining the number of occurrences of the binding reagent oligonucleotides), a cell label **815c**, and a universal label **815u**. In some embodiments the barcode **815** is hybridized to the

poly(dT) region **815t** of binding reagent oligonucleotides **825**. In some embodiments barcoded binding reagent oligonucleotides **840** are generated by extending (e.g., by reverse transcription) the barcode **815** hybridized to the binding reagent oligonucleotide **825**. In some embodiments, barcoded binding reagent oligonucleotides **840** comprise primer adapter **825pa**, an antibody molecular label **825am** (e.g., a unique molecular label sequence), an antibody barcode **825ab** (e.g., a unique identifier sequence), an alignment sequence **825bb**, poly(dT) region **815t**, molecular label **815m**, cell label **815c**, and universal label **815u**.

(210) In some embodiments, the barcoded binding reagent oligonucleotides disclosed herein comprises two unique molecular label sequences: a molecular label sequence derived from the barcode (e.g., molecular label **815m**) and a molecular label sequence derived from a binding reagent oligonucleotide (e.g., antibody molecular label **825am**, the first molecular label sequence of a sample indexing oligonucleotide, the second molecular label sequence of a cellular component-binding reagent specific oligonucleotide, the molecular label of a secreted factor-binding reagent specific oligonucleotide). As used herein, “dual molecular indexing” refers to methods and compositions disclosed herein employing barcoded binding reagent oligonucleotides (or products thereof) that comprise a first unique molecular label sequence and second unique molecular label sequence (or complementary sequences thereof). In some embodiments, the methods of sample identification and of quantitative analysis of cellular component targets disclosed herein can comprise obtaining the sequence of information of the barcode molecular label sequence and/or the binding reagent oligonucleotide molecular label sequence. In some embodiments, the number of barcode molecular label sequences associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the number of copies of the at least one cellular component target in the one or more of the plurality of cells. In some embodiments, the number of binding reagent oligonucleotide molecular label sequences associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the number of copies of the at least one cellular component target in the one or more of the plurality of cells. In some embodiments, the number of both the binding reagent oligonucleotide molecular label sequences and barcode molecular label sequences associated with the unique identifier sequence for the cellular component-binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the number of copies of the at least one cellular component target in the one or more of the plurality of cells.

(211) The use of PCR to amplify the amount of material before starting the sequencing protocol adds the potential for artifacts, such as artifactual recombination during amplification occurs when premature termination products prime a subsequent round of synthesis). In some embodiments, the methods of dual molecular indexing provided herein allow the identification of PCR chimeras given sufficient sequencing depth. Additionally, in some embodiments, the addition of the unique molecular label sequence to the binding reagent oligonucleotide increases stochastic labelling complexity. Thus, in some embodiments, the presence of the unique molecular label sequence in the binding reagent oligonucleotide can overcome UMI diversity limitations. In some embodiments the methods of dual molecular indexing provided herein decrease the number of cellular component targets flagged as “saturated” during post-sequencing molecular coverage calculations by at least about 2% (e.g., 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 40%, 50%, 75%, 100%, 150%, 200%, 250%, 500%, 1000%, or higher and overlapping ranges therein) compared to if the methods and compositions are not used.

(212) Probes, Binding Reagents, and Solid Supports

(213) The first solid support and/or the second solid support can be sized and shaped to approximate a cell. In some embodiments, the first solid support and/or the second solid support

has the dimensions of a cell (e.g., a mammalian cell, a yeast cell, an insect cell, a plant cell, a bacterial cell, or any combination thereof). The first solid support, second solid support, and/or third solid support can comprise a synthetic particle or a planar surface. At least one of the plurality of oligonucleotide barcodes can be immobilized or partially immobilized on the synthetic particle. At least one of the plurality of oligonucleotide barcodes can be enclosed or partially enclosed in the synthetic particle. The synthetic particle can be disruptable. The synthetic particle can comprise a bead. The bead can comprise: a sepharose bead, a streptavidin bead, an agarose bead, a magnetic bead, a conjugated bead, a protein A conjugated bead, a protein G conjugated bead, a protein A/G conjugated bead, a protein L conjugated bead, an oligo(dT) conjugated bead, a silica bead, a silica-like bead, an anti-biotin microbead, an anti-fluorochrome microbead, or any combination thereof; a material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic, ceramic, plastic, glass, methylstyrene, acrylic polymer, titanium, latex, sepharose, cellulose, nylon, silicone, and any combination thereof; or a disruptable hydrogel particle.

(214) In some embodiments, each of the plurality of oligonucleotide barcodes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(215) In some embodiments, each of the plurality of anchor probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(216) In some embodiments, each of the plurality of capture probes comprises a linker functional group, the synthetic particle comprises a solid support functional group, and the support functional group and the linker functional group are associated with each other. The linker functional group and the support functional group can be individually selected from the group consisting of C6, biotin, streptavidin, primary amine(s), aldehyde(s), ketone(s), and any combination thereof.

(217) The secreted factor-binding reagent and the capture probe can be capable of binding to distinct epitopes of the same secreted factor. In some embodiments, one or more of the secreted factor-binding reagents, the capture probe, and the anchor probe comprise an antibody or fragment thereof. The antibody or fragment thereof can comprise a monoclonal antibody. The antibody or fragment thereof can comprise a Fab, a Fab', a F(ab').sub.2, a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, a multispecific antibody formed from antibody fragments, a single-domain antibody (sdAb), a single chain comprising complementary scFvs (tandem scFvs) or bispecific tandem scFvs, an Fv construct, a disulfide-linked Fv, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, an aptamer, an affibody, an affilin, an affitin, an affimer, an alphabody, an anticalin, an avimer, a DARPin, a Fynomer, a Kunitz domain peptide, a monobody, or any combination thereof. The capture probe and/or the anchor probe can be conjugated to the first solid support and/or the second solid support by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, an addition to carbon-carbon multiple bond, an oxidation reaction, a click reaction, or any combination thereof.

(218) The at least one secreted factor can comprise a lymphokine, an interleukin, a chemokine, or any combination thereof. The at least one secreted factor can comprise a cytokine, a hormone, a molecular toxin, or any combination thereof. The at least one secreted factor can comprise a nerve growth factor, a hepatic growth factor, a fibroblast growth factor, a vascular endothelial growth factor, a platelet-derived growth factor, a transforming growth factor, an osteoinductive factor, an

interferon, a colony stimulating factor, or any combination thereof. The at least one secreted factor can comprise angiogenin, angiopoietin-1, angiopoietin-2, bNGF, cathepsin S, Galectin-7, GCP-2, G-CSF, GM-CSF, PAI-1, PDGF-AA, PDGF-BB, PDGF-AB, PlGF, PlGF-2, SDF-1, Tie2, VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3, 6Ckine, angiopoietin-1, angiopoietin-2, BLC, BRAK, CD186, ENA-78, Eotaxin-1, Eotaxin-2, Eotaxin-3, EpCAM, GDF-15, GM-CSF, GRO, HCC-4, I-309, IFN- γ , IL-1 α , IL-1 β , IL-1R4 (ST2), IL-2, IL-2R, IL-3, IL-3R α , IL-5, IL-6, IL-6R, IL-7, IL-8, IL-8 RB, IL-11, IL-12, IL-12p40, IL-12p70, IL-13, IL-13 R1, IL-13R2, IL-15, IL-15R α , IL-16, IL-17, IL-17C, IL-17E, IL-17F, IL-17R, IL-18, IL-18BP α , IL-18 R α , IL-20, IL-23, IL-27, IL-28, IL-31, IL-33, IP-10, I-TAC, LIF, LIX, LRP6, MadCAM-1, MCP-1, MCP-2, MCP-3, MCP-4, M-CSF, MIF, MIG, MIP-1 gamma, MIP-1 α , MIP-1 β , MIP-1 δ , MIP-3 α , MIP-3 β , MPIF-1, PARC, PF4, RANTES, Resistin, SCF, SCYB16, TACI, TARC, TSLP, TNF- α , TNF-R1, TRAIL-R4, TREM-1, Activin A, Amphiregulin, Axl, BDNF, BMP4, cathepsin S, EGF, FGF-1, FGF-2, FGF-7, FGF-21, Follistatin, Galectin-7, Gash, GDF-15, HB-EGF, HGF, IGFBP-1, IGFBP-3, LAP, NGF R, NrCAM, NT-3, NT-4, PAI-1, TGF- α , TGF- β , TGF- β 3, TRAIL-R4, ADAMTS1, cathepsin S, FGF-2, Follistatin, Galectin-7, GCP-2, GDF-15, IGFBP-6, LIF, MMP-9, pro-MMP9, RANK, RANKL, RANTES, SDF-1, CXCR4, or any combination thereof.

(219) The surface cellular target can comprise a carbohydrate, a lipid, a protein, an extracellular protein, a cell-surface protein, a cell marker, a B-cell receptor, a T-cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an intracellular protein, or any combination thereof. The surface cellular target can comprise a carbohydrate, a lipid, a protein, or any combination thereof. The surface cellular target can comprise CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD15u, CD15s, CD15su, CD16, CD16b, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD75s, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85a, CD85d, CD85j, CD85k, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107a, CD107b, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD118, CD119, CD120a, CD120b, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD129, CD130, CD131, CD132, CD133, CD134, CD135, CD136, CD137, CD138, CD139, CD140a, CD140b, CD141, CD142, CD143, CD144, CDw145, CD146, CD147, CD148, CDw149, CD150, CD151, CD152, CD153, CD154, CD155, CD156a, CD156b, CD156c, CD157, CD158e, CD158i, CD158k, CD159a, CD159c, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167a, CD167b, CD168, CD169, CD170, CD171, CD172a, CD172b, CD172g, CD173, CD174, CD175, CD175s, CD176, CD177, CD178, CD179a, CD179b, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CD199, CD200, CD201, CD202b, CD203c, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CDw210b, CD212, CD213a1, CD213a2, CD215, CD217a, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235a, CD235b, CD236, CD236R, CD238, CD239, CD240CE, CD240DCE, CD240D, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD252, CD253, CD254, CD256, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD286, CD289, CD290, CD292, CDw293, CD294, CD295, CD296, CD297, CD298, CD299, CD300a, CD300c, CD300e, CD301,

CD302, CD303, CD304, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD308, CD309, CD312, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD324, CD325, CD326, CD327, CD328, CD329, CD331, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD339, CD340, CD344, CD349, CD350, CD351, CD352, CD353, CD354, CD355, CD357, CD358, CD360, CD361, CD362, CD363, CD364, CD365, CD366, CD367, CD368, CD369, CD370, CD371, BCMA, a HLA protein, β 2-microglobulin, or any combination thereof.

(220) Methods for Simultaneous Single Cell Secretome and Transcriptome Analysis

(221) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell. The method can comprise: contacting one or more single cells with a first plurality of first solid supports, the one or more single cells are capable of secreting a plurality of secreted factors, each first solid support comprises a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the first solid support with a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization, the oligonucleotide barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.

(222) In some embodiments, contacting one or more single cells with a first plurality of first solid supports comprises: partitioning the one or more single cells and the first plurality of first solid supports to a plurality of first partitions, a first partition of the plurality of first partitions comprises a single cell of the one or more single cells and a single first solid support of the first plurality of first solid supports.

(223) In some embodiments, the method comprises, prior to contacting the first solid support with a plurality of secreted factor-binding reagents: pooling the single first solid supports from each first partition of the plurality of first partitions to generate a second plurality of first solid supports. In some embodiments, contacting the first solid support with a plurality of secreted factor-binding reagents comprises contacting the second plurality of first solid supports with the plurality of secreted factor-binding reagents.

(224) In some embodiments, the method comprises, after contacting the second plurality of first solid supports with the plurality of secreted factor-binding reagents, removing one or more secreted factor-binding reagents of the plurality of secreted factor-binding reagents that are not contacted with the second plurality of first solid supports to generate a third plurality of first solid supports. In some embodiments, removing the one or more secreted factor-binding reagents not contacted with the second plurality of first solid supports comprises: removing the one or more secreted factor-binding reagents not contacted with the respective at least one of the secreted factor bound by a capture probe.

(225) In some embodiments, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization comprises: partitioning the third

plurality of first solid supports to a plurality of second partitions, a second partition of the plurality of second partitions comprises a single first solid support from the third plurality of first solid supports; and in the second partition comprising the single first solid support, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides for hybridization.

(226) Disclosed herein include methods of measuring the number of copies of a secreted factor secreted by a single cell and the number of copies of a nucleic acid target in a single cell. The method can comprise: contacting one or more single cells with a first plurality of second solid supports to form one or more single cells associated with a second solid support, the one or more single cells comprise a surface cellular target and copies of a nucleic acid target, the one or more single cells are capable of secreting a plurality of secreted factors, each second solid support comprises a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to the surface cellular target, and the capture probe is capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. The method can comprise: contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent. The method can comprise: contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization, the oligonucleotide barcodes each comprise a first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the copies of a nucleic acid target to generate a plurality of barcoded nucleic acid molecules each comprising a sequence complementary to at least a portion of the nucleic acid target and the first molecular label. The method can comprise: extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to at least a portion of the unique factor identifier sequence and the first molecular label. The method can comprise: obtaining sequence information of the plurality of barcoded nucleic acid molecules, or products thereof, to determine the copy number of the nucleic acid target in each of the one or more single cells. The method can comprise: obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, to determine the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.

(227) In some embodiments, contacting one or more single cells with a first plurality of second solid supports to form one or more single cells associated with a second solid support comprises: partitioning the one or more single cells and the plurality of second solid supports to a plurality of first partitions, a first partition of the plurality of first partitions comprises a single cell of the one or more single cells and a single second solid support of the plurality of second solid supports, the single cell is capable of becoming associated with a second solid support via the anchor probe binding to the surface cellular target.

(228) In some embodiments, the method comprises, prior to contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents: pooling the single cells associated with a second solid support from each first partition of the plurality of first partitions to generate a first plurality of single cells associated with a second solid support. In some embodiments, contacting the one or more single cells associated with a second solid support with a plurality of secreted factor-binding reagents comprises contacting the first plurality of single cells associated with a second solid support with the plurality of secreted factor-binding reagents.

(229) In some embodiments, the method comprises, after contacting the first plurality of single cells associated with a second solid support with the plurality of secreted factor-binding reagents, removing one or more secreted factor-binding reagents of the plurality of secreted factor-binding reagents that are not contacted with the first plurality of single cells associated with a second solid support to generate a second plurality of single cells associated with a second solid support. In some embodiments, removing the one or more secreted factor-binding reagents not contacted with the first plurality of single cells associated with a second solid support comprises: removing the one or more secreted factor-binding reagents not contacted with the respective at least one of the secreted factor bound by a capture probe.

(230) The method can comprise: prior to contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization: partitioning the second plurality of single cells associated with a second solid support to a plurality of second partitions, a second partition of the plurality of second partitions comprises a single cell and a single second solid support from the second plurality of single cells associated with a second solid support; in the second partition comprising the single cell and the single second solid support, contacting a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target for hybridization. The method can comprise lysing the single cell in the second partition. Lysing the single cell can comprise heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.

(231) FIGS. 7A-7D show a schematic illustration of a non-limiting exemplary workflow for simultaneous measurement of the number of copies of a secreted factor and a nucleic acid target. A barcode (e.g., a stochastic barcode, an oligonucleotide barcode **702**) can comprise a target binding region (e.g., a poly(dT) **710**) that can bind to nucleic acid targets (e.g., poly-adenylated RNA transcripts **714** or other nucleic acid targets, such as for example, secreted factor-binding reagent specific oligonucleotide **720**, whether associated with antibodies or have dissociated from antibodies) via a poly(dA) tail **718**, or other nucleic acid targets, for labeling or barcoding (e.g., unique labeling). The target-binding region can comprise a gene-specific sequence, an oligo(dT) sequence, a random multimer, or any combination thereof. The oligonucleotide barcode **702** can also comprise a number of labels. The oligonucleotide barcode **702** can include first molecular label (ML) **708** and a sample label (e.g, partition label, cell label (CL) **706**) for labeling the transcripts and/or tracking sample origins of the RNA transcripts (or nucleic acid targets, such as for example, antibody oligonucleotides, whether associated with antibodies or have dissociated from antibodies), respectively, along with one or more additional sequences flanking the first molecular label **708**/cell label **706** region of each barcode **702** for subsequent reactions, such as, for example, a first universal sequence **704** (e.g., Read 1 sequence). The repertoire of sequences of the molecular labels in the oligonucleotide barcodes per sample can be sufficiently large for stochastic labeling of RNA transcripts. The sample label can be, for example, a partition label, and/or a cell label. In some embodiments the barcode is associated with a solid support (e.g., a particle **712**). A plurality of barcodes **702** can be associated with particle **712**. In some embodiments, the particle is a bead. The bead can be a polymeric bead, for example a deformable bead or a gel bead, functionalized with barcodes or stochastic barcodes (such as gel beads from 10× Genomics (San Francisco, CA)). In some implementation, a gel bead can comprise a polymer-based gels. Gel beads can be generated, for example, by encapsulating one or more polymeric precursors into droplets. Upon exposure of the polymeric precursors to an accelerator (e.g., tetramethylethylenediamine (TEMED)), a gel bead may be generated. Poly-adenylated RNA transcripts **714** can comprise RNA sequence **716r** and poly(dA) tail **718**. Secreted factor-binding reagent specific oligonucleotide **720** can comprise a second universal sequence **722**, a molecular label (e.g., a second molecular label **724**) a unique factor identifier sequence **726**, a sequence complementary to the target binding region (e.g., a poly(A) tail **728**), or complements thereof. In

some embodiments secreted factor binding reagent specific oligonucleotide **720** is associated with a secreted factor-binding reagent (e.g., antibody **730**).

(232) The workflow can comprise hybridization **700a** of the secreted factor binding reagent specific oligonucleotide **720** and oligonucleotide barcode **702**. The workflow can comprise hybridization **700a** of the poly-adenylated RNA transcript **714** and oligonucleotide barcode **702**. The workflow can comprise extending **700b** the oligonucleotide barcode **702** hybridized to the secreted factor binding reagent specific oligonucleotide **720** to generate a barcoded secreted factor binding reagent specific oligonucleotide **734** comprising a complement of the unique factor identifier sequence **726rc**, a complement of the second molecular label **724rc**, and a complement of the second universal sequence **722rc**. In some embodiments, the extension reaction **700b** can comprise extending the oligonucleotide barcode **702** hybridized to the poly-adenylated RNA transcript **714** to generate a barcoded nucleic acid molecule **736** comprising cDNA **1416c** (the reverse complementary sequence of RNA sequence **716r**). The workflow can comprise denaturation **700c** (e.g., with use of heating and/or chemicals). The workflow can comprise downstream **700d** primer extension, amplification and/or sequencing of barcoded secreted factor binding reagent specific oligonucleotides as described herein. The workflow can comprise downstream **700e** primer extension, amplification and/or sequencing of barcoded cDNAs as described herein.

(233) Barcoded secreted factor binding reagent specific oligonucleotide **734** can serve as a template for one or more extension reactions (e.g., random priming and extension) and/or amplification reactions (e.g., PCR). For example, barcoded secreted factor binding reagent specific oligonucleotide **734** can undergo a first round of amplification (“PCR1”) **700f** employing amplification primers **738** and **740** that can anneal to first universal sequence and second universal sequence (or complements thereof), respectively. PCR1 **700f** can generate first amplified barcoded secreted factor binding reagent specific oligonucleotide **742**. PCR1 **700f** can comprise 1-30 cycles (e.g., 15 cycles). First amplified barcoded secreted factor binding reagent specific oligonucleotide **742** can undergo a second round of amplification (“PCR2”) **700g** employing amplification primers **744** and **746** that can anneal to first universal sequence and second universal sequence (or complements thereof), respectively. PCR2 **700g** can generate second amplified barcoded secreted factor binding reagent specific oligonucleotide **748**. PCR2 **700g** can add sequencing adapter **750** via an overhang in primer **746**. PCR2 **700g** can comprise 1-30 cycles (e.g., 15 cycles). The workflow can comprise library amplification (“Index PCR”) **700h**. Index PCR **700h** can comprise library amplification of second amplified barcoded secreted factor binding reagent specific oligonucleotide **748** with sequencing library amplification primers **752** and **754**. Sequencing library amplification primers **752** and **754** can anneal to first universal sequence and second universal sequence (or complements thereof) and/or sequencing adapter **750**. Library PCR **700h** can add sequencing adapters (e.g., P5 **758** and P7 **764**) and sample index **760** and/or **762** (e.g., i5, i7) via overhangs in sequencing library amplification primers **752** and **754**. Library PCR amplicons **756** can be sequenced and subjected to downstream methods of the disclosure. Sequencing **700i** using 150 bp×2 sequencing can reveal the cell label, the first molecular label and/or unique factor identifier sequence (or a partial sequence of the unique factor identifier sequence) on read 1, the unique factor identifier sequence (or a partial sequence of the unique factor identifier sequence) and/or the second molecular label on read 2, and a sample index on index 1 read and/or index 2 read.

(234) In some embodiments, barcoded secreted factor binding reagent specific oligonucleotide **734** can undergo a first round of amplification (“PCR1”) **700j** employing amplification primers **758** and **760** that can anneal to first universal sequence and second universal sequence (or complements thereof), respectively. PCR1 **700j** can generate first amplified barcoded secreted factor binding reagent specific oligonucleotide **762**. PCR1 **700j** can comprise 1-30 cycles (e.g., 15 cycles). PCR1 **700j** can add sequencing adapter **750** via an overhang in primer **760**. The workflow can comprise

library amplification (“Index PCR”) **700k**. Index PCR **700k** can comprise library amplification of first amplified barcoded secreted factor binding reagent specific oligonucleotide **762** with sequencing library amplification primers **764** and **766**. Sequencing library amplification primers **764** and **766** can anneal to first universal sequence and second universal sequence (or complements thereof) and/or sequencing adapter **750**. Library PCR **700k** can add sequencing adapters (e.g., P5 **758** and P7 **764**) and sample index **760** and/or **762** (e.g., i5, i7) via overhangs in sequencing library amplification primers **764** and **766**. Library PCR amplicons **768** can be sequenced and subjected to downstream methods of the disclosure. Sequencing **700l** using 150 bp×2 sequencing can reveal the cell label, the first molecular label and/or unique factor identifier sequence (or a partial sequence of the unique factor identifier sequence) on read 1, the unique factor identifier sequence (or a partial sequence of the unique factor identifier sequence) and/or the second molecular label on read 2, and a sample index on index 1 read and/or index 2 read.

(235) In some embodiments, the plurality of oligonucleotide barcodes are associated with a third solid support. A second partition of the plurality of second partitions can comprise a single third solid support. The first partition and/or second partition can be a well or a droplet. Each oligonucleotide barcode can comprise a first universal sequence. The oligonucleotide barcode can comprise a target-binding region comprising a capture sequence. The target-binding region can comprise a poly(dT) region. The secreted factor-binding reagent specific oligonucleotide can comprise a sequence complementary to the capture sequence configured to capture the secreted factor-binding reagent specific oligonucleotide. The sequence complementary to the capture sequence can comprise a poly(dA) region. In some embodiments, the plurality of barcoded secreted factor-binding reagent specific oligonucleotides comprise a complement of the first universal sequence. The secreted factor-binding reagent specific oligonucleotide can comprise a second universal sequence.

(236) In some embodiments, obtaining sequence information of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, comprises: amplifying the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof, using a primer capable of hybridizing to the first universal sequence, or a complement thereof, and a primer capable of hybridizing to the second universal sequence, or a complement thereof, to generate a plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides; and obtaining sequencing data of the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof.

(237) The secreted factor-binding reagent specific oligonucleotide can comprise a second molecular label. In some embodiments, at least ten of the plurality of secreted factor-binding reagent specific oligonucleotides comprise different second molecular label sequences. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are identical. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are different. In some embodiments, the number of unique first molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the number of unique second molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by each of the one or more single cells. In some embodiments, the method comprises determining the number of copies of the at least one secreted factor secreted by each of the one or more single cells based on the

number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof. In some embodiments, the method comprises determining the number of copies of the at least one secreted factor secreted by each of the one or more single cells based on the number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof. In some embodiments, obtaining the sequence information comprises attaching sequencing adaptors to the plurality of barcoded secreted factor-binding reagent specific oligonucleotides, or products thereof. The secreted factor-binding reagent specific oligonucleotide can be configured to be detachable from the secreted factor-binding reagent. The method can comprise dissociating the secreted factor-binding reagent specific oligonucleotide from the secreted factor-binding reagent.

(238) Determining the copy number of the nucleic acid target in each of the one or more single cells can comprise determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences, complements thereof, or a combination thereof, associated with the plurality of barcoded nucleic acid molecules, or products thereof. The method can comprise: contacting random primers with the plurality of barcoded nucleic acid molecules, each of the random primers comprises a third universal sequence, or a complement thereof; and extending the random primers hybridized to the plurality of barcoded nucleic acid molecules to generate a plurality of extension products. The method can comprise amplifying the plurality of extension products using primers capable of hybridizing to the first universal sequence or complements thereof, and primers capable of hybridizing the third universal sequence or complements thereof, thereby generating a first plurality of barcoded amplicons. Amplifying the plurality of extension products can comprise adding sequences of binding sites of sequencing primers and/or sequencing adaptors, complementary sequences thereof, and/or portions thereof, to the plurality of extension products. The method can comprise determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the first plurality of barcoded amplicons, or products thereof. Determining the copy number of the nucleic acid target in each of the one or more single cells can comprise determining the number of each of the plurality of nucleic acid targets in each of the one or more single cells based on the number of the first molecular labels with distinct sequences associated with barcoded amplicons of the first plurality of barcoded amplicons comprising a sequence of the each of the plurality of nucleic acid targets. The sequence of the each of the plurality of nucleic acid targets can comprise a subsequence of the each of the plurality of nucleic acid targets. The sequence of the nucleic acid target in the first plurality of barcoded amplicons can comprise a subsequence of the nucleic acid target.

(239) The method can comprise amplifying the first plurality of barcoded amplicons using primers capable of hybridizing to the first universal sequence or complements thereof, and primers capable of hybridizing the third universal sequence or complements thereof, thereby generating a second plurality of barcoded amplicons. Amplifying the first plurality of barcoded amplicons can comprise adding sequences of binding sites of sequencing primers and/or sequencing adaptors, complementary sequences thereof, and/or portions thereof, to the first plurality of barcoded amplicons. The method can comprise determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the second plurality of barcoded amplicons, or products thereof. In some embodiments, the first plurality of barcoded amplicons and/or the second plurality of barcoded amplicons comprise whole transcriptome amplification (WTA) products.

(240) The method can comprise synthesizing a third plurality of barcoded amplicons using the plurality of barcoded nucleic acid molecules as templates to generate a third plurality of barcoded

amplicons. Synthesizing a third plurality of barcoded amplicons can comprise performing polymerase chain reaction (PCR) amplification of the plurality of the barcoded nucleic acid molecules. Synthesizing a third plurality of barcoded amplicons can comprise PCR amplification using primers capable of hybridizing to the first universal sequence, or a complement thereof, and a target-specific primer. The method can comprise obtaining sequence information of the third plurality of barcoded amplicons, or products thereof. Obtaining the sequence information can comprise attaching sequencing adaptors to the third plurality of barcoded amplicons, or products thereof. The method can comprise determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular labels with distinct sequences associated with the third plurality of barcoded amplicons, or products thereof.

(241) The nucleic acid target can comprise a nucleic acid molecule. The nucleic acid molecule can comprise ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation product, RNA comprising a poly(A) tail, a sample indexing oligonucleotide, a cellular component-binding reagent specific oligonucleotide, or any combination thereof. In some embodiments, extending the plurality of oligonucleotide barcodes comprising extending the plurality of oligonucleotide barcodes using a reverse transcriptase and/or a DNA polymerase lacking at least one of 5' to 3' exonuclease activity and 3' to 5' exonuclease activity. The DNA polymerase can comprise a Klenow Fragment. The reverse transcriptase can comprise a viral reverse transcriptase (e.g., a murine leukemia virus (MLV) reverse transcriptase or a Moloney murine leukemia virus (MMLV) reverse transcriptase). In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence are the same. In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence are different. In some embodiments, the first universal sequence, the second universal sequence, and/or the third universal sequence comprise the binding sites of sequencing primers and/or a sequencing adaptor, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing adaptors comprise a P5 sequence, a P7 sequence, complementary sequences thereof, and/or portions thereof. In some embodiments, the sequencing primers comprise a Read 1 sequencing primer, a Read 2 sequencing primer, complementary sequences thereof, and/or portions thereof. In some embodiments, at least 10 of the plurality of oligonucleotide barcodes comprise different first molecular label sequences. In some embodiments, the plurality of oligonucleotide barcodes each comprise a cell label. Each cell label of the plurality of oligonucleotide barcodes can comprise at least 6 nucleotides. In some embodiments, oligonucleotide barcodes associated with the same third solid support comprise the same cell label. In some embodiments, oligonucleotide barcodes associated with different third solid supports comprise different cell labels.

(242) Compositions and Kits

(243) Disclosed herein include compositions (e.g., kits). The composition can comprise: a first solid support comprising a plurality of capture probes capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

(244) Disclosed herein include compositions (e.g., kits). The composition can comprise: a second solid support comprising a plurality of capture probes and a plurality of anchor probes, each of the plurality of anchor probes is capable of specifically binding to a surface cellular target, and the capture probe is capable of specifically binding to at least one of a plurality of secreted factors secreted by a single cell; and a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide

comprising a unique factor identifier sequence for the secreted factor-binding reagent.

(245) The secreted factor-binding reagent specific oligonucleotide can comprise a second molecular label sequence. The second molecular label sequence can be 2-20 nucleotides in length. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and wherein the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are identical. In some embodiments, the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and wherein the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are different.

(246) The secreted factor-binding reagent specific oligonucleotide can comprise a second universal sequence. The second universal sequence can comprise a binding site of a sequencing primers and/or sequencing adaptor, complementary sequences thereof, and/or portions thereof. The sequencing adaptor can comprise a P5 sequence, a P7 sequence, complementary sequences thereof, and/or portions thereof. The sequencing primer can comprise a Read 1 sequencing primer, a Read 2 sequencing primer, complementary sequences thereof, and/or portions thereof.

(247) The cellular component-binding reagent specific oligonucleotide can comprise a poly(dA) region. The secreted factor-binding reagent specific oligonucleotide can comprise an alignment sequence adjacent to the poly(dA) region. The alignment sequence can be one or more nucleotides in length. The alignment sequence can be two or more nucleotides in length. The alignment sequence can comprise a guanine, a cytosine, a thymine, a uracil, or a combination thereof. The alignment sequence can comprise a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, a poly(dU) sequence, or a combination thereof. The alignment sequence can be 5' to the poly(dA) region.

(248) The secreted factor-binding reagent specific oligonucleotide can be associated with the secreted factor-binding reagent through a linker. The linker can comprise a carbon chain. The carbon chain can comprise 2-30 carbons. The carbon chain can comprise 12 carbons. The linker can comprise 5' amino modifier C12 (5AmMC12), or a derivative thereof. The secreted factor-binding reagent specific oligonucleotide can be attached to the secreted factor-binding reagent. The secreted factor-binding reagent specific oligonucleotide can be covalently attached to the secreted factor-binding reagent. The secreted factor-binding reagent specific oligonucleotide can be non-covalently attached to the secreted factor-binding reagent. The secreted factor-binding reagent specific oligonucleotide can be conjugated to the secreted factor-binding reagent. The secreted factor-binding reagent specific oligonucleotide can be conjugated to the secreted factor-binding reagent through a chemical group selected from the group consisting of a UV photocleavable group, a streptavidin, a biotin, an amine, and a combination thereof.

(249) The composition can comprise a DNA polymerase (e.g., a Klenow Fragment) lacking at least one of 5' to 3' exonuclease activity and 3' to 5' exonuclease activity. The composition can comprise a reverse transcriptase, such as a viral reverse transcriptase (e.g., murine leukemia virus (MLV) reverse transcriptase or a Moloney murine leukemia virus (MMLV) reverse transcriptase). The composition can comprise a buffer, a cartridge, or both. The composition can comprise a plurality of oligonucleotide barcodes. The plurality of oligonucleotide barcodes are associated with a third solid support. The composition can comprise third solid supports.

(250) Terminology

(251) In at least some of the previously described embodiments, one or more elements used in an embodiment can interchangeably be used in another embodiment unless such a replacement is not technically feasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims.

(252) One skilled in the art will appreciate that, for this and other processes and methods disclosed

herein, the functions performed in the processes and methods can be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations can be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.

(253) With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Any reference to “or” herein is intended to encompass “and/or” unless otherwise stated.

(254) It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”

(255) In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

(256) As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves,

thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

(257) From the foregoing, it will be appreciated that various embodiments of the present disclosure have been described herein for purposes of illustration, and that various modifications may be made without departing from the scope and spirit of the present disclosure. Accordingly, the various embodiments disclosed herein are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

Claims

1. A method for measuring the number of copies of a secreted factor secreted by one or more single cells, comprising: contacting one or more single cells with a first plurality of capturing synthetic particles, wherein the one or more single cells are capable of secreting a plurality of secreted factors, wherein each capturing synthetic particle comprises a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell, wherein contacting one or more single cells with a first plurality of capturing synthetic particles comprises partitioning the one or more single cells and the first plurality of capturing synthetic particles to a plurality of first partitions, wherein a first partition of the plurality of first partitions comprises a single cell of the one or more single cells and a single capturing synthetic particle of the first plurality of capturing synthetic particles; pooling the single capturing synthetic particles from each first partition of the plurality of first partitions to generate a second plurality of capturing synthetic particles; contacting the second plurality of capturing synthetic particles with a plurality of secreted factor-binding reagents each capable of specifically binding to a secreted factor bound by a capture probe, wherein each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent; hybridizing a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides, wherein the oligonucleotide barcodes each comprise a first molecular label; extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to the unique factor identifier sequence and the first molecular label; and obtaining sequencing data of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides to determine the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells.
2. The method of claim 1, comprising, after contacting the second plurality of capturing synthetic particles with the plurality of secreted factor-binding reagents, removing one or more secreted factor-binding reagents of the plurality of secreted factor-binding reagents that are not bound with the second plurality of capturing synthetic particles to generate a third plurality of capturing synthetic particles, wherein removing the one or more secreted factor-binding reagents not bound with the second plurality of capturing synthetic particles comprises: removing the one or more secreted factor-binding reagents not bound with the respective at least one of the secreted factor bound by a capture probe.
3. The method of claim 2, wherein hybridizing a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides comprises: partitioning the third plurality

of capturing synthetic particles to a plurality of second partitions, wherein a second partition of the plurality of second partitions comprises a single capturing synthetic particle from the third plurality of capturing synthetic particles; and in the second partition comprising the single capturing synthetic particle, hybridizing a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides.

4. The method of claim 1, wherein the one or more single cells comprises T cells, B cells, tumor cells, myeloid cells, blood cells, or a mixture thereof.

5. The method of claim 1, wherein the at least one secreted factor comprises a cytokine, a hormone, a molecular toxin, or any combination thereof.

6. The method of claim 1, wherein the secreted factor-binding reagent and the capture probe are capable of binding to distinct epitopes of the same secreted factor.

7. The method of claim 1, wherein one or more of the secreted factor-binding reagents and the capture probe comprise an antibody or fragment thereof.

8. A method for measuring the number of copies of a secreted factor secreted by one or more single cells and the number of copies of a nucleic acid target in one or more single cells, comprising: contacting one or more single cells with a first plurality of dual capturing synthetic particles to form one or more single cells associated with a dual capturing synthetic particle, wherein the one or more single cells comprise a surface cellular target and copies of a nucleic acid target, wherein the one or more single cells are capable of secreting a plurality of secreted factors, wherein each dual capturing synthetic particle comprises a plurality of capture probes and a plurality of anchor probes, wherein each of the plurality of anchor probes is capable of specifically binding to the surface cellular target, and wherein the capture probe is capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell; contacting the one or more single cells associated with a dual capturing synthetic particle with a plurality of secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, wherein each of the plurality of secreted factor-binding reagents comprises a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent; hybridizing a plurality of oligonucleotide barcodes with the secreted factor-binding reagent specific oligonucleotides and the copies of the nucleic acid target, wherein the oligonucleotide barcodes each comprise a first molecular label; extending the plurality of oligonucleotide barcodes hybridized to the copies of a nucleic acid target to generate a plurality of barcoded nucleic acid molecules each comprising a sequence complementary to at least a portion of the nucleic acid target and the first molecular label; extending the plurality of oligonucleotide barcodes hybridized to the secreted factor-binding reagent specific oligonucleotides to generate a plurality of barcoded secreted factor-binding reagent specific oligonucleotides each comprising a sequence complementary to the unique factor identifier sequence and the first molecular label; obtaining sequencing data of the plurality of barcoded nucleic acid molecules to determine the copy number of the nucleic acid target in at least one of the one or more single cells; and obtaining sequencing data of the plurality of barcoded secreted factor-binding reagent specific oligonucleotides to determine the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells.

9. The method of claim 3, wherein the plurality of oligonucleotide barcodes are associated with a barcoding synthetic particle, wherein the first partition and/or second partition is a well or a droplet, and wherein a second partition of the plurality of second partitions comprises a single barcoding synthetic particle.

10. The method of claim 1, wherein each oligonucleotide barcode comprises a first universal primer sequence, and wherein the plurality of barcoded secreted factor-binding reagent specific oligonucleotides comprise a complement of the first universal primer sequence.

11. The method of claim 10, wherein the secreted factor-binding reagent specific oligonucleotide comprises a second universal primer sequence, and wherein obtaining sequencing data of the

plurality of barcoded secreted factor-binding reagent specific oligonucleotides comprises: amplifying the plurality of barcoded secreted factor-binding reagent specific oligonucleotides using a primer capable of hybridizing to the first universal primer sequence, or a complement thereof, and a primer capable of hybridizing to the second universal primer sequence, or a complement thereof, to generate a plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides; and obtaining sequencing data of the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides.

12. The method of claim 1, wherein the secreted factor-binding reagent specific oligonucleotide comprises a second molecular label, and wherein: (i) the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and wherein the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are identical; or (ii) the second molecular label sequences of at least two secreted factor-binding reagent specific oligonucleotides are different, and wherein the unique identifier sequences of the at least two secreted factor-binding reagent specific oligonucleotides are different.

13. The method of claim 1, wherein the number of distinct first molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells.

14. The method of claim 12, wherein the number of distinct second molecular label sequences associated with the unique factor identifier sequence for the secreted factor-binding reagent capable of specifically binding to the at least one secreted factor in the sequencing data indicates the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells.

15. The method of claim 1, comprising determining the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells based on the number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of barcoded secreted factor-binding reagent specific oligonucleotides in the sequencing data.

16. The method of claim 11, comprising determining the number of copies of the at least one secreted factor secreted by at least one of the one or more single cells based on the number of first molecular labels and/or second molecular labels with distinct sequences associated with the plurality of amplified barcoded secreted factor-binding reagent specific oligonucleotides in the sequencing data.

17. The method of claim 1, wherein the capturing synthetic particle has the dimensions of a cell, wherein the cell is a mammalian cell, a yeast cell, an insect cell, a plant cell, or a bacterial cell.

18. The method of claim 8, wherein the surface cellular target comprises a carbohydrate, a lipid, a protein, or any combination thereof.
